Z33 Crypto

Exchange News & More

Author: adminz33

Aspirin could cut risk of death in cancer patients by 20%

Peter C Elwood1, Gareth Morgan1, Christine Delon2, Majd Protty3, Julieta Galante4,5, Janet Pickering1, John Watkins1,6, Alison Weightman7 and Delyth Morris8

1Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK

2Freelance statistician, London, UK

3Cardiff Lipidomics Group, Cardiff University, UK

4University of Cambridge, Cambridge, UK

5National Institute for Health Research (NIHR) Applied Research Collaboration East of England, Cambridge, UK

6Public Health Wales, Cardiff, UK

7Specialist Unit for Review Evidence, Cardiff University, Cardiff, UK

8University Library Service, Cardiff University, Cardiff, UK


Abstract

Background: Despite the accumulation of research papers on aspirin and cancer, there is doubt as to whether or not aspirin is an acceptable and effective adjunct treatment of cancer. The results of several randomised trials are awaited, and these should give clear evidence on three common cancers: colon, breast and prostate. The biological effects of aspirin appear likely however to be of relevance to cancer generally, and to metastatic spread, rather than just to one or a few cancers, and there is already a lot of evidence, mainly from observational studies, on the association between aspirin and survival in a wide range of cancers.

Aims: In order to test the hypothesis that aspirin taking is associated with an increase in the survival of patients with cancer, we conducted a series of systematic literature searches to identify clinical studies of patients with cancer, some of whom took aspirin after having received a diagnosis of cancer.

Results: Three literature searches identified 118 published observational studies in patients with 18 different cancers. Eighty-one studies report on aspirin and cancer mortality and 63 studies report on all-cause mortality. Within a total of about a quarter of a million patients with cancer who reported taking aspirin, representing 20%–25% of the total cohort, we found aspirin to be associated with a reduction of about 20% in cancer deaths (pooled hazard ratio (HR): 0.79; 95% confidence intervals: 0.73, 0.84 in 70 reports and a pooled odds ratio (OR): 0.67; 0.45, 1.00 in 11 reports) with similar reductions in all-cause mortality (HR: 0.80; 0.74, 0.86 in 56 studies and OR: 0.57; 0.36, 0.89 in seven studies). The relative safety of aspirin taking was examined in the studies and the corresponding author of every paper was written to asking for additional information on bleeding. As expected, the frequency of bleeding increased in the patients taking aspirin, but fatal bleeding was rare and no author reported a significant excess in fatal bleeds associated with aspirin. No author mentioned cerebral bleeding in the patients they had followed.

Conclusions: There is a considerable body of evidence suggestive of about a 20% reduction in mortality in patients with cancer who take aspirin, and the benefit appears not to be restricted to one or a few cancers. Aspirin, therefore, appears to deserve serious consideration as an adjuvant treatment of cancer, and patients with cancer, and their carers, have a right to be informed of the available evidence.

Keywords: aspirin, cancer, survival, mortality, bleeding, thromboembolism

Correspondence to: Gareth Morgan
Email: morganfforrdbeck@gmail.com

Published: 02/07/2021
Received: 13/10/2020

Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction

The first suggestive evidence of benefit to patients with cancer from aspirin was reported over 50 years ago. Studies of animals with cancer showed that aspirin is associated with a reduction in the development of metastases [1, 2]. Since then, despite the reporting of much further evidence on biological effects of aspirin, and the reporting of many studies on aspirin and survival, there is still uncertainty about the role of aspirin as a possible adjuvant treatment of patients with cancer.

A number of small and inadequate randomised trials have been reported [36] and the pooling of results from these gives a suggestive reduction of 9% in cancer deaths in the 722 patients with cancer who had been randomised to aspirin (hazard ratio (HR): 0.91; 95% confidence interval (CI): 0.79, 1.04) [7]. While this result is only suggestive, a trial which developed within the cohort of the US Physicians Health Study of cancer prevention by aspirin is more strongly supportive. Just over 500 subjects in the cohort developed cancer, and those who had been randomised to aspirin showed a reduction in cancer deaths (HR: 0.68, 95% CI: 0.52, 0.90) [8].

Another source of evidence on the range of cancers to which aspirin may be relevant comes from opportunistic long-term follow-up studies of patients who had been involved in early randomised trials of aspirin and vascular disease. In addition to reporting a subsequent reduction in cancer incidence, Rothwell et al [9] and Mills and Wu [10] showed that deaths from a wide range of cancers were reduced in subjects who had been randomised to aspirin, and furthermore, the occurrence of metastatic spread was reduced in a range of cancers, including colon, brain, liver, lung and ‘other or multiple sites’ [11].

A number of new ad hoc randomised trial have been set up to test aspirin treatment in a few cancers and results from these are awaited [1215]. These, however, are testing aspirin in only a very few cancers – principally colon, but also breast and prostate – while the effects of aspirin on biological mechanisms relevant to cancer lead to the possibility of benefit in most, if not all cancers [1618]. Indeed, because of its manifold effects on biological processes, Zhang et al [19] suggest that aspirin is ‘a master regulator of the hallmarks of cancer’.

The bulk of published evidence on aspirin and the treatment of cancer comes, however, from observational studies and in this report, we present the results of 118 published observational studies to test the hypothesis that aspirin is of benefit to a wide range of cancers and not just one or a few common cancers. We also present evidence that aspirin, relative to cancer and in comparisons with other cancer treatments, is a very safe drug.


Methods

We conducted three consecutive systematic literature searches and meta-analyses of published observational studies of aspirin taken by patients with cancer. Detailed reports on the first two searches have been published [7, 20]. A description of the most recent search procedure is given in Supplementary File 1, and in Supplementary File 2 a brief description of each of the studies judged to be relevant in the most recent search is presented. Together the three searches covered up to March 2020.

Given that most of the available studies have been on the three common cancers: colon, breast and prostate, and in view of the fact that aspirin is being tested in randomised trials, we first present pooled evidence on aspirin and these three cancers. We then present evidence from 36 published reports of 15 other cancers, each of which has been examined in only one or a very few studies.

The procedures adopted followed the PRISMA guidelines throughout [21] and a full description of the search strategy is given in Supplementary File 1. In brief: each of the three systematic searches using keywords was conducted by AW and DM in MEDLINE and EMBASE. The searches were limited to human studies in peer-reviewed journals. Relevant studies were selected by two authors (PE and GM) if (a) the studied population comprised patients diagnosed with cancer; (b) aspirin appears to have been taken regularly after cancer diagnosis; (c) the studies were randomised trials, case–control studies or cohort studies. Reference lists of the relevant studies identified were searched for other relevant reports. At least one author on each selected paper in all three searches was written to and asked specifically about gastrointestinal (GI) bleeding in the patients included in their study, together with appropriate further questions.

Data on cancer deaths and deaths from all-causes in the most recent search to March 2020 are listed in Supplementary File 3, first for studies that had expressed association as HRs, followed by studies which had used odds ratios (ORs), risk ratios (RRs) or percent survival. The methodological quality of the studies was assessed and graded independently by two authors (AW and PE) using the Newcastle–Ottawa Scale [22]. We have also added to each paper listed in Supplementary File 3 a comment as to the level of certainty that aspirin had been taken – or had not been taken – throughout follow-up.

Most of the risk estimates reported by the authors were expressed as HRs, and these and their 95% CI were taken from the original articles and log-transformed to obtain the estimate of the treatment effect (TE). The standard errors (seTE) were determined by subtracting the lower log-transformed CI boundary from the upper log-transformed CI boundary and dividing this by 3.92 (2*1.96). Where HRs were not reported, ORs, RRs and their 95% CI, or number of events among patients taking aspirin and those not on aspirin, were taken from the original articles. ORs and exact 95% CIs were calculated where needed, and all were then log-transformed for meta-analysis.

Summary risk estimates of random effects models are shown as forest plots in Supplementary File 4. HR meta-analyses were conducted using the meta package, version 4.13.0 in R 4.0.2, open source. Analysis with the metagen function used sm = HR for the underlying summary method and the DerSimonian–Laird method [23] was used to estimate the between-study variance (τ and τ2). Meta-analyses of the reports as ORs were conducted using Stata/SE 16.1, and used the restricted maximum likelihood method to estimate the between-study variance and these are shown as forest plots in Supplementary File 5.

Finally, funnel plots were constructed and estimates of the probability of publication bias were derived. The forest plot added trim and fill which mirrored the studies followed by a cumulative forest plot based on decreasing standard error. This was only undertaken on a minimum of 10 papers hence there is only one examination for OR. These are all shown in Supplementary File 6.


Results

Three systematic literature searches on the topic of this report were conducted by the authors: in 2016 [7], in 2018 [20] and in 2020 up to March 2020 (Supplementary File 1). In each report, there are two outcomes, death from cancer and death from any cause, almost all of which have been presented as HRs. The new studies are described in Supplementary File 3 and their results are listed and pooled in Supplementary File 4. Some of the deaths have however been reported as OR, relative risk, etc., and all these have been converted to ORs. These ORs are presented separately from the HRs in Supplementary File 3 and are listed and pooled in Supplementary File 5. Some results however have been presented as additional survival in months or years, or during defined periods of time, such as 5 years. These are mentioned in the text, but do not appear in any table or Supplementary file.

In addition, we were concerned about undesirable side effects of the aspirin and in addition to abstracting relevant data from the published reports, following each of the three searches we wrote to an author of every report, asking for details of any unwanted side effect and in particular bleeding attributable to aspirin. A few authors supplied evidence on bleeding further to that in their published report, and these details are quoted in the text.

Figure 1 describes the findings of the three searches.

Figure 1. Flow diagram describing the findings of the three systematic literature searches.

Mortality

For colon cancer mortality, our three literature searches identified a total of 24 studies in which the association with aspirin was reported as HRs. Together, these give a pooled HR of 0.72 (95% CI: 0.63, 0.82), and a single report showed an OR (OR of 0.78 (0.66, 0.93) (Table 1 and Supplementary File 4). For all-cause mortality, 20 studies of colon cancer reported HRs, giving a pooled association with aspirin of 0.83 (95% CI: 0.75, 0.92) and a single HR reported an OR of 0.78 (0.65, 0.92) (Table 1 and Supplementary File 4)

For breast cancer mortality, 13 studies reported as HRs and these give a pooled HR: 0.84 (0.72, 0.98). Four further studies give pooled OR: 0.75 (0.36, 1.57). For all-cause mortality in the breast cancer studies, nine reports give a pooled HR of 0.94 (0.70, 1.25).

For prostate cancer mortality, the pooling of 15 studies gives an HR of 0.89 (0.78, 1.02) and there was one study with an OR of 1.02 (0.78, 1.34). For all-cause mortality in prostate cancer reports, seven studies give an HR of 1.00 (0.78, 1.27) and in one the OR is 1.06 (0.94, 1.19).

For cancers other than colon, breast and prostate, the supplementary files list ‘other’ cancers: nasopharynx [96, 102], GI cancers, including oropharynx, stomach, oesophagus and rectum, [41, 88, 97, 106, 121, 124], liver [93, 103], gallbladder in four parts [101], pancreas [125], bladder [98, 112, 114], ovary [81, 8386, 113], endometrium [87, 89], head & neck [88, 9092, 104, 123], lung [82, 94, 108, 122], leukaemia [79], glioma [100], melanoma [99] and two [39, 80] present a mixture of cancers.

Not all the estimates of association in these reports of ‘other’ cancers are significant at p < 0.05. However, only three are consistent with an oropharynx possible harmful effect of aspirin, having a confidence limit which includes 1, but none of the three is significant at p < 0.05 with both confidence limits above 1.

Together, these reports of ‘other’ cancers give a pooled HR for cancer mortality of 0.79 (0.70, 0.88) in 18 studies and a pooled OR of 0.49 (0.26, 0.95) in five studies. All-cause mortality in 21 of these other cancers gives a pooled HR of 0.67 (0.60, 0.75) in 21 studies and the five studies that did not report HRs give a pooled OR of 0.47 (0.26, 0.83).

The forest plots of all these data are shown in Supplementary Files 4 and 5, and Table 2 brings together all the available data on cancer deaths and on all-cause mortality.

Table 1. Summary of Eggers test for bias and of trim and fill analysis.

Table 2. A summary of the overall findings of the association between aspirin taking and mortality in 106 reports.

A number of authors give estimates of the association with aspirin in terms of the duration of the additional survival in patients taking the drug. Thus, Albandar [117] who followed 174 US veterans with colorectal cancer to death reported that the median survival of patients taking aspirin was 941 versus 384 days in those not taking aspirin. Several papers record an increased survival associated with aspirin taken by patients with liver cancer: in one 18 months additional survival [93]; in another 6% more patients survived 10 years with aspirin after diagnosis [103], and the median overall survival period after embolisation was longer for patients taking aspirin (57 versus 23 months) [119]. In a study of endometrial cancer, 91% of patients taking aspirin survived 10 years compared with 81% of patients not on aspirin [87]. In a study of patients with lung cancer, patients on aspirin survived 1.69 and only 1.02 years if not on aspirin [96]. In a study of pancreatic cancer, the 3-year survival was reported to be 61% in patients taking aspirin versus 26.3% in patients not taking aspirin [118], and finally, the 3-year survival of US veterans with head and neck cancer was 79% in those taking aspirin, compared with only 56% of those not taking aspirin [92].

Using a different approach, a group in Liverpool used data for over 44,000 patients with colon cancer to derive a predictive equation which relates a number of factors present at diagnosis to survival [45]. Entering the details for a non-diabetic man aged 70 with colon cancer into the predictive formula, the inclusion of aspirin taking increases the estimate of survival by about 5 years, and for a woman, about 4 years.

Finally, as a test of the hypothesis posed in this report, we compared the association of aspirin and cancer mortality in the 15 less common cancers with cancer mortality in colon cancer. In this comparison, we use colon cancer mortality as the ‘gold estimate’ of the effect of aspirin on the grounds that the effect of aspirin has been more thoroughly investigated in colon cancer, than in any other cancer; colon cancer is the only cancer for which the UK National Institute for Clinical Excellence has given a limited recommendation for aspirin, [120] and the U.S. Preventive Services Task Force and other professional bodies give guidance for the use of aspirin in colon cancer [121].

This comparison shows:

Colon Cancer mortality:

24 studies give a pooled HR: 0.72 (95% CI: 0.63, 0.82),

No significant publication bias z = −0.7276, p = 0.4668.

Cancer mortality in less common cancers

18 studies give a pooled HR: 0.79 (95% CI: 0.70, 0.88),

Significant publication bias z = −2.8110, p = 0.0049.

Bleeding

A search for evidence on bleeding, and fatal bleeding attributable to aspirin was made, and this included writing to the corresponding author on all the 118 papers included in the three searches. Many of the studies however had been based on recorded data, with no direct contact with the patients involved, and authors of such reports had little or no knowledge about bleeding in the patients they described.

Many of the authors reported the expected excess in GI bleeding in the patients on aspirin. However, only a very few reported fatal bleeds. In one study, 3% of the patients taking aspirin and 3.2% of those not taking aspirin had had a fatal bleed [40]. Tsoi et al [49], who studied a cohort of over 18,000 patients with colon cancer reported that deaths of aspirin users who developed GI bleeding were 0.40%, compared with 0.36% of the patients not taking aspirin. A study of patients with liver cancer treated by transarterial chemoembolisation reported that six patients in the aspirin group and seven patients in the non-aspirin group died because of upper GI bleeding [93]. One paper makes mention of the reduction in bleeding in patients who took a PPI along with the aspirin (OR: 0.85; 0.80, 0.91) [49]. All the references to bleeds relate to GI bleeds and no author made mention of cerebral bleeding.


Discussion

This report provides both confirmatory and new evidence on the benefit of aspirin in reducing mortality in patients being treated for cancer. Replication is an important procedure in science and the present study confirms the findings of our first report with 50 studies [7], and our second report with 29 studies [20]. The present study is a further replicate with 39 new observational studies.

The meta-analyses we now present are all based on pooling of the data provided by 118 observational studies comprising about a quarter of a million patients with cancer who were recorded as taking aspirin. This reveals that aspirin taking is associated with a reduction of cancer deaths of about one fifth in a range of 18 cancers (HR: 0.79 (0.73, 0.84) in 70 observational studies and OR: 0.67 (0.45, 1.00) in 11 studies (Table 2 and Supplementary Files 4 and 5). The effect of aspirin on all-cause mortality is closely similar (HR: 0.80 (0.74, 0.86) in 56 observational studies and OR: 0.57 (0.36, 0.89) in 7 studies). A reasonable interpretation of these results is – that at any time after a diagnosis of a wide range of different cancers, about 20% more of the patients who take aspirin are likely to be alive, compared with patients not taking aspirin.

The evidence of publication bias throughout this work is a most important issue. Bias due to the selective publication of positive findings for aspirin was expected, and for some of the pooled results the magnitude of this bias is greater than could be reasonably expected in chance grounds alone (Supplementary File 6). While conclusions drawn from these 118 papers have, therefore, to be cautious, the evidence is strengthened by the absence of significant bias at p < 0.05 for the data for colon cancer. It is also encouraging that the trim and fill analysis on the less common cancers maintained the beneficial TE for both cancer specific mortality and all-cause mortality.

Bleeding

A bleed, either GI or intra-cerebral, is a crisis for a patient, but the seriousness of a bleed attributable to aspirin should be evaluated against the likely benefits attributable to its use and furthermore the severity of the additional bleeds attributable to aspirin should be considered and not just their frequency [122, 123]. In relation to the treatment of cancer, our examination of the 118 reports gives a considerable degree of reassurance on aspirin, and particularly on the most serious bleeds. It is of relevance that most of the patients appear to have been taking low-dose aspirin primarily for cardiovascular protection.

Low-dose aspirin is however associated with additional GI bleeds in between 0.8 and 5.0 patients per 1,000 person years aged 50–84 years in the general population [124]. This represents an increase above spontaneous GI bleeding of between about 50% [125] and 90% [121]. It is important to note that these increases imply that only one in every two or every three bleeds that occur in patients taking low-dose aspirin is likely to be truly attributable to the aspirin, the other bleeds being spontaneous and nothing to do with aspirin.

The most serious bleeds are those that lead to death and our concern on this led us, early in our investigations of aspirin and cancer, to conduct a careful evaluation of fatal bleeding [126] A meta-analysis based on 11 randomised trials showed that the additional bleeds attributable to aspirin are less serious than spontaneous bleeds and are seldom, if ever fatal (relative risk of death: 0.45; (0.25, 0.80), and the risk of a fatal bleed in the totality of subjects randomised to aspirin, relative to subjects randomised to placebo was RR: 0.77 (0.41, 1.42). As we reported in our overview [126], others have reported similar findings of a reduction in the proportion of fatal bleeds in patients taking aspirin [9, 127130].

Findings on bleeding in the recent ASPREE trial of prophylactic aspirin are of interest as more than 19,000 subjects with a median age of 74 years were followed for 5 years. Eighty-nine subjects randomised to aspirin, or 1.9 in every 1,000 experienced a bleed each year, compared with 48 bleeds, or just over 1.1 per thousand per year in those not taking aspirin. Granted this was not a trial of aspirin treatment, but it is of relevance to the safety of the drug that only two fatal bleeds occurred, and neither was in a subject taking aspirin [131].

The most serious side effect of aspirin, intra-cerebral bleeding, is fortunately rare [132], and no author in our literature review mentioned cerebral bleeding within the patients they followed. The risk associated with aspirin is estimated to be around 1.39 (95% CI: 1.08, 1.78) [125] equivalent to one or two additional haemorrhagic strokes per year in every 10,000 subjects [133].

Hypertension is the major factor in haemorrhagic stroke and in one major overview of randomised trials there was a doubling of cerebral haemorrhages for a rise of 20 mmHg in blood pressure (RR: 2.18; 95% CI: 1.65, 2.87) [127]. The relevance of hypertension was further highlighted in a trial of aspirin based on 20,000 patients with hypertensive disease, all of whom were adequately treated with anti-hypertensive drugs. There were no additional cerebral bleeds attributable to aspirin: the same number of patients on aspirin experienced cerebral bleeds (19 patients) as those on placebo (20 patients) [133].


Strengths and limitations of this study

In addition to the risks of publication bias as detailed above, a most important limitation is that almost all the evidence we present are from observational studies. A number of randomised trials of therapeutic aspirin are in progress but these focus entirely on either one, or a few of the common cancers: colon [1215], breast [12, 14] and prostate [12, 15]. Our concern, however, is for all cancers and not one or a few cancers, and as others have pointed out many of the actions of aspirin on cancer development, growth and metastatic spread, appear likely to be relevant to a wide range of cancers [619].

It is important to note that amongst the uncertainties in these observational studies, two uncertainties appear to stand out in their probable relevance to every observational study, and to the possible size of their effects. These are: first: uncertainties about the classification of patients with regard to continuous aspirin taking, and uncertainties about the non-taking of aspirin by the ‘controls’, and secondly, co-morbidity in the patients taking aspirin.

Few authors give reassurance about continued aspirin taking during follow-up, and no authors comment on the possibility of ‘contamination’ of control subjects starting to take ‘over the counter’ aspirin during the follow-up. An additional column in Supplementary File 3 lists quotations from the papers reviewed and these show that most authors assumed that if there is evidence of aspirin taking at the time of diagnosis, it can reasonably be assumed that aspirin taking was continuous during follow-up. Thus, ‘Low-dose aspirin use was defined as a minimum of one filled prescription after cancer diagnosis’ [89] and another: ‘the patients were receiving aspirin from diagnosis to at least 1 year after treatment initiation’ [90]. One author pointed out however that ‘the inverse association with aspirin appeared to be only among men who reported using aspirin regularly’, [76] and another noted that a reduction in mortality was ‘notably among patients filling prescriptions for a large quantity of low dose aspirin tablets during the (follow-up) period [77]. Another author found that prescribed aspirin alone was not associated with decreased mortality, but when OTC aspirin was added, a large reduction was detected [39].

A recent study by a group in Dublin examined the influence of approaching death on end-of-life aspirin use in patients with breast or colorectal cancer. They found that the use of aspirin declined ‘considerably’ during the 2 years before death, and at the time of death rates of aspirin use had dropped from around 60% to around 20% for colorectal cancer and from around 80% to around 45% for breast cancer [134].

The only comment about aspirin taking by control subjects comes from an overview of 12 studies in which the authors state that the pooled survival in patients on aspirin was only HR: 0.96 (0.88, 1.04) but if non-aspirin taking was more tightly defined as less than once per week, the HR was 0.89 (0.82, 0.98) [135].

The other important limitation is confounding by co-morbidity. Many authors mention that the aspirin takers in their study were older than the control patients not on aspirin. While this can be adjusted for statistically, the fact that a number of studies state that most of the patients who were taking aspirin were doing so because of a prior vascular event or prevalent vascular disease. Clearly, the morbidity that had led some of the patients to take aspirin can have eroded any benefit achievable by aspirin and while many of the papers mention this, few give details.

Yet a further limitation arises from possible miscoding of the causes of death in these studies. In the SEER programme on mortality in patients with cancer in the USA, it was found that 11% of cancer deaths had been attributed to vascular disease [136]. Any such miscoding will lead to an underestimate of the reduction in cancer deaths associated with aspirin.

The very broad range in the estimates of effect of aspirin leading to high heterogeneity estimates in our meta-analyses is worrying, and some of the differences between studies seem to defy any reasonable explanation. And yet, this was predicted from the beginning of the work on aspirin treatment [7]. There are many biases and sources of possible differences between the series of patients in the various studies, including differences in age and social factors, differences in other treatments and in general clinical management [41, 48]. Then there are possible differences in consistency of aspirin taking and the differences in co-morbidity already mentioned. Both poor aspirin taking and co-morbidity in patients taking aspirin will increase heterogeneity, and are probably inevitable in a series of studies such as we present. On the other hand, it seems unlikely that such differences could account for the overall benefits we find to be associated with aspirin taking.


Conclusions

We judge that the body of evidence now available on the efficacy and the safety of aspirin justifies its use as an adjunct treatment in a wide range of cancers. Clinical care includes an ethical imperative for shared decision making [137] and we, therefore, believe that doctors should present, and patients with cancer should be encouraged to raise the topic of aspirin taking with their doctors. At the same time, we stress that aspirin is not a possible alternative to any other treatment, although in poorer countries aspirin could be one of very few, or perhaps the only acceptable treatment on the grounds of cost and availability [138].

Further research into aspirin and cancer would clearly be of great value, and studies including observational and randomised trial should be encouraged, especially if focused upon one of the less common cancers.


Conflicts of interest

The author(s) declare that they have no conflict of interest. All the authors have read the paper and agree with its content.


Funding

No special funding was obtained for any of the work described in this paper. Julieta Galante was supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East of England. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.


References

1. Gasic GJ, Gasic TB and Stewart CC (1968) Anti-metastatic effects associated with platelet reduction Proc Natl Acad Sci USA 61 46–52 https://doi.org/10.1073/pnas.61.1.46

2. Gasic GJ, Gasic TB, and Murphy S (1972) Anti-metastatic effect of aspirin Lancet 2 932–933 https://doi.org/10.1016/S0140-6736(72)92581-0 PMID: 4116642

3. Lipton A, Scialla S, and Harvey H, et al (1982) Adjuvant antiplatelet therapy with aspirin in colorectal cancer J Med 13 419–429

4. Lebeau B, Chastang C, and Muir JF, et al (1993) No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomised clinical trial of 303 patients Cancer 71 1741–1745 https://doi.org/10.1002/1097-0142(19930301)71:5&lt;1741::AID-CNCR2820710507&gt;3.0.CO;2-Q PMID: 8383578

5. Cregan ET, Twito DI, and Johansson S, et al (1991) A randomised prospective assessment of recombinant leukocyte A interferon with or without aspirin in advanced renal adenocarcinoma J Clin Oncol 9 2104–2109 https://doi.org/10.1200/JCO.1991.9.12.2104

6. Liu JF, Jamieson GG, and Wu TC, et al (2009) A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia Ann Surg Oncol 16 1397–1402 https://doi.org/10.1245/s10434-009-0382-z PMID: 19241108

7. Elwood PC, Morgan G, and Pickering JE, et al (2016) Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analysis of published studies PLoS One 11(4) e0152402 https://doi.org/10.1371/journal.pone.0152402 PMCID: 4838306

8. Downer MK, Allard CB, and Preston MA, et al (2017) Regular aspirin use and the risk of lethal prostate cancer in the physicians health study Eur Urol 72 821–827 https://doi.org/10.1016/j.eururo.2017.01.044 PMID: 28189429

9. Rothwell PM, Price JF, and Fowkes G, et al (2012) Short-term effects of daily aspirin on cancer incidence, mortality and non-vascular death: analysis of the time course of risks and benefits in 51 randomised trials Lancet 379 1602–1612 https://doi.org/10.1016/S0140-6736(11)61720-0 PMID: 22440946

10. Mills EJ, WU P, and Alberton M, et al (2012) Low-dose aspirin and cancer mortality: a meta-analysis of randomised trials Am J Med 125 560–567 https://doi.org/10.1016/j.amjmed.2012.01.017 PMID: 22513195

11. Rothwell PM, Fowkes FGR, and Belch JFF et al (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 327 31–41 https://doi.org/10.1016/S0140-6736(10)62110-1

12. Coyle C, Cafferty FH, and Rowley S, et al (2016) Add-aspirin: a phase III, double-blind, placebo control randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours Contemp Clin Trials 51 56–64 https://doi.org/10.1016/j.cct.2016.10.004 PMID: 27777129 PMCID: 5127874

13. Ali R, Toh HC, and Toh HC, et al (2011) The utility of aspirin in Dukes C and high risk Dukes B CRC – the ASCOLT study: study protocol for a randomised controlled trial Trials 12 261 https://doi.org/10.1186/1745-6215-12-261

14. Chen WY, Winer EP, and Ballman KV, et al (2017) ABC TRIAL: a randomised double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer J Clin Oncol 37

15. Powles T (2018) PROVENT: a randomised double blind feasibility trial randomised trial to examine the clinical effectiveness of aspirin and/or vitamin D3 to prevent disease progression in men on active surveillance for prostate cancer Eur J Surg Oncol 44

16. Chan AT, Ogino S and Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer JAMA 302 649–659 https://doi.org/10.1001/jama.2009.1112 PMID: 19671906 PMCID: 2848289

17. Langley RW, Burdett S, and Tierney JF, et al (2011) Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy Br J Cancer 105 1107–1113 https://doi.org/10.1038/bjc.2011.289 PMID: 21847126 PMCID: 3208483

18. Langley RE (2013) Clinical evidence for the use of aspirin in the treatment of cancer Ecancermedicalscience 7 297 https://doi.org/10.3332/ecancer.2013.297 PMID: 23589726 PMCID: 3622409

19. Zhang X, Feng Y, and Liu X, et al (2019) Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer J Cancer Res Clin Oncol 145 1387–1403 https://doi.org/10.1007/s00432-019-02902-6 PMID: 31037399

20. Elwood PC, Pickering JE, and Morgan G, et al (2018) Systematic review update of observational studies further supports aspirin role in cancer treatment: time to share evidence and decision-making with patients PLoS One 13(9) e0203957 https://doi.org/10.1371/journal.pone.0203957 PMCID: 6155524

21. Moher D, Liberati A, and Tetzlaff J, et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS One 6(7) e1000097

22. Wells G, Shea B, and O’Connell D, et al (2011) The Newcastle-Ottaway scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis

23. DerSimonian R and Laird N (1986) Meta-analysis in clinical trials Control Clin Trials 7 177–188 https://doi.org/10.1016/0197-2456(86)90046-2 PMID: 3802833

24. Fuchs C, Meyerhardt JA, and Heseltine DL, et al (2005) Influence of regular aspirin on survival for patients with stage III colon cancer. Findings from intergroup trial CALGB 89803 J Clin Oncol 23(16) 3530 https://doi.org/10.1200/jco.2005.23.16_suppl.3530

25. Bastiaannet E, Sampieri K, and Dekkers OM, et al (2012) Use of aspirin postdiagnosis improves survival for colon cancer patients Br J Cancer 106 1564–1570 https://doi.org/10.1038/bjc.2012.101 PMID: 22454078 PMCID: 3341868

26. Coghill AE, Newcomb PA, and Campbell PT, et al (2011) Prediagnostic NSAIDs use and survival after diagnosis of colorectal cancer Gut 60 491–498 https://doi.org/10.1136/gut.2010.221143

27. Liao X, Lockhead P, and Nishara R, et al (2012) Aspirin use, tumour PIK3CA mutation and colorectal cancer survival N Engl J Med 367 1597–1606 https://doi.org/10.1056/NEJMoa1207756

28. Walker AJ, Grainge MJ, and Card TR (2012) Aspirin and other NSAID drug use and colorectal cancer survival: a cohort study Br J Cancer 107 1602–1607 https://doi.org/10.1038/bjc.2012.427 PMID: 23011483 PMCID: 3493766

29. Domingo E, Church DN, and Sieber O, et al (2013) Evaluation of PIK3CA mutation as a predictor of benefit from NSAID drug therapy in colorectal cancer J Clin Oncol 34 4297–4305 https://doi.org/10.1200/JCO.2013.50.0322

30. McCowan C, Munro AJ, and Donnan PT, et al (2013) Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal specific mortality Eur J Cancer 49 1049–1057 https://doi.org/10.1016/j.ejca.2012.10.024

31. Sun Nishihara QR, Chan AT, and Ogino S (2013) Aspirin and colorectal cancer incidence and mortality by ctnnb1 expression: a molecular pathological epidemiology (MPE) study Cancer Epidemiol Biomarkers Prev 22 472–473

32. Cardwell CR, Kunzmann AT, and Cantwell MM, et al (2014) Low-dose aspirin after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort Gastroenterol 146 700–708 https://doi.org/10.1053/j.gastro.2013.11.005

33. Goh HH, Leong WQ, and Chew MH, et al (2014) Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer Anticancer Res 34 7407–7414 PMID: 25503181

34. Ng K, Meyerhardt JA, and Chan AT, et al (2015) Aspirin and COX-2 inhibitor use in patients with stage III colon cancer J Natl Cancer Inst 107 345 https://doi.org/10.1093/jnci/dju345

35. Zanders MM, van Herk-Sukel MP, and Vissers PA, et al (2015) Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Br J Cancer 113 401–410 https://doi.org/10.1038/bjc.2015.259

36. Restivo A, Cocco IMF, and Casula G, et al (2015) Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer Br J Cancer 113 1133–1139 https://doi.org/10.1038/bjc.2015.336 PMID: 26372700 PMCID: 4647877

37. Bains SJ, Mahic M, and Myklebust TA, et al (2016) Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study J Clin Oncol 34 2501–2508 https://doi.org/10.1200/JCO.2015.65.3519 PMID: 27247217

38. Shimoike N, Fujikawa T, and Yoshimoto Y, et al (2016) Does antiplatelet therapy affect short-term and long-term outcomes of patients undergoing surgery for colorectal cancer? – surgical radicality versus perioperative antiplatelet-related morbidity risks J Gastroenterol Hepatol Res 5 1962–1969 https://doi.org/10.17554/j.issn.2224-3992.2016.05.605

39. Veitonmaki T, Murtola TJ, and Maattanen L, et al (2015) Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial Prostate 75 1394–1402 https://doi.org/10.1002/pros.23020 PMID: 26073992

40. Ventura L, Miccinesi G, and Barchielli A, et al (2016) Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy Eur J Cancer Prev 27 134–139 https://doi.org/10.1097/CEJ.0000000000000319 PMID: 27845951

41. Frouws MA, Bastiaannet E, and LangleyMadis RE, et al (2017) Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study Br J Cancer 116 405–413 https://doi.org/10.1038/bjc.2016.425 PMID: 28072768 PMCID: 5294482

42. Giampieri R, Restivo A, and Pusceddu V, et al (2017) The role of aspirin as antitumoral agent for heavily pretreated patients with metastatic colorectal cancer receiving capecitabine monotherapy Clin Colorectal Cancer 16 38–43 https://doi.org/10.1016/j.clcc.2016.07.011

43. Gray RT, Cantwell MM, and Coleman HG, et al (2017) Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study Clin Transl Gastroenterol 8 e91 https://doi.org/10.1038/ctg.2017.18 PMID: 28448072 PMCID: 5543466

44. Hamada T, Cao Y, and Qian ZR, et al (2017). Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status J Clin Oncol 35 1836–1844 https://doi.org/10.1200/JCO.2016.70.7547 PMID: 28406723 PMCID: 5455595

45. Hippisley-Cox J and Coupland C (2017) Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study Br Med J 357 2497–2522 https://doi.org/10.1136/bmj.j2497

46. Hua X, Phipps AI, and Burnett-Hartman AN, et al (2017) Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival J Clin Oncol 35 2806–2813 https://doi.org/10.1200/JCO.2017.72.3569 PMID: 28617623 PMCID: 5562174

47. Murphy C, Turner N, and Wong HI, et al (2017) Examining the impact of regular aspirin use and PIK3CA on survival in stage 2 colon cancer Intern Med J 47 88–98 https://doi.org/10.1111/imj.13312

48. Gray RT, Coleman HG, and Hughes CH, et al (2018) Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study BMC Cancer 18 228 https://doi.org/10.1186/s12885-018-4142-y PMID: 29486728 PMCID: 6389196

49. Tsoi KF, Chan FC, and Hiral HW et al (2018) Risk of gastrointestinal bleeding and benefit from colorectal cancer reduction from long-term use of low-dose aspirin: a retrospective study of 612 509 patients J Gastroenterol Hepatol 33 1728–1736 https://doi.org/10.1111/jgh.14261 PMID: 29665624

50. Blair CK, Sweeney C, and Anderson KE et al (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women Breast cancer Res Treat 101 191–197 https://doi.org/10.1007/s10549-006-9277-x

51. Wernli KJ, HamptonJM, and Trentham-Dietz A et al (2011) Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors Pharmacoepidemiol Drug Saf 20 131–137 https://doi.org/10.1002/pds.2064 PMID: 21254283 PMCID: 3074001

52. Fraser DM, Sullivan FM, and Thompson AM, et al (2014) Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study Br J Cancer 111 623–627 https://doi.org/10.1038/bjc.2014.264 PMID: 24945997 PMCID: 4119969

53. Holmes MD, Chen WY, and Li L, et al (2014) Aspirin intake and survival after breast cancer J Clin Oncol 28 1467–1472 https://doi.org/10.1200/JCO.2009.22.7918

54. Barron TI, Murphy LM, and Brown C, et al (2015) De-novo post-diagnostic aspirin use and mortality in women with stage I-III breast cancer Cancer Epidemiol Biomarkers Prev 24 898–904 https://doi.org/10.1158/1055-9965.EPI-14-1415 PMID: 25791705

55. Cronin-Fenton D, Heide-Jorgensen U, and Ahern TP, et al (2016) Low-dose non-steroidal antiinflammatory drugs, selective COX-2 inhibitor prescriptions and breast cancer recurrence. A Danish population based cohort study Proceedings of the Pharmacoepidemiology and Drug Safety Conference, Boston

56. McCarthy AM, He W, and Regan S, et al (2017) Impact of PIK3CA tumor mutation on the association of aspirin or NSAID use and time to breast cancer recurrence J Clin Oncol 35(15_Suppl) 1521 https://doi.org/10.1200/JCO.2017.35.15_suppl.1521

57. Mc Menamin UC, Cardwell CR, and Hughes CM et al (2017) Low-dose aspirin use and survival in breast cancer patients: a nationwide cohort study Cancer Epidemiol 47 20–27 https://doi.org/10.1016/j.canep.2016.12.008 PMID: 28088656

58. Shiao J, Thomas KM, and RaHuanhimi AS, et al (2017) Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients Breast Cancer Res Treat 161 463–471 https://doi.org/10.1007/s10549-016-4081-8

59. Bens A, Friis S, and Dehlendorff C, et al (2018) Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study Prev Med 115 186–193 https://doi.org/10.1016/j.ypmed.2018.09.015

60. Frisk G, Ekberg S, and Lidbrink E, et al (2018) No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study Breast Cancer Res 20 142 https://doi.org/10.1186/s13058-018-1065-0 PMID: 30458873 PMCID: 6247765

61. Strasser-Wippl K, Higgins MJ, and Chapman JAW, et al (2018). Effects of celecoxib and low-dose aspirin on outcomes in adjuvant aromatase inhibitor-treated patients: CCTG MA.27 J Natl Cancer Inst 110 1003–1008 https://doi.org/10.1093/jnci/djy017

62. Wang T, Parada H, and McClain KM, et al (2018) Pre-diagnostic aspirin and mortality after breast cancer Cancer Causes Control 29 417–425 https://doi.org/10.1007/s10552-018-1020-5 PMID: 29516320

63. McCarthy AM, KumarNP, and Wei H, et al (2020) Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer BMC Cancer 20 347 https://doi.org/10.1186/s12885-020-06810-8 PMID: 32326897 PMCID: 7181475

64. Stock DC, Groome PA, and Siemens DR, et al (2008) Effects of non-selective NSAIDs on the aggressiveness of prostate cancer Prostate 68 1655–1665 https://doi.org/10.1002/pros.20834 PMID: 18698582

65. Choe KS, Cowan JE, and Chan JM, et al (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy J Clin Oncol 30 3540–3544 https://doi.org/10.1200/JCO.2011.41.0308 PMID: 22927523 PMCID: 3454771

66. Dhillon PK, Kenfield SA, and Stampfer MJ, et al (2012) Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort Cancer Prev Res 5 1223–1228 https://doi.org/10.1158/1940-6207.CAPR-12-0171

67. Daugherty SER, Pfeiffer R, and Ghazarian A, et al (2013) Frequency of aspirin use and prostate cancer mortality among prostate cancer cases in the control arm of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial Am Assoc Cancer Res 73(8) 15

68. Assayag J, Pollak MN and Azoulay L (2014) The use of aspirin and the rosk of mortality in patients with prostate cancer J Urol 193 1220–1225 https://doi.org/10.1016/j.juro.2014.11.018

69. Caon J, Paquette M, and Hamm J, et al (2014). Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy? Prostate Cancer 2014 184297 https://doi.org/10.1155/2014/184297 PMID: 24729876 PMCID: 3960556

70. Flahavan EM, Bennett K, and Sharp L, et al (2014) A cohort study investigating aspirin use and survival in men with prostate cancer Ann Oncol 25 154–159 https://doi.org/10.1093/annonc/mdt428

71. Grytli HH, Fagerland MW, and Fossa SD et al (2014) Associaton between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high risk or metastatic disease Eur Urol 65 635–641 https://doi.org/10.1016/j.eururo.2013.01.007

72. Jacobs, EJ, Newton CC, and Stevens VJ, et al (2014) Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer J Clin Oncol 32 3716–3722 https://doi.org/10.1200/JCO.2013.54.8875 PMID: 25332245

73. Jacobs CD, Chun SG, and Yan J, et al (2014) Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy Cancer Biol Ther 15 699–706 https://doi.org/10.4161/cbt.28554 PMID: 24658086 PMCID: 4049786

74. Osborn VW, Chen SC, and Weiner J, et al (2016) Impact of aspirin on clinical outcomes for African American men with prostate cancer undergoing radiation Tumori 102 65–70 https://doi.org/10.5301/tj.5000424

75. Zhou CK, Daugherty SE, and Liao LM, et al (2017) Do aspirin and other NSAIDs confer a survival benefit in men diagnosed with prostate cancer? A pooled analysis of NIH-AARP and PLCO cohorts Cancer Prev Res 10 410–420 https://doi.org/10.1158/1940-6207.CAPR-17-0033

76. Hurwitz LM, Joshu CE, and Barber JR, et al (2018) Aspirin use and risk of lethal prostatic cancer in the atherosclerosis risk in communities cohort Cancer Research. Proceedings of the AACR Annual Meeting

77. Skriver C, Dehlendorff C, and Borre M, et al (2019) Use of low-dose aspirin and mortality after prostate cancer diagnosis. A nationwide cohort study Ann Intern Med 170 443–452 https://doi.org/10.7326/M17-3085 PMID: 30831581

78. Prause LW, Manka L, and Millan C, et al (2019) Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau) World J Urol 38(10) 2485–2491 https://doi.org/10.1007/s00345-019-03054-5 PMID: 31865534

79. Chae YK, Trinh L, and Jain P, et al (2014) Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukaemia Blood 22 1424–1426 https://doi.org/10.1182/blood-2013-07-517102

80. Chae Y, Hong DS, and Kim KH (2013) PIK3CA mutations, aspirin use and mortality in patients with women’s cancers or colorectal cancers treted in early phase clinical trials. POSTER Epidemiology Primary and Secondary Prevention. Abstract No 1454.

81. BeeghlyFadiel A, Holman G, and Stansel SP, et al (2015) Aspirin, NSAIDs and ovarian cancer survival from electronic medical records Clinical Cancer Research. Proceedings of the 10th Biennual Ovarian Cancer Research Symposium, United States

82. McMenamin UC, Cardwell CR, and Hughes CM, et al (2015) Low-dose aspirin and survival from lung cancer: a population-based cohort study BMC Cancer 15 911 https://doi.org/10.1186/s12885-015-1910-9

83. Nagle CM, Ibiebele TI, and DeFrazio A, et al (2015) Aspirin, non-aspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival Cancer Epidemiol 39 196–199 https://doi.org/10.1016/j.canep.2014.12.010 PMID: 25666512

84. Bar D, Lavie O, and Stein N, et al (2016) The effect of metabolic co-morbidities and commonly used drugs on the prognosis of patients with ovarian cancer Eur J Obstet Gynaecol Reprod Biol 207 227–231 https://doi.org/10.1016/j.ejogrb.2016.09.005

85. Merritt MA, Rice MS, and Barnard ME, et al (2018) Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study Lancet Oncol 19 1107–1116 https://doi.org/10.1016/S1470-2045(18)30373-5 PMID: 30029888 PMCID: 6242286

86. Verdoot F, Kjaer SK, and Dehlendorff C, et al (2018) Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study Br J Cancer 118 611–615 https://doi.org/10.1038/bjc.2017.449

87. Matuso K, Cahoon SS, and Yoshihara K, et al (2016) Association of low-dose aspirin and survival of women with endometrial cancer Obstet Gynecol 128 127–137 https://doi.org/10.1097/AOG.0000000000001491

88. MacFarlane TV, Murchie P and Watson MC (2015) Aspirin and other non-steroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer Cancer Epidemiol 39 1015–1022 https://doi.org/10.1016/j.canep.2015.10.030 PMID: 26590503

89. Sperling CD, Verdoodt F, and Aalborg G, et al (2019) Low-dose aspirin use and endometrial cancer mortality – a nationwide cohort study Pharmacoepidemiol Drug Saf 2 194–195

90. Kim SA, Roh JL, and Kim SB, et al (2017) Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up Int J Clin Oncol 23(1) 52–58 https://doi.org/10.1007/s10147-017-1165-3

91. Hedberg ML, Peyser ND, and Bauman JE, et al (2019) Use of nonsteroidal anti-inflammatory drugs predicts improved patients survival for PIC3CAaltered head and neck cancer J Exp Med 216 419–427 https://doi.org/10.1084/jem.20181936 PMID: 30683736 PMCID: 6363423

92. Lumley CJ, Kaffenberger TM, and Desale S, et al (2018) Post-diagnostic aspirin use and survival in veterans with head and neck cancer Head Neck 41 1220–1226 https://doi.org/10.1002/hed.25518

93. Li JH, Wang Y, and Xie XY, et al (2019) Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pair analysis Am J Cancer Res 6 2109–2116

94. Maddison P (2017) Effects of aspirin on small-cell lung cancer mortality and metastatic presentation Lung Cancer 106 67–69 https://doi.org/10.1016/j.lungcan.2017.01.018 PMID: 28285696

95. Erickson P, Gardner LD, and Loffredo CA, et al (2018) Racial and ethnic differences in the relationship between aspirin use and non-small cell lung cancer risk and survival Cancer Epidemiol Biomarkers Prev 27 1518–1526 https://doi.org/10.1158/1055-9965.EPI-18-0366 PMID: 30171037 PMCID: 6279562

96. Chuang, Hsieh M, and Tsai Y et al (2018) Survival benefit associated with aspirin use in inoperable non-small cell lung cancer patients: a population-based retrospective cohort study Am J Respir Crit Care Med 197 A6420

97. Spence AD, Busby J, and Johnson BT, et al (2017) Low-dose aspirin use does not increase survival in 2 independent population based cohort of patients with Esophageal or gastric cancer Gastroenterol 154 849–860 https://doi.org/10.1053/j.gastro.2017.10.044

98. Lyon TD, Frank I, and Shah PH, et al (2018) The association of aspirin use with survival following radical cystoscopy Urology 200 1014–1021 https://doi.org/10.1016/j.juro.2018.05.119

99. Rachidi S, Wallace K, and Li H, et al (2018) Postdiagnosis aspirin use and overall survival in patients with melanoma. J Am Acad Dermatol 78 949–956 https://doi.org/10.1016/j.jaad.2017.12.076 PMID: 29317280

100. Seliger C, Schaertl J, and Gerken M, et al (2018) Use of statins or NSAIDs and survival of patients with high grade glioma PLoS One 13 e0207858 https://doi.org/10.1371/journal.pone.0207858

101. Jackson S, Pleiffer RM, and Liu Z, et al (2019) Association between aspirin use and biliary tract cancer survival JAMA Oncol 5 1802–1804 https://doi.org/10.1001/jamaoncol.2019.4328 PMID: 31621809 PMCID: 6802421

102. Luo SD, Chen WC, and Wu CN, et al (2020) Low-dose aspirin use significantly improves the survival of late-stage NPC: a propensity score-matched conort study in Taiwan Cancers 12 1551 https://doi.org/10.3390/cancers12061551

103. Simon TG, Duberg AS, and Aleman S et al (2020) Association of aspirin with hepatocellular carcinoma and liver-related mortality N Engl J Med 382 1018–1028 https://doi.org/10.1056/NEJMoa1912035 PMID: 32160663 PMCID: 7317648

104. Rafei H, LumleyC, and Han J et al (2017) Aspirin use and survival in head and neck squamous cell cancer (HNC) patients J Clin Oncol 35 (15 suppl) 6042 https://doi.org/10.1200/JCO.2017.35.15_suppl.6042

105. Reimers MS, Bastiaannet E, and Langley RE, et al (2014) Expression of HLA class 1 antigen, aspirin use and survival after a diagnosis of colon cancer JAMA Intern Med 174 732–739 https://doi.org/10.1001/jamainternmed.2014.511 PMID: 24687028

106. van Staald-uinen J, Frouws M, and Reimers M, et al (2016) The effect of aspirin and non-steroidal anti-inflammatory drug use after diagnosis on survival of eosophageal cancer patients Br J Cancer 114 1053–1059 https://doi.org/10.1038/bjc.2016.65

107. Cardwell CR, Flahavan EM, and Hughes CM, et al (2014) Low-dose aspirin and survival in men with prostate cancer: a study using the UK clinical practice research datalink Cancer Causes Control 25 33–43 https://doi.org/10.1007/s10552-013-0306-x

108. Fontaine E, McShane J, and Page R, et al (2010) Aspirin and non-small cell lung cancer resections: effect on long-term survival Eur J Cardiothorac Surg 38 21–26 https://doi.org/10.1016/j.ejcts.2010.01.015 PMID: 20359903

109. Din FVN, Theodoratou E, and Farrington SM, et al (2010) Effect of aspirin and NSIADs on risk and survival from colorectal cancer Gut 59 1670–1679 https://doi.org/10.1136/gut.2009.203000 PMID: 20844293

110. Bowers LW, Maximo LXF, and Brenner AJ, et al (2014) NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions Cancer Res 74 4446–4457 https://doi.org/10.1158/0008-5472.CAN-13-3603 PMID: 25125682

111. Murray LJ, Cooper JA, and Hughes CM, et al (2014) Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK clinical practice research datalink Breast Cancer Res 16 R34 https://doi.org/10.1186/bcr3638 PMID: 24708725 PMCID: 4053148

112. Pastore AL, Palleschi G, and Fuschi A, et al (2015) Can daily intake of aspirin and /or statins influence the behaviour of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection BMC Cancer 15 120 https://doi.org/10.1186/s12885-015-1152-x

113. Bandrup L. (2015) Drugs with potential chemopreventive properties in relations to epithelial ovarian cancer – a nationwide case-control study Dan Med J 62(7) B5117

114. Gupta R, Das RK, and Gupta S, et al (2017) Role of aspirin in patients with bladder cancer receiving intravesical BCG: a prospective observational study J Clin Diagn Res 11 PC01–PC04

115. Holmes MD, Olsson H, and Pawitan Y, et al (2014) Aspirin intake and breast cancer survival – a nationwide study using prospectively recorded data in Sweden BMC Cancer 14 391–398 https://doi.org/10.1186/1471-2407-14-391

116. Kwan ML, Habel LA, and Slattery ML, et al (2007) NSAIDs and breast cancer recurrence in a prospective cohort study Cancer Causes Control 18 613–612 https://doi.org/10.1007/s10552-007-9003-y PMID: 17404892 PMCID: 3461348

117. Albandar HJ, Markert R, and Agarawal S (2018) The relationship between aspirin use and mortality in colorectal cancer J Gastroentest Oncol 9 133–137

118. Pretzsch E, d’Haese JG, and Renz B, et al (2021) Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matched analysis BMC Surg 21 98 https://doi.org/10.1186/s12893-021-01083-9 PMID: 33618686 PMCID: 7901208

119. Boas FE, Brown KT, and Ziv E, et al (2019) Aspirin is associated with improved liver function after embolization of hepatocellular carcinoma Am J Roentgenol 213 1–7 https://doi.org/10.2214/AJR.18.20846

120. National institute for Clinical Excellence (2019) Consider daily aspirin, to be taken for more than 2 years years, to prevent colorectal cancer in people with the Lynch syndrome [https://www.nice.org.uk/search?q=Aspirin+and+the+Lynch+Syndrome]

121. Chubak J, Kaminebi A, and Buist DSM et al (2015) Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. preventive services task force. Evidence syntheses, No. 133 Kaiser Permanente Research Affiliates Evidence-based Practice Center, Rockville (MD): Agency for Healthcare Research and Quality; Report No.: 15-05228-EF-1); USSep 2015

122. Morgan G (2009) Aspirin for primary prevention of vascular events Public Health 123 787–788 https://doi.org/10.1016/j.puhe.2009.10.007 PMID: 19914670

123. Elwood P (2014) Aspirin prophylaxis: putting gut bleeds into perspective Gastroenterol Hepatol 10 61–62

124. Thorat MA and Cuzick J (2015) Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population Eur J Epidemiol 30 5–18 https://doi.org/10.1007/s10654-014-9971-7

125. Patrono C, Garcia Rodriguez LA, and Landolfi R, et al (2005) Low dose aspirin for the prevention of atherosclerosis N Engl J Med 353 2373–2383 https://doi.org/10.1056/NEJMra052717 PMID: 16319386

126. Elwood PC, Morgan G, and Galante J, et al (2016) Systematic review and meta-analysis of randomised trials to ascertain fatal gastrointestinal bleeding events attributable to preventive low-dose aspirin: no evidence of increased risk PLoS One 11 e0166166 https://doi.org/10.1371/journal.pone.0166166 PMID: 27846246 PMCID: 5113022

127. Antithrombotic Trialists’ Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 1849–1860 https://doi.org/10.1016/S0140-6736(09)60503-1 PMID: 19482214 PMCID: 2715005

128. Lanas A, Wu P, and Medin J, et al (2011) Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis Clin Gastroenterol Hepatol 9 762–768 https://doi.org/10.1016/j.cgh.2011.05.020 PMID: 21699808

129. McQuaid KR and Laine L (2006) Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomised controlled trials Am J Med 119 624–638 https://doi.org/10.1016/j.amjmed.2005.10.039 PMID: 16887404

130. Wu C, Alotaibi GS, and Alsaleh K, et al (2015) Case-fatality of recurrent venous thromboenbolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention Thromb Res 135 243–248 https://doi.org/10.1016/j.thromres.2014.10.033

131. Mahady SE, Margolis KL, and Chan A, et al (2020) Major gastrointestinal bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial Gut 70(4) 8

132. Cuzick J, Thorat MA, and Bosetti C, et al (2015) Estimates of benefits and harms of prophylactic use of aspirin in the general population Ann Oncol 26(1) 47–57 https://doi.org/10.1093/annonc/mdu225 PMCID: 4269341

133. Hansson L, Zanchetti A, and Carruthers SG, et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) trial. HOT study group Lancet 351 1755–1762 https://doi.org/10.1016/S0140-6736(98)04311-6 PMID: 9635947

134. Murphy L, Brown C, & Smith A, et al (2019) End-of-life prescribing of aspirin in patients with breast ot colorectal cancer Support Palliat Care 9 e6 https://doi.org/10.1136/bmjspcare-2017-001370

135. Dixon SC, Nagle CM, and Wentzensen N, et al (2017) Use of common analgesic medications and ovarian cancer survival: results for a pooled analysis in the overian cancer association consortium Br J Cancer 116 1223–1228 https://doi.org/10.1038/bjc.2017.68 PMID: 28350790 PMCID: 5418444

136. Sturgeon KM, Deng L, and Bluethmann SM, et al (2019) A population based study of cardiovascular disease mortality risk in US cancer patients Eur Heart J 40 3889–3897 https://doi.org/10.1093/eurheartj/ehz766 PMID: 31761945 PMCID: 6925383

137. Elwyn G, Tilburt J and Montori VM (2012) The ethical imperative for shared decision making Eur J Person Centred Healthc 1 129–131 https://doi.org/10.5750/ejpch.v1i1.645

138. Chan M (2010) Cancer in developing countries: facing the challenge [https://www.who.int/dg/speeches/2010/iaea_forum_20100921/en/]


Supplementary materials

Supplementary File 1. Search strategy.

SUPPLEMENTARY FILE 1

ASPIRIN AND CANCER SURVIVAL IA systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers

Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante, Janet Pickering, John Watkins, Alison Weightman, Delyth Morris

Search strategy

Search strategy developed using the following search filters for study design.

• Observational studies: SIGN filter (http://www.sign.ac.uk/methodology/filters.html#obs)

• Randomised controlled trials: Cochrane highly sensitive search filter (http://handbook.cochrane.org/chapter_6/box_6_4_c_cochrane_hsss_2008_sensmax_ovid.htm)

MEDLINE and Medline in Process (searched 11 March 2020)

1. randomized controlled trial.pt.

2. controlled clinical trial.pt.

3. randomized.ab.

4. placebo.ab.

5. drug therapy.fs.

6. randomly.ab.

7. trial.ab.

8. groups.ab.

9. or/1-8

10. Epidemiologic studies/

11. exp case control studies/

12. exp cohort studies/

13. Case control.tw.

14. (cohort adj (study or studies)).tw.

15. Cohort analy*.tw.

16. (Follow up adj (study or studies)).tw.

17. (observational adj (study or studies)).tw.

18. Longitudinal.tw.

19. Retrospective.tw.

20. Cross sectional.tw.

21. Cross-sectional studies/

22. or/10-21

23. 9 or 22

24. exp animals/ not humans.sh.

25. 23 not 24

26. Exp neoplasms/

27. (cancer* or malign* or tumour* or tumor*).tw

28. 26 or 27

29. Aspirin/

30. (aspirin* or “acetylsalicylic acid”).tw

31. 29 or 30

32. 25 and 28 and 31

33. Limit 32 to ed”20180529-20200311”

EMBASE (searched 11 March 2020)

1. Random*.tw

2. Clinical trial*.mp

3. Exp health care quality/

4. placebo.ab.

5. or/1-4

6. clinical study/

7. case control study/

8. family study/

9. longitudinal study/

10. retrospective study/

11. prospective study/

12. Cohort analysis/

13. (Cohort adj (study or studies)).mp.

14. (Case control adj (study or studies)).tw.

15. (follow up adj (study or studies)).tw.

16. (observational adj (study or studies)).tw.

17. (epidemiologic* adj (study or studies)).tw.

18. (cross sectional adj (study or studies)).tw.

19. or/6-18

20. 5 or 19

21. exp animal/ not human.sh.

22. 20 not 21

23. Exp neoplasms/

24. (cancer* or malign* or tumour* or tumor*).tw

25. 23 or 24

26. Aspirin/

27. (aspirin* or “acetylsalicylic acid”).tw

28. 26 or 27

29. 22 and 25 and 28

30. Limit 29 to “year = Aug 2017 to March 2020”

Supplementary File 2. Details of the new studies included in the review.

A systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers

Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante, Janet Pickering, John Watkins, Alison Weightman, Delyth Morris

SUPPLEMENTARY FILE 2

Description of papers identified in the 2021 literature search.

Those which reported Hazard Ratios (HRs) are shown first, followed by those which reported RRs, OR, etc.

Details of papers identified in the literature searches in 2016 are given in Elwood et al [7] and those identified in the 2018 search are given in Elwood et al [20].

1. Studies in which results are reported as hazard ratios

Reports on ‘other’ cancers, described in our report published in 2016 (Elwood et al [7]):

[83] Nagle et al (2015) Ovarian cancer

[108] Fontaine et al (2010) Lung cancer

[112] Pastore et al (2015) Bladder cancer

[80] Chae et al (2013) Mix of female cancers

[79] Chae et al (2014) Lymphocytic cancer

[88] McFarlaine et al (2015) Head and neck

Reports on ‘other’ cancers, described in our report published in 2018 (Elwood et al [20]):

[84] Bar et al (2016) Ovarian cancer

[87] Matuso et al (2016) Endometrium

[93] Li et al (2016) Liver cancer

[39] Veitonmaki et al (2016) Lung

[94] Maddison et al (2017 Lung

[90] Kim et al (2018) Head and neck

2. Studies in which results are reported as RRs, ORs, etc.

Supplementary File 3. Results: estimates of association: aspirin and mortality.

A systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers

Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante, Janet Pickering, John Watkins, Alison Weightman, Delyth Morris

SUPPLEMENTARY FILE 3

Results of studies identified in the 2021 literature search.

Those which reported Hazard Ratios (HRs) are shown first, followed by those which reported RRs , OR, etc.

Results of studies identified in the literature searches in 2016 are given in Elwood et al [7] and those identified in the 2018 search are given in Elwood et al [20]

1. Studies in which results are reported as hazard ratios

Papers on ‘other’ cancers, described in our report published in 2016 (Elwood et al [7]):

Nagel et al [83] (2015)

Fontaine et al [108] (2010)

Pastore et al [112] (2015)

Chae et al [80] (2013)

Chae et al [79] (2014)MacFarlane et al [88] (2015)

Papers on ‘other’ cancers, described in our report published in 2018 (Elwood et al [20]):

Bar et al [84] (2016)

Matuso et al [87] (2016)

Li et al [93] (2016)

Veitonmaki et al [39] (2015)

Maddison et al [94] (2017)

Kim et al [90] (2017)

2. Studies in which results are reported as RRs, ORs, etc.

Supplementary File 4. Forest plots for estimates of aspirin and mortality as HRs.

Supplementary file 4

ASPIRIN AND CANCER SURVIVAL I.

A systematic review and meta-analyses of 117 observational studies of aspirin and 18 cancers

Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante, Janet Pickering, John Watkins, Alison Weightman, Delyth Morris

Five forest plots of aspirin and deaths from cancer: Colon, breast, prostate, other cancers, all cancers

Five forest plots of aspirin and deaths from all-causes: Colon, breast, prostate, other cancers, all cancers


Aspirin and Colon Cancer Mortality


Aspirin and Breast Cancer Mortality


Aspirin and Prostate Cancer Mortality


Aspirin and Cancer Mortality in Other Cancers


Aspirin and Cancer Mortality in All Cancers Combined


Aspirin and Colon Cancer, All-Cause Mortality


Aspirin and Breast Cancer, All-Cause Mortality


Aspirin and Prostate Cancer, All-Cause Mortality


Aspirin and All-Cause Mortality in Other Cancers


Aspirin and All-Cause Mortality in All Cancers

Supplementary File 5. Forest plots for aspirin and mortality as ratios other than HR.

ASPIRIN AND CANCER SURVIVAL I.

A systematic review and meta-analyses of 114 observational studies of aspirin and 18 cancers

Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante, Janet Pickering, John Watkins, Alison Weightman, Delyth Morris

Supplementary file 5

Associations reported a ORs RRs and percentage survival all converted to ORs


Cancer-specific mortality

All cancers

Other cancers

Breast cancer


All-cause mortality

All cancers

Other cancers

Supplementary File 6. Estimates of publication bias.


All cancers combined

All cancers combined mortality

13 cases added with Trim and fill

All Cancers Combined Cancer mortality:

Trim and Fill and Cumulative forest plot ranked by SE with trim and fill.

Forest plot in order of SE with trim and fill mirrored studies added below.

Cumulative forest plot ranked by SE with Trim and fill at end.

Published value 0.79 (0.73, 0.84)

Results with trim and fill 0.85 (0.79, 0.91)

Results are robust with trim and fill.

All Cancers Combined All-Cause Mortality

19 cases added with Trim and fill

All Cancers Cancer All-Cause mortality:

Trim and Fill and Cumulative forest plot ranked by SE with trim fill

Forest plot ranked by SE with trim and fill mirrored studies added below.

Cumulative forest plot ranked by SE with Trim and fill at end.

Published value 0.80 (0.74, 0.86)

Results with trim and fill 0.94 (0.87, 1.02)

Results are not robust with trim and fill.


Breast Cancer

Breast Cancer Mortality

Six cases added with Trim and fill

Breast Cancer Mortality:

Trim and Fill and Cumulative forest plot ranked by SE with trim fill

Forest plot ranked by SE with trim and fill mirrored studies added below.

Cumulative forest plot ranked by SE with Trim and fill at end.

Published value 0.84 (0.72, 0.98)

Results with trim and fill 1.00 (0.85, 1.19)

Results are not robust with trim and fill.

Breast Cancer All-Cause Mortality

Zero cases added with Trim and Fill

Breast Cancer All-Cause mortality:

Trim and Fill and Cumulative forest plot ranked by SE with trim fill

Forest plot ranked by SE.

No Trim and fill as no cases added.

Cumulative forest plot ranked by SE. No Trim and fill.

Published value 0.94 (0.70, 1.25)

The same

Non-effect is robust with trim and fill.


Colon Cancer

Colon Cancer Mortality,

No cases added with Trim and fill

Colon Cancer mortality: Cumulative forest plot ranked by SE.

Published value 0.72 (0.63, 0.82)

Colon results are robust.

Colon Cancer All-Cause Mortality

Eight cases added with Trim and fill

Colon Cancer All-Cause mortality:

Trim and Fill and Cumulative forest plot ranked by SE with trim fill

Forest plot ranked by SE with trim and fill mirrored studies added below.

Cumulative forest plot ranked by SE with Trim and fill at end.

Published value 0.83 (0.75, 0.92)

Results with trim and fill 0.97 (0.87, 1.07)

Results are not robust with trim and fill.


Other Cancers

Other Cancers Mortality

Five cases added with Trim and fill

Other Cancers Cancer mortality:

Trim and Fill and Cumulative forest plot ranked by SE with trim fill

Forest plot ranked by SE with trim and fill mirrored studies added below.

Cumulative forest plot ranked by SE with Trim and fill at end.

Published value 0.79 (0.70, 0.88)

Results with trim and fill 0.86 (0.77, 0.98)

Results are robust with trim and fill.

Other Cancers All-Cause Mortality

Seven cases added with Trim and fill.

Other Cancers All-Cause Mortality

Trim and Fill and Cumulative forest plot ranked by SE with trim fill

Forest plot ranked by SE with trim and fill mirrored studies added below.

Cumulative forest plot ranked by SE with Trim and fill at end.

Published value 0.67 (0.60, 0.75)

Results with trim and fill 0.74 (0.66, 0.83)

Results are robust with trim and fill.


Prostate Cancer

Prostate Cancer Mortality

Six cases added with Trim and fill.

Prostate Cancer mortality

Trim and Fill and Cumulative forest plot ranked by SE with trim fill

Forest plot ranked by SE with trim and fill mirrored studies added below.

Cumulative forest plot ranked by SE with Trim and fill at end.

Published value 0.89 (0.78, 1.02)

Results with trim and fill 1.00 (0.87, 1.14)

Non-effect is robust with trim and fill.

Prostate Cancer All-Cause Mortality

Two cases added with Trim and Fill

Prostate Cancer All-Cause mortality:

Trim and Fill and Cumulative forest plot ranked by SE with trim fill

Forest plot ranked by SE with trim and fill mirrored studies added below.

Cumulative forest plot ranked by SE with Trim and fill at end.

Published value 1.00 (0.78, 1.27)

Results with trim and fill 1.13 (0.88, 1.43)

Non-effect is robust with trim and fill.

Egger’s test

On ORs for 10+ studies of cancer-specific mortality meta-analysis for all cancers

Regression-based Egger test for small-study effects

Random-effects model

Method: REML

H0: beta1 = 0; no small-study effects

beta1 = -0.79

SE of beta1 = 1.180

z = -0.67

Prob > |z| = 0.5011 (this is the p value)

No evidence of publication bias.

Chrome OS was born 10 years ago. Here are the highlights in its rise to power

Ten years ago to this date, the computing world was forever changed. But it wasn’t because of something that was done by Apple or Microsoft. Rather, it was Google.

On June 15, 2011, the first public version of Chrome OS was released. It was initially foreign to a lot of technology journalists, but it ended up ushering in a new type of operating system that is now entrenched in schools, businesses, and even your home.

In the 10 years since its debut, ChromeOS has really evolved. It’s moved past just running a web browser as your operating system to becoming something with features that rival MacOS and even Windows 10. Happy birthday, Google Chrome OS! Here’s a little look at your journey to celebrate.

Born from a web browser

When Chrome OS was first released to the public in 2011, (following its preview as Chromium OS in 2009), Google banked on the success it saw with the Chrome web browser. Chrome OS was literally designed as an extension of Chrome. It was a full-on OS that consisted of a web browser and a web browser only. It wasn’t your traditional operating system.

There were no programs to download or constant updates to check for. Everything in Chrome OS was based on the web, with “links” to your content, known as web apps. The Chrome user interface provided you to access the web.

Google had introduced its own take on cloud computing to consumers. That is a system where most of your content lives online, away from an actual device running the OS. That might have sounded foreign, but that was part of what made Chrome OS unique. It meant that devices with Chrome OS, which we’ve come to know as Chromebooks, booted in seconds.

Unlike the extensive setup required on Windows PCs, it also meant Chrome OS devices were also completely shareable in seconds with a guest mode. Chrome Web Apps, extensions, and all of your content depended on access to Wi-F, the web, and your Google account. Sign in on any Chromebook, and you’ll find all your stuff there.

Chrome OS was secure, without the need for antivirus. You didn’t have to deal with the typical hassles of computing, Nothing but the web, as Google would say.

Google even ended up partnering with laptop makers you’d only see work with Microsoft and Windows to expand the reach of Chrome OS. It was a change for the industry.

Google got manufacturers to buy in on its grand vision of computing, and in July 2011, Samsung and Acer revealed their first Chromebooks. This was a massive leap for Chrome OS, getting the platform off the CR-48 Google device that only select influencers held, away from something that you can install on existing PCs, and into the hands of more consumers via dedicated hardware.

Evolving beyond the web browser

With Chromebooks garnering public interest, as well as criticism from tech reviewers, Google worked hard to push Chrome OS further. Each new Chrome OS release delivered new features and design overhauls of the underlying user interface. The first of those came in 2012 with Chrome OS version 19, known as Aura. This release moved Chrome closer to looking like Windows, pushing it past just a browser with tabs. It introduced a window manager, overlapping windows, a Taskbar, and a launcher for you to access your cloud-based apps. This is the basis for how we know Chrome OS today.

Like Microsoft did with Surface, Google even ended up doing something new. It introduced its own Chrome OS device with the Chromebook Pixel. That was then followed by a shift for the OS in 2016 when Google announced it would bring Android Google Play to select Chrome OS devices. Prior to that, in 2013, Google introduced the ability to run Linux apps through the Crouton utility. Google topped things off with the announcement of the ability to run native Linux apps in 2018.

With popularity up, ChromeOS was becoming much more than just a web browser that runs on top of a device. It was evolving into a full-blown MacOS- and Windows-like operating system.

Clearly, Google needed special hardware for it, so Google went on to launch its own Chrome OS device, the Google Pixelbook, in 2018. That was followed by the Pixel Slate, as well as the Pixelbook Go.

To pair up hardware with software, Google added touch-friendly features, a tablet mode, and many other things to Chrome OS, getting it to the point where we are today. It even brought over the Google Assistant to Chromebooks in late 2019, unlocking the power of Google’s A.I. on all Chrome OS devices.

And what about Windows? Well, Google worked with its partners at Parallels to bring Windows apps to select Chromebooks, even when offline. What a journey!

Taking on Windows and MacOS

Over 10 years, Google has had a lot of success with Chrome OS. A report from the International Data Corporation finds that Chromebooks make up more than 26% of all computer sales in the U.S. Another study finds that Chromebooks feature the second-most popular user-oriented OS, ahead of MacOS and only behind Windows.

A lot of that is largely due to the pandemic and Chromebooks being affordable, but there’s no doubt that Chrome OS and Chromebooks are on their way to the top eventually. Microsoft even attempted to mimic Chrome OS with a lightweight web-based OS known as Windows 10X, but the project was canned. And Google is even learning from Microsoft and Apple. Google introduced features like Phone Hub, which aims to bring your Android phone closer to your Chromebook.

There are even rumors that Google might separate Chrome out of Chrome OS, morphing the OS into its own entity. No doubt, Chrome OS is growing big, and off to new places for the next 10 years.

Editors’ Recommendations




Teen gunned down in Scarborough – Toronto Sun

Article content

A teenager was shot to death Saturday afternoon at a Scarborough highrise.

Article content

Toronto Police say the deadly shooting occurred on Antrim Cr., near Kennedy Rd. and Hwy. 401.

Officers responded to reports that someone had been shot and found a teenager suffering from life-threatening gunshot wounds at the scene.

Officers performed CPR and the patient was taken on an emergency run to the hospital where he was pronounced dead.

We apologize, but this video has failed to load.

Homicide detectives have taken charge of the investigation into what is expected to be the city’s 35th murder of the year.

Anyone with any information regarding this killing is urged to call the Homicide unit at 416-808-7400 or Crime Stoppers at 1-800-222-TIPS.

jstevenson@postmedia.com

4 Penny Stocks Reddit Traders Are Buying Right Now

Top Reddit Penny Stocks to Watch in 2021

Looking at the top penny stocks to buy on Reddit can be a great strategy in 2021. However, it’s worth noting that the highly speculative nature of all penny stocks tends to be even greater when we add in the social media factor. But, if speculation and volatility are what you’re after, these penny stocks could be right for you. 

One thing to consider is what exactly is affecting the stocks movement. Did a new piece of news come out? Is a balance sheet on the horizon? These are important questions to ask yourself that will help to determine the right point to buy or sell penny stocks

The next thing to consider is its status as either a short squeeze penny stock or a meme penny stock. These two terms are not new, however they have come into play in 2021. On one hand, short squeeze penny stocks are those that many investors are betting against. 

[Read More] Is Making Money With Penny Stocks Possible in 2021?

This is something we saw with AMC stock, GME stock, and BB stock this year. But, just because a penny stock is highly shorted, does not mean that it will rise meteorically like the three stocks mentioned above. A meme penny stock on the other hand is one that is highly talked about on social media. 

This could be due to large social sentiment, an emotional connection to it, or just the fact that it is flat out trending. While all of these items will play a role in the price of a penny stock, knowing which one has the most impact will put you ahead of the competition. All things considered, here are four penny stocks that Reddit traders are buying right now. 

4 Reddit Penny Stocks to Watch Right Now

  1. Tellurian Inc. (NASDAQ: TELL
  2. Obalon Therapeutics Inc. (NASDAQ: OBLN
  3. Conformis Inc. (NASDAQ: CFMS
  4. Clearside Biomedical Inc. (NASDAQ: CLSD

Tellurian Inc. (NASDAQ: TELL)

Tellurian Inc. is a popular energy penny stock that is performing well this week. TELL actively develops its portfolio of natural gas production, liquefied natural gas marketing, and infrastructure assets. Its assets include a 27.6 million tons per annum LNG terminal facility and a pipeline in Louisiana. Currently Tellurian owns 9,373 net acres of natural gas production assets.

This is quite a large amount, and puts Tellurian at the forefront of the energy industry. As the pandemic comes to an end, the demand for energy is increasing substantially. This makes sense given that more people are traveling via planes and cars, adding to the greater demand for fuel. Additionally, the world is still relatively in the early stages of reopening, meaning that the potential could still be on the horizon. 

On June 8th the company announced that it has entered a sale and purchase agreement with Vitol Inc. This agreement is to deliver 3 million tons of liquefied natural gas every year over a 10 year period. This deal has been valued at around $12 billion in revenue over this time.

“Tellurian continues to execute on our plan to market Driftwood LNG volumes on indices that our customers want. Vitol expressed interest in the development of Driftwood early on, and it is fulfilling to finalize this agreement with the world’s largest independent trader of energy.”

The President and CEO of Tellurian, Octavio Simoes

When the announcement was made, TELL stock understandably soared. Although its price did correct in the days following, many believe in the long term potential of this deal and Tellurian. In the past month, shares of TELL have shot up by over 75% and in the past six months by over 240%. Considering this, will TELL stock be on your watchlist this year?

Penny_Stocks_to_Watch_Tellurian_Inc._(TELL_Stock_Chart)

Obalon Therapeutics Inc. (NASDAQ: OBLN)

Obalon Therapeutics is a biotech penny stock that we’ve discussed frequently over the past few months. For those unfamiliar, it develops and commercializes medical devices. Its integrated medical products are aimed at treating obesity and other weight loss needs.

Its flagship product known as the Obalon Balloon System is designed to provide weight loss in a non-invasive way. It is a swallowable capsule that contains an inflatable balloon attached to a micro-catheter. This is a breakthrough product as current methods of obesity treatment are relatively invasive and cost prohibitive.

OBLN can be considered a “meme stock” based on its trading activity and high mentioned across social media. OBLN stock is mentioned frequently on Reddit through communities like r/Robinhoodpennystocks and r/pennystocks. This means that it has achieved a high popularity status among retail traders.

It’s hard to pinpoint exactly why OBLN stock is up by over 280% in the past month and over 480% in the past six months. However, we could attribute some of this bullish momentum to its status as a meme stock. While this alone is not a reason to add OBLN to your buy list, it could be a factor to consider. Additionally, its weight loss products are not yet fully commercialized, meaning that there could be some long term potential left to be discovered. 

Another explanation for its recent movement is the recently completed merger with ReShape Lifesciences. As of today, the merged company now known as ReShape Lifesciences Inc. will trade on the NASDAQ Capital Market beginning on June 16th. This is exciting, and has investors hopeful about the future of the company. So will OBLN stock make your penny stock watchlist this month?

Penny_Stocks_to_Watch_Obalon_Therapeutics_Inc_OBLN_Stock_Chart

Conformis Inc. (NASDAQ: CFMS)

Conformis Inc. is another biotech penny stock showing high market performance lately. While CFMS is not a producer of pharmaceuticals like other biotech companions, it is focused on medical devices. These devices are regarded as being game changers in its respective industry. For some context, Conformis produces, develops, manufactures, and sells joint replacement implants. 

It offers a variety of personalized knee replacement products, such as iTotal CR and iTotal PS. Right now, the alternative to its products are off-the-shelf implants. These are expensive, and often ill-fitting. With its personalized approach, CFMS has the potential to change the way that knee and joint replacement products are used. Conformis has not reported any company specific news recently. But this does not mean the company has been up to nothing. 

[Read More] 3 Penny Stocks To Buy On Robinhood For Under $4 Right Now

On May 20th it presented at the Canaccord Genuity Musculoskeletal conference. On May 26th, Conformis presented at the Oppenheimer MedTech, Tolls & Diagnostics Summit. Despite its lack of recent company-specific news, CFMS does show a lot of potential as a biotech penny stock to watch.

This is due to both its groundbreaking products, issued patents/patents pending, and the future potential of its technology. However, in the past month, Conformis stock has shot up by over 44% and in the past six months, by over 80%. With all of this in mind, CFMS could be an interesting candidate for your penny stocks watchlist.

Penny_Stocks_to_Watch_Conformis_Inc._(CFMS_Stock_Chart)

Clearside Biomedical Inc. (NASDAQ: CLSD)

Following an exciting announcement made recently, shares of CLSD stock have shot up by over 26% in the past five days. But before we dive into this update, let’s look at what this company does. Clearside Biomedical is a company developing and delivering treatments for the restoration and preservation of vision for people with serious eye diseases. One of its products, CLS-AX, is an axitinib-type drug for suprachoroidal injection in Phase I/2a clinical trial.

On June 15th, Clearside released positive safety results from cohort 1 of OASIS Phase 1/2a clinical trial of CLS-AX. This is what has caused shares of the company to rise more than 35% at one point during the trading day on June 15th. The company’s trading volume also stood around 407% higher than its average. In the past month, shares of CLSD stock are up by over 63% despite its small correction on June 16th. 

“We are very encouraged by the Cohort 1 results of the OASIS trial and we are immediately beginning Cohort 2 enrollment as planned. The initial data from Cohort 1 clearly achieved our safety and tolerability endpoints.

While still early and recognizing there are a limited number of patients, we believe the Cohort 1 data supports our hypothesis that the combination of targeted and compartmentalized suprachoroidal delivery and the potent pan-VEGF attributes of axitinib may facilitate an effective treatment option for patients suffering from wet AMD.”

The Chief Medical Officer and Chief Development Officer at CLSD Thomas A. Ciulla

With these recent advancements in mind, CLSD could be an interesting candidate for your list of penny stocks to watch. 

Penny_Stocks_to_Watch_Clearside_Biomedical_Inc_CLSD_Stock_Chart

Are Reddit Penny Stocks Worth Buying?

The short answer to this is that it all depends on your strategy. If volatility is what you’re after, buying penny stocks because you found them on Reddit could be a viable option. However, if you’re looking to make short term advancements in your portfolio, it may not be the best choice.

[Read More] 4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now

Investing in penny stocks is all about knowing what type of trader you are. And for that reason, considering your investment and portfolio goals will always be a major benefit. So what do you think, are Reddit penny stocks worth buying?



Midam Ventures, LLC | (305) 306-3854 | 1501 Venera Ave, Coral Gables, FL 33146 | news@pennystocks.com

Crossword blog: a month of special weekend puzzles when it’s OK to phone a friend

Crossword blog

In the Sunday Telegraph and the i newspaper, July weekends of ‘barred’ puzzles belong to their female setters

Mon 21 Jun 2021 11.18 BST

At the weekend, a different kind of crossword emerges. There are no black squares. The puzzles have titles. And there are actually instructions, because the answers are often not quite what you’ll be writing in the grid.

We’ve said that 2021 is as good a time as any for trying barred puzzles. To be more specific: July 2021 is the perfect month to make the leap.

Some background: there are more female solvers than male and generations of female editors (at the Telegraph, the New York Times and others) have honed the form, but something we note here now and again is the paucity of women among those who write the things.

Last year, the editor of the i newspaper’s Inquisitor (who sets here as Enigmatist) ran four consecutive puzzles by female contributors Nutmeg, Vismut, Chalicea and Skylark. The name of the event – Ladies’ Month – is so redolent of Wimbledon you can practically smell the barley water.

This July, it’s happening again and the Sunday Telegraph’s Enigmatic Variations is doing the same, including a debut in the series from one Sea-kale. I’m anticipating lots of enjoyable jiggery-pokery and possibly even some connections between the puzzles.

What should you know before diving in? “My advice is to buy the Chambers app,” says Enigmatic Variations editor proXimal, giving us permission to feel OK about using its function where you can type CR?SS?ORD if you’ve got some crossing letters but not the entry itself.

Enigmatist reminds us that not having black squares means that even the weirder words will yield eventually because so many more of the others cross with them. And don’t get bogged down with the special instructions before you start solving, says proXimal: “It is hardly ever the case that even experienced barred-grid solvers understand all of the preamble from the outset.”

Once you get going, help is available. Enigmatist provides a contact address inviting solvers to contact him “at any time” and adds:

Phone a friend, especially one who is a bit more experienced. This is always a good way to learn the ropes. After the solution is published, read the posts on the excellent Fifteensquared and Jon Summers’ idothei.

And proXimal:

Big Dave’s blog provides hints, so that is a great place for new solvers to learn how to approach these puzzles and get guidance on individual clues. Many solvers take days on and off to solve, so putting it down and coming back to it is always a good idea! Keep going back to the preamble and remember to challenge your presumptions, which may not always be correct.

I would add: if you allow yourself to get frightened, that spoils the fun. It’s a lovely feeling, knowing that every time you add an entry, you are probably adding another component of an endgame or trick you had no chance of seeing at the start.

“Feedback was favourable,” says Enigmatist of 2020’s Ladies’ Month and proXimal says he will be following the responses to Enigmatic Variations joining in.

Both editors tell me that there’s been more interest in these things over the past 15 months. If you’re tempted to join in, let us know how you fare. No spoilers!

Holmes loses latest bid to keep Boies documents out of trial – Reuters

Theranos founder Elizabeth Holmes exits Robert F. Peckham U.S. Courthouse after the first day of federal court hearings, in San Jose, California, U.S. May 4, 2021. REUTERS/Kate Munsch

  • Judge upholds finding that firm represented company
  • Trial scheduled to begin in August

The company and law firm names shown above are generated automatically based on the text of the article. We are improving this feature as we continue to test and develop in beta. We welcome feedback, which you can provide using the feedback tab on the right of the page.

(Reuters) – Theranos founder Elizabeth Holmes has lost her latest bid to keep communications involving her and her company’s former law firm, Boies Schiller Flexner, out of her upcoming fraud trial on the grounds that they are shielded by attorney-client privilege.

U.S. District Judge Edward Davila in San Jose, California, on Thursday overruled an objection Holmes lodged last month, leaving in place a magistrate judge’s finding that the disputed documents were not privileged.

Lance Wade and Kevin Downey of Williams & Connolly, lawyers for Holmes, did not immediately respond to requests for comment. Nor did the office of the U.S. Attorney for the Northern District of California, which is prosecuting the case.

Prosecutors say that Holmes and former Theranos chief operating officer Ramesh “Sunny” Balwani defrauded investors and customers by falsely claiming to have developed technology that could run a wide range of tests on a single drop of blood. The defendants have pleaded not guilty.

Holmes has repeatedly sought to exclude communications with Boies Schiller Flexner and its top attorney David Boies from her trial, scheduled to begin next month. The disputed materials include communications between Theranos personnel, including Holmes, and the firm, but none exclusively between Holmes and the firm, according to court documents.

U.S. Magistrate Judge Nathanael Cousins in June found that the documents were not privileged because Boies and his firm represented Theranos, not Holmes.

In her objection to that order, Holmes said that, while she never officially retained the Boies firm, it appeared as counsel of record for her in court proceedings.

Davila, however, said that was not enough to overturn the magistrate judge’s order.

“Given the lack of personal engagement letter or retainer agreement presented and conflicting statements made about David Boies and Boies Schiller’s representation of Theranos and Holmes, the scope and length of the representation remains unclear,” he wrote. “Thus, the court does not find there was clear error committed in relation to the evidence considered when evaluating the scope of Holmes’ attorney-client relationship with Boies Schiller.”

Holmes has also fought, so far unsuccessfully, to keep other key evidence out of the trial, including customer complaints about Theranos tests and a 2016 report from the U.S. Centers for Medicare and Medicaid Services finding extensive quality control issues at the company.

Before its collapse, Theranos was valued at $9 billion and made Holmes, a Stanford University dropout who founded the company in 2003 at age 19, a Silicon Valley star.

The case is U.S. v. Holmes, U.S. District Court, Northern District of California, No. 18-cr-00258.

For the government: Assistant U.S. Attorney Jeff Schenk

For Holmes: Lance Wade and Kevin Downey of Williams & Connolly

Read more:

Holmes’ communications with Boies firm fair game in trial -judge

IN BRIEF: Theranos’ Holmes really doesn’t want jurors seeing Boies emails

Brendan Pierson reports on product liability litigation and on all areas of health care law. He can be reached at brendan.pierson@thomsonreuters.com.

Ex-Eaze consultants sentenced to prison for pot payment scheme – Reuters

Cannabis is seen under a magnifying glass at a Tweed retail store in St John’s, Newfoundland and Labrador, Canada October 17, 2018. REUTERS/Chris Wattie

  • Two men schemed to conceal marijuana purchases using sham merchants
  • Both convicted of conspiracy to commit bank fraud in March
  • Defense highlighted discrepancy between state and federal law on cannabis

(Reuters) – A Manhattan federal judge sentenced two former consultants for Eaze Technologies Inc to prison on Friday for their roles in a scheme to dupe U.S. banks into handling more than $100 million in payments to the online cannabis marketplace.

U.S. District Judge Jed Rakoff sentenced Hamid (Ray) Akhavan, 43, to two and a half years in prison and Ruben Weigand to 15 months in prison. A jury convicted the two men on one count each of conspiracy to commit bank fraud in March.

During the hearings, Rakoff sharply criticized the federal sentencing guidelines, which called for life in prison for Akhavan and up to 24 years for Weigand.

Prosecutors had argued that the $108 million in fraudulently processed payments should be considered a form of loss, which leads to higher recommended sentences under the guidelines.

“It appears to me that there has never been a case where the guidelines have been more irrational, silly and ridiculous than in their application to this case,” Rakoff said. “It boils my blood that the sentencing commission has not learned better.”

Rakoff also ordered Akhavan to pay a $100,000 fine and forfeit $17.2 million, which prosecutors said was what he made on the scheme.

Weigand had agreed after trial to forfeit $384,000 he earned related to the scheme. He was also ordered on Friday to pay a $50,000 fine.

Attorneys for both men had argued for time served. Both defendants had already spent several months in detention.

At trial, prosecutors presented evidence that the two men schemed to disguise payments to Eaze as payments to other sham retailers between 2016 and 2019.

Prosecutors called Akhavan the “mastermind” of the ruse to get the payments past banks and card payment networks, which have policies prohibiting marijuana transactions.

The substance is legal in California, where Eaze operates, but remains illegal under federal law.

Weigand, a German national, opened merchant accounts at European banks for the phony companies, prosecutors said.

The defendants’ lawyers had argued that the U.S. card-issuing banks, which prosecutors had to show were defrauded to win a conviction, did not care whether customers were buying marijuana.

They called witnesses who testified that Eaze customers can still use Visa and Mastercard for payments on the site through a third-party digital wallet provider.

The case is U.S. v. Weigand et al, U.S. District Court, Southern District of New York, No. 1:20-cr-00188.

For the government: Nicholas Folly, Tara La Morte and Emily Deininger of the U.S Attorney’s Office for the Southern District of New York

For Akhavan: William Burck, Christopher Tayback and Sara Clark of Quinn Emanuel Urquhart & Sullivan

For Weigand: Michael Gilbert of Sheppard Mullin, Shriram Harid, Steven Pellechi and Amy Lesperance of Dechert and Michael Artan

Read More:Men who set up payments for ‘Uber of weed’ go to trialMastercard exec says card company sought to avoid marijuana legal riskConsultants convicted of Eaze marijuana payments scheme

Jody Godoy reports on banking and securities law. Reach her at jody.godoy@thomsonreuters.com

Week Ahead in Securities: June 21, 2021 – Reuters

The company and law firm names shown above are generated automatically based on the text of the article. We are improving this feature as we continue to test and develop in beta. We welcome feedback, which you can provide using the feedback tab on the right of the page.

(Reuters) – Here are some upcoming events of interest to the securities law community. Unless otherwise noted, all times are local, and court appearances are virtual due to the COVID-19 pandemic.

Monday, June 21

9:00 a.m. – U.S. District Judge Jon Tigar in Oakland will hold a pretrial conference in a proposed shareholder class action alleging social media giant Twitter inflated its share price in 2015 with misleading statements about its user engagement metrics. While most shareholder lawsuits are dismissed or settle, the case is set for trial in September.

Twitter has denied the allegations. The case is In re Twitter Inc. Securities Litigation No. 16-cv-05314. For plaintiffs: Tor Gronberg of Robbins Geller Rudman & Dowd and others. For Twitter: Kathleen Goodhart of Cooley and others.

10:00 a.m. – Funds invested in mortgage-backed securities will urge the 2nd U.S. Circuit Court of Appeals in New York to reverse a judgment against them in a dispute over proceeds from the $5.4 billion sale of the Stuyvesant Town apartment complex in Manhattan. The Appaloosa Management funds say profit from the sale should have gone to them, because the property’s mortgage was part of the pool they invested in, rather than the loan servicer and lender.

The case is Appaloosa Investment LPI et al. v. Federal Home Loan Mortgage et al., 2nd U.S. Circuit Court of Appeals, No. 20-1708. For Appaloosa: Thomas Redburn Jr of Lowenstein Sandler. For CWC: Gregory Cross of Venable. For FHFA: Christopher Johnson of McKool Smith.

10:00 a.m. – U.S. District Court Judge John Tharp Jr. in Chicago will sentence former Deutsche Bank AG trader James Vorley on seven counts of wire fraud for manipulating the precious metals futures markets by placing fraudulent orders using a tactic known as spoofing. He was convicted alongside former colleague Cedric Chanu in September. Prosecutors have said he should serve more than four years in prison, while Vorley’s attorneys have asked for time served.

The case is U.S. v. Vorley et al., U.S. District Court, Northern District of Illinois, No. 18-cr-00035. For Vorley: Roger Burlingame of Dechert. For the government: Avi Perry of the DOJ Criminal Division, Fraud Section.

Wednesday, June 23

10:00 a.m. – Petróleos de Venezuela SA will urge the 2nd U.S. Circuit Court of Appeals in New York to reverse a $150 million judgment in favor of bondholder Dresser-Rand Company in a dispute over the Vezezuelan state-owned oil company’s default on the notes.

The case is Dresser-Rand Company v. Petroleos de Venezuela SA, 2nd U.S. Circuit Court of Appeals, No. 20-1990. For Dresser-Rand: Kim Watterson of Reed Smith. For PDVSA: Dennis Tracey III of Hogan Lovells US.

Know of an event that could be included in Week Ahead in Securities? Contact Jody Godoy at jody.godoy@thomsonreuters.com

Jody Godoy reports on banking and securities law. Reach her at jody.godoy@thomsonreuters.com

Citing Arthrex, Donziger says private prosecutor unconstitutional – Reuters

Attorney Steven Donziger arrives for his criminal contempt trail at the Manhattan Federal Courthouse, May 10, 2021. REUTERS/Brendan McDermid

  • SCOTUS ruling in United States v. Arthrex basis to “void” case
  • Private prosecutors in criminal case lack proper supervision

The company and law firm names shown above are generated automatically based on the text of the article. We are improving this feature as we continue to test and develop in beta. We welcome feedback, which you can provide using the feedback tab on the right of the page.

(Reuters) – American lawyer Steven Donziger has once again asked a Manhattan federal judge to dismiss his criminal case arising from his battles against Chevron Corp over pollution in the Ecuadorian rainforest, arguing that a U.S. Supreme Court ruling issued earlier this week suggests the private prosecution charging him is unconstitutionally appointed.

In a motion to dismiss filed on Tuesday, Donziger who is charged with criminal contempt argued that the high court’s ruling, which found certain administrative judges’ appointment violate the U.S. Constitution because they lack supervision, should “void” his case because the private prosecutors acting for the United States in his case similarly lack proper supervision.

Lead private prosecutor Rita Glavin did not immediately respond to a request for comment.

Donziger’ criminal case springs from post-judgment orders in a civil case brought by Chevron in which a district judge in 2014 barred enforcement in the United States of a $9.5 billion judgment, which Donziger had won in an Ecuadorian court, against the oil major. U.S. District Judge Lewis Kaplan found the judgment had been obtained through fraud.

The disbarred human rights lawyer is charged, among other things, with failing to turn over his computer, phones and other electronic devices and refusing court orders to surrender his passport in the civil case Chevron won in 2014.

In Tuesday’s motion, Donziger and his attorney Martin Garbus of Offit Kurman argue that the Supreme Court’s June 21 ruling in United States v. Arthrex Inc “ma(kes) all the more clear” the private prosecutor’s appointment is unconstitutional.

The U.S. Department of Justice does not supervise the private prosecution in Donziger’s case, according to the filing.

In the high court’s decision, a slim majority of the justices ruled that the appointment of judges on the Patent Trial and Appeal Board violated a constitutional provision intended to ensure accountability for powerful government officials.

“The same constitutional principles necessarily limit appointments under (the Federal Rules of Criminal Procedure),” Garbus’ motion says.

“It follows that the appointment of the private prosecutor here exceeded the district court’s constitutional authority,” it adds.

Donziger was tried in May after being confined at home for nearly two years amid repeated postponements of his trial due to the coronavirus pandemic and issues with his legal representation.

He faces a maximum of six months behind bars.

The case is United States v. Donziger, U.S. District Court for the Southern District of New York, No. 1:19-cr-00561.

For United States: Rita Glavin of Glavin and Brian Maloney of Seward & Kissel

For Donziger: Martin Garbus of Offit Kurman and Ronald Kuby of the Law Office of Ronald L. Kuby

Read more:

Attorney Donziger, prosecutors clash over contempt charges in pollution case

Lawyer who sued Chevron over Ecuador pollution faces N.Y. contempt trial

Judge ‘reluctantly’ postpones attorney Donziger’s trial for fifth time

Chevron wins U.S. ruling blocking $8.6 billion Ecuador rainforest award

Sebastien Malo reporters on environmental, climate and energy litigation. Reach him at sebastien.malo@thomsonreuters.com

Week Ahead in Securities: July 5, 2021 – Reuters

The company and law firm names shown above are generated automatically based on the text of the article. We are improving this feature as we continue to test and develop in beta. We welcome feedback, which you can provide using the feedback tab on the right of the page.

Here are some upcoming events of interest to the securities law community. Unless otherwise noted, all times are local, and court appearances are virtual due to the COVID-19 pandemic.

Wednesday, July 7

10:00 a.m. – A hearing is scheduled before U.S. District Judge Edward Davila in San Jose on Theranos founder Elizabeth Holmes’ motion to suppress evidence of customer complaints about the company’s blood tests at her upcoming fraud trial. Holmes is accused of defrauding patients and investors by falsely claiming to have developed technology to run dozens of tests on a single drop of blood.

The case is U.S. v. Holmes, U.S. District Court, Northern District of California, No. 18-cr-00258. For the government: Assistant U.S. Attorney Jeff Schenk. For Holmes: Lance Wade and Kevin Downey of Williams & Connolly.

Friday, July 9

9:00 a.m. – Costco investor Fred Davoli will urge the 9th U.S. Circuit Court of Appeals in Seattle to revive his securities class action alleging the bulk retailer had lax cybersecurity and inadequate financial controls.

The case is Davoli v. COSTCO, 9th U.S. Circuit Court of Appeals, No. 20-35821. For Davoli: Nicholas Porritt of Levi & Korsinsky. For Costco: Gregory Watts of Wilson Sonsini Goodrich & Rosati.

3:00 p.m. – U.S. District Judge Virginia Hernandez Covington in Tampa will hold a final pretrial conference ahead of a jury trial in the U.S. Securities and Exchange Commission’s lawsuit against broker-dealer Spartan Securities Group Ltd and others. The SEC alleges that Spartan was part of a scheme to create and sell “blank check” microcap companies that appeared to be actual businesses. The defendants have denied the allegations.

The case is U.S. Securities and Exchange Commission v. Spartan Securities Group LTD et al., U.S. District Court, Middle District of Florida, No. 19-cv-00448. For the SEC: Christine Nestor. For Spartan: Caleb Kruckenberg of the New Civil Liberties Alliance.

Know of an event that could be included in Week Ahead in Securities? Contact Jody Godoy at jody.godoy@thomsonreuters.com

Jody Godoy reports on banking and securities law. Reach her at jody.godoy@thomsonreuters.com


  • bitcoinBitcoin (BTC) $ 39,487.00
  • ethereumEthereum (ETH) $ 2,715.48
  • tetherTether (USDT) $ 1.00
  • binance-coinBinance Coin (BNB) $ 334.53
  • cardanoCardano (ADA) $ 1.38
  • xrpXRP (XRP) $ 0.726588
  • usd-coinUSD Coin (USDC) $ 0.999449
  • dogecoinDogecoin (DOGE) $ 0.200582
  • polkadotPolkadot (DOT) $ 19.26
  • uniswapUniswap (UNI) $ 23.44
  • binance-usdBinance USD (BUSD) $ 1.00
  • chainlinkChainlink (LINK) $ 24.03
  • bitcoin-cashBitcoin Cash (BCH) $ 541.84
  • solanaSolana (SOL) $ 36.52
  • litecoinLitecoin (LTC) $ 141.31
  • wrapped-bitcoinWrapped Bitcoin (WBTC) $ 39,463.00
  • matic-networkPolygon (MATIC) $ 1.05
  • ethereum-classicEthereum Classic (ETC) $ 51.28
  • stellarStellar (XLM) $ 0.276518
  • terra-lunaTerra (LUNA) $ 14.87
  • theta-tokenTheta Network (THETA) $ 6.07
  • vechainVeChain (VET) $ 0.088987
  • daiDai (DAI) $ 1.00
  • internet-computerInternet Computer (ICP) $ 39.15
  • filecoinFilecoin (FIL) $ 56.52
  • compound-usd-coincUSDC (CUSDC) $ 0.022128
  • okbOKB (OKB) $ 18.79
  • tronTRON (TRX) $ 0.069800
  • aaveAave (AAVE) $ 355.91
  • moneroMonero (XMR) $ 248.22
  • cdaicDAI (CDAI) $ 0.021576
  • compound-ethercETH (CETH) $ 54.37
  • ftx-tokenFTX Token (FTT) $ 37.62
  • eosEOS (EOS) $ 4.09
  • pancakeswap-tokenPancakeSwap (CAKE) $ 17.36
  • cosmosCosmos (ATOM) $ 12.81
  • crypto-com-chainCrypto.com Coin (CRO) $ 0.124663
  • the-graphThe Graph (GRT) $ 0.667559
  • shiba-inuShiba Inu (SHIB) $ 0.000006
  • neoNEO (NEO) $ 43.52
  • amp-tokenAmp (AMP) $ 0.061181
  • leo-tokenLEO Token (LEO) $ 3.01
  • klay-tokenKlaytn (KLAY) $ 1.07
  • tezosTezos (XTZ) $ 3.17
  • makerMaker (MKR) $ 2,939.06
  • bitcoin-svBitcoin SV (BSV) $ 139.09
  • algorandAlgorand (ALGO) $ 0.823093
  • celsius-degree-tokenCelsius Network (CEL) $ 5.89
  • compound-governance-tokenCompound (COMP) $ 460.10
  • iotaIOTA (MIOTA) $ 0.863136
  • axie-infinityAxie Infinity (AXS) $ 43.15
  • avalanche-2Avalanche (AVAX) $ 13.66
  • bittorrent-2BitTorrent (BTT) $ 0.003433
  • quant-networkQuant (QNT) $ 173.63
  • thorchainTHORChain (RUNE) $ 7.92
  • elrond-erd-2Elrond (EGLD) $ 106.63
  • terrausdTerraUSD (UST) $ 1.00
  • hedera-hashgraphHedera Hashgraph (HBAR) $ 0.213870
  • staked-etherLido Staked Ether (STETH) $ 2,690.22
  • kusamaKusama (KSM) $ 212.28
  • decredDecred (DCR) $ 134.64
  • huobi-tokenHuobi Token (HT) $ 10.42
  • sushiSushi (SUSHI) $ 8.66
  • dashDash (DASH) $ 161.82
  • theta-fuelTheta Fuel (TFUEL) $ 0.304690
  • havvenSynthetix Network Token (SNX) $ 9.59
  • wavesWaves (WAVES) $ 16.04
  • huobi-btcHuobi BTC (HBTC) $ 39,334.00
  • nemNEM (XEM) $ 0.165830
  • chilizChiliz (CHZ) $ 0.263382
  • blockstackStacks (STX) $ 1.34
  • zcashZcash (ZEC) $ 116.70
  • enjincoinEnjin Coin (ENJ) $ 1.40
  • heliumHelium (HNT) $ 13.41
  • safemoonSafeMoon (SAFEMOON) $ 0.000002
  • true-usdTrueUSD (TUSD) $ 1.00
  • flowFlow (FLOW) $ 21.76
  • yearn-financeyearn.finance (YFI) $ 32,419.00
  • holotokenHolo (HOT) $ 0.006492
  • bitcoin-cash-abc-2Bitcoin Cash ABC (BCHA) $ 59.41
  • bitcloutBitClout (CLOUT) $ 100.01
  • nearNear (NEAR) $ 2.44
  • zilliqaZilliqa (ZIL) $ 0.080869
  • nexoNEXO (NEXO) $ 1.77
  • telcoinTelcoin (TEL) $ 0.017370
  • basic-attention-tokenBasic Attention Token (BAT) $ 0.661647
  • bitcoin-goldBitcoin Gold (BTG) $ 54.73
  • decentralandDecentraland (MANA) $ 0.721445
  • xdce-crowd-saleXDC Network (XDC) $ 0.077263
  • paxos-standardPaxos Standard (PAX) $ 1.00
  • 1inch1inch (1INCH) $ 2.35
  • bancorBancor Network Token (BNT) $ 3.60
  • qtumQtum (QTUM) $ 7.89
  • kucoin-sharesKuCoin Token (KCS) $ 10.42
  • harmonyHarmony (ONE) $ 0.077634
  • siacoinSiacoin (SC) $ 0.015647
  • digibyteDigiByte (DGB) $ 0.051273
  • ethosVoyager Token (VGX) $ 3.35
  • ontologyOntology (ONT) $ 0.843151
  • ankrAnkr (ANKR) $ 0.095629
  • perpetual-protocolPerpetual Protocol (PERP) $ 16.57
  • 0x0x (ZRX) $ 0.858066
  • xsushixSUSHI (XSUSHI) $ 10.11
  • nxmNexus Mutual (NXM) $ 102.84
  • iconICON (ICX) $ 1.08
  • mdexMdex (MDX) $ 1.18
  • zencashHorizen (ZEN) $ 60.39
  • titanswapTitanSwap (TITAN) $ 6.86
  • compound-usdtcUSDT (CUSDT) $ 0.021307
  • ravencoinRavencoin (RVN) $ 0.072401
  • swissborgSwissBorg (CHSB) $ 0.705520
  • fantomFantom (FTM) $ 0.243247
  • omisegoOMG Network (OMG) $ 4.35
  • pirate-chainPirate Chain (ARRR) $ 3.29
  • nanoNano (NANO) $ 4.44
  • umaUMA (UMA) $ 9.51
  • curve-dao-tokenCurve DAO Token (CRV) $ 1.63
  • gatechain-tokenGateToken (GT) $ 3.58
  • iostokenIOST (IOST) $ 0.025251
  • constellation-labsConstellation (DAG) $ 0.232915
  • ecomiECOMI (OMI) $ 0.002868
  • renbtcrenBTC (RENBTC) $ 39,352.00
  • liquity-usdLiquity USD (LUSD) $ 1.01
  • husdHUSD (HUSD) $ 1.00
  • liskLisk (LSK) $ 3.43
  • wazirxWazirX (WRX) $ 1.09
  • reserve-rights-tokenReserve Rights Token (RSR) $ 0.037436
  • arweaveArweave (AR) $ 11.16
  • golemGolem (GLM) $ 0.466042
  • mina-protocolMina Protocol (MINA) $ 2.43
  • ultraUltra (UOS) $ 0.565765
  • the-sandboxThe Sandbox (SAND) $ 0.633937
  • neutrinoNeutrino USD (USDN) $ 1.00
  • kavaKava.io (KAVA) $ 6.05
  • olympusOlympus (OHM) $ 459.22
  • livepeerLivepeer (LPT) $ 16.81
  • pundi-x-2Pundi X (PUNDIX) $ 1.55
  • vergeVerge (XVG) $ 0.023950
  • bitcoin-diamondBitcoin Diamond (BCD) $ 2.10
  • fei-protocolFei Protocol (FEI) $ 1.00
  • republic-protocolREN (REN) $ 0.428202
  • celoCelo (CELO) $ 2.80
  • bakerytokenBakerySwap (BAKE) $ 2.03
  • alien-worldsAlien Worlds (TLM) $ 0.273000
  • skaleSKALE (SKL) $ 0.264127
  • pundi-xPundi X [OLD] (NPXS) $ 0.001354
  • wootrade-networkWootrade Network (WOO) $ 0.663529
  • mediblocMedibloc (MED) $ 0.058922
  • loopringLoopring (LRC) $ 0.252377
  • statusStatus (SNT) $ 0.080690
  • sethsETH (SETH) $ 2,707.19
  • compound-uniswapcUNI (CUNI) $ 0.470060
  • gnosisGnosis (GNO) $ 205.90
  • pax-goldPAX Gold (PAXG) $ 1,815.85
  • chiaChia (XCH) $ 226.06
  • winkWINkLink (WIN) $ 0.000395
  • venusVenus (XVS) $ 27.87
  • nervos-networkNervos Network (CKB) $ 0.010664
  • hbtc-tokenHBTC Captain Token (HBC) $ 14.95
  • maidsafecoinMaidSafeCoin (MAID) $ 0.627081
  • energy-web-tokenEnergy Web Token (EWT) $ 7.18
  • fetch-aiFetch.ai (FET) $ 0.404608
  • oxygenOxygen (OXY) $ 1.37
  • alpha-financeAlpha Finance (ALPHA) $ 0.778348
  • ergoErgo (ERG) $ 6.69
  • waxWAX (WAXP) $ 0.167654
  • ocean-protocolOcean Protocol (OCEAN) $ 0.601940
  • asdAscendEx Token (ASD) $ 0.350409
  • fraxFrax (FRAX) $ 1.00
  • tokamak-networkTokamak Network (TON) $ 6.95
  • tribe-2Tribe (TRIBE) $ 0.589982
  • origin-protocolOrigin Protocol (OGN) $ 0.798229
  • gemini-dollarGemini Dollar (GUSD) $ 1.00
  • ton-crystalTON Crystal (TON) $ 0.409249
  • alchemix-usdAlchemix USD (ALUSD) $ 0.999743
  • tomochainTomoChain (TOMO) $ 2.93
  • audiusAudius (AUDIO) $ 1.13
  • vethor-tokenVeThor Token (VTHO) $ 0.006340
  • dawn-protocolDawn Protocol (DAWN) $ 3.54
  • numeraireNumeraire (NMR) $ 38.51
  • osmosisOsmosis (OSMO) $ 1.76
  • ardorArdor (ARDR) $ 0.240227
  • balancerBalancer (BAL) $ 22.37
  • rocket-poolRocket Pool (RPL) $ 15.80
  • mirror-protocolMirror Protocol (MIR) $ 3.06
  • iexec-rlciExec RLC (RLC) $ 3.33
  • dentDent (DENT) $ 0.002448
  • unibrightUnibright (UBT) $ 1.55
  • polymath-networkPolymath Network (POLY) $ 0.264215
  • band-protocolBand Protocol (BAND) $ 6.47
  • stormStormX (STMX) $ 0.024306
  • injective-protocolInjective Protocol (INJ) $ 6.80
  • my-neighbor-aliceMy Neighbor Alice (ALICE) $ 12.71
  • serumSerum (SRM) $ 4.38
  • persistencePersistence (XPRT) $ 5.91
  • iotexIoTeX (IOTX) $ 0.022350
  • coin98Coin98 (C98) $ 1.13
  • superfarmSuperFarm (SUPER) $ 0.702366
  • alchemixAlchemix (ALCX) $ 365.35
  • prometeusPrometeus (PROM) $ 12.48
  • evolution-financeEvolution Finance (EVN) $ 668.78
  • nusdsUSD (SUSD) $ 1.01
  • raydiumRaydium (RAY) $ 3.44
  • swipeSwipe (SXP) $ 2.29
  • tensetTenset (10SET) $ 2.28
  • reef-financeReef Finance (REEF) $ 0.015482
  • orbsOrbs (ORBS) $ 0.085208
  • anchor-protocolAnchor Protocol (ANC) $ 2.07
  • ethlendAave [OLD] (LEND) $ 3.50
  • steemSteem (STEEM) $ 0.496799
  • uquid-coinUquid Coin (UQC) $ 19.26
  • kleverKlever (KLV) $ 0.035392
  • stratisStratis (STRAX) $ 1.91
  • singularitynetSingularityNET (AGIX) $ 0.227755
  • funfairFUNToken (FUN) $ 0.018064
  • metadiumMetadium (META) $ 0.117374
  • playdappPlayDapp (PLA) $ 1.04
  • civicCivic (CVC) $ 0.277220
  • yield-guild-gamesYield Guild Games (YGG) $ 2.10
  • feg-tokenFEG Token (FEG) $ 0.00000000
  • conflux-tokenConflux (CFX) $ 0.213574
  • akash-networkAkash Network (AKT) $ 2.53
  • arkArk (ARK) $ 1.14
  • illuviumIlluvium (ILV) $ 288.43
  • dodoDODO (DODO) $ 1.30
  • orion-protocolOrion Protocol (ORN) $ 6.20
  • celer-networkCeler Network (CELR) $ 0.032002
  • sapphireSapphire (SAPP) $ 0.292911
  • chromawayChromia (CHR) $ 0.314734
  • secretSecret (SCRT) $ 1.23
  • yfii-financeDFI.money (YFII) $ 4,392.87
  • orchid-protocolOrchid Protocol (OXT) $ 0.294936
  • ampleforthAmpleforth (AMPL) $ 1.03
  • lukso-tokenLUKSO Token (LYXE) $ 11.75
  • nknNKN (NKN) $ 0.264467
  • trust-wallet-tokenTrust Wallet Token (TWT) $ 0.484418
  • kiroboKirobo (KIRO) $ 0.567124
  • cartesiCartesi (CTSI) $ 0.441659
  • augurAugur (REP) $ 25.48
  • ellipsisEllipsis (EPS) $ 0.598055
  • kyber-network-crystalKyber Network Crystal (KNC) $ 1.62
  • kardiachainKardiaChain (KAI) $ 0.063193
  • ledgisLedgis (LED) $ 1.42
  • zkswapZKSwap (ZKS) $ 0.735459
  • allianceblockAllianceBlock (ALBT) $ 0.701885
  • aioz-networkAIOZ Network (AIOZ) $ 0.251745
  • electroneumElectroneum (ETN) $ 0.008690
  • e-radixe-Radix (EXRD) $ 0.139727
  • metaheroMetahero (HERO) $ 0.033120
  • tether-goldTether Gold (XAUT) $ 1,813.39
  • galaGala (GALA) $ 0.020561
  • storjStorj (STORJ) $ 1.07
  • hiveHive (HIVE) $ 0.411460
  • mathMATH (MATH) $ 1.10
  • defipulse-indexDeFiPulse Index (DPI) $ 337.75
  • cream-2Cream (CREAM) $ 192.43
  • render-tokenRender Token (RNDR) $ 0.970710
  • kyber-networkKyber Network Crystal Legacy (KNCL) $ 1.62
  • melonEnzyme (MLN) $ 100.19
  • vectorspaceVectorspace AI (VXV) $ 3.41
  • noia-networkSyntropy (NOIA) $ 0.303051
  • rif-tokenRSK Infrastructure Framework (RIF) $ 0.189505
  • instadappInstadapp (INST) $ 7.88
  • clover-financeClover Finance (CLV) $ 1.10
  • api3API3 (API3) $ 4.19
  • phaPhala Network (PHA) $ 0.767790
  • wpp-tokenWPP Token (WPP) $ 0.045291
  • everipediaEveripedia (IQ) $ 0.013646
  • usdpUSDP Stablecoin (USDP) $ 0.992866
  • smooth-love-potionSmooth Love Potion (SLP) $ 0.215043
  • thorchain-erc20THORChain (ERC20) (RUNE) $ 8.32
  • beldexBeldex (BDX) $ 0.089505
  • escoin-tokenEscoin Token (ELG) $ 2.37
  • wrapped-nxmWrapped NXM (WNXM) $ 60.76
  • ampleforth-governance-tokenAmpleforth Governance Token (FORTH) $ 15.39
  • aragonAragon (ANT) $ 3.76
  • lido-daoLido DAO (LDO) $ 4.68
  • ankrethankrETH (AETH) $ 2,583.76
  • sun-tokenSun Token (SUN) $ 0.025767
  • btc-standard-hashrate-tokenBTC Standard Hashrate Token (BTCST) $ 17.50
  • metalMetal (MTL) $ 1.96
  • keep-networkKeep Network (KEEP) $ 0.290063
  • ethernity-chainEthernity Chain (ERN) $ 11.21
  • badger-daoBadger DAO (BADGER) $ 13.51
  • seursEUR (SEUR) $ 1.19
  • nucypherNuCypher (NU) $ 0.221443
  • linearLinear (LINA) $ 0.044267
  • hxroHxro (HXRO) $ 0.484379
  • power-ledgerPower Ledger (POWR) $ 0.284287
  • auctionBounce (AUCTION) $ 26.73
  • zipmex-tokenZipmex Token (ZMT) $ 1.94
  • oasis-networkOasis Network (ROSE) $ 0.080973
  • aelfaelf (ELF) $ 0.262989
  • bitsharesBitShares (BTS) $ 0.044731
  • deroDero (DERO) $ 11.21
  • sbtcsBTC (SBTC) $ 39,572.00
  • quark-chainQuarkChain (QKC) $ 0.018076
  • tokocryptoTokocrypto (TKO) $ 1.56
  • aavegotchiAavegotchi (GHST) $ 1.97
  • nominexNominex (NMX) $ 4.01
  • unit-protocolUnit Protocol (COL) $ 0.025979
  • arteryArtery (ARTR) $ 1.42
  • newscrypto-coinNewscrypto Coin (NWC) $ 0.741099
  • mask-networkMask Network (MASK) $ 7.06
  • gasGas (GAS) $ 8.16
  • concierge-ioTravala.com (AVA) $ 2.20
  • wanchainWanchain (WAN) $ 0.639414
  • convex-crvConvex CRV (CVXCRV) $ 1.60
  • utrustUTRUST (UTK) $ 0.247742
  • bytomBytom (BTM) $ 0.065751
  • gitcoinGitcoin (GTC) $ 7.81
  • monacoinMonaCoin (MONA) $ 1.35
  • origintrailOriginTrail (TRAC) $ 0.304491
  • compound-0xc0x (CZRX) $ 0.017764
  • district0xdistrict0x (DNT) $ 0.141423
  • safepalSafePal (SFP) $ 0.977177
  • velasVelas (VLX) $ 0.048525
  • stasis-eursSTASIS EURO (EURS) $ 1.18
  • harvest-financeHarvest Finance (FARM) $ 177.93
  • komodoKomodo (KMD) $ 0.816344
  • crypto20CRYPTO20 (C20) $ 3.11
  • hathorHathor (HTR) $ 0.489369
  • apeswap-financeApeSwap Finance (BANANA) $ 2.14
  • thorstarterThorstarter (XRUNE) $ 0.174787
  • rally-2Rally (RLY) $ 0.450041
  • digitalbitsDigitalBits (XDB) $ 0.130442
  • bonfidaBonfida (FIDA) $ 2.01
  • terra-virtua-kolectTerra Virtua Kolect (TVK) $ 0.254568
  • cotiCOTI (COTI) $ 0.146250
  • diviDivi (DIVI) $ 0.039818
  • truefiTrueFi (TRU) $ 0.261513
  • alpaca-financeAlpaca Finance (ALPACA) $ 0.898665
  • rookKeeperDAO (ROOK) $ 163.16
  • frax-shareFrax Share (FXS) $ 2.98
  • reddcoinReddcoin (RDD) $ 0.003131
  • usdxUSDX (USDX) $ 1.00
  • lockchainLockTrip (LOC) $ 5.64
  • paccoinPAC Protocol (PAC) $ 0.005848
  • unfederalreserveunFederalReserve (ERSDL) $ 0.246501
  • syscoinSyscoin (SYS) $ 0.149709
  • rari-governance-tokenRari Governance Token (RGT) $ 10.58
  • fx-coinFunction X (FX) $ 0.331342
  • mainframeHifi Finance (MFT) $ 0.009721
  • stablexswapStableXSwap (STAX) $ 4.58
  • kinKin (KIN) $ 0.000064
  • vaiVai (VAI) $ 0.857655
  • radicleRadicle (RAD) $ 6.38
  • klerosKleros (PNK) $ 0.169356
  • populousPopulous (PPT) $ 2.43
  • boringdao-btcBoringDAO BTC (OBTC) $ 40,087.00
  • litentryLitentry (LIT) $ 3.94
  • compound-basic-attention-tokencBAT (CBAT) $ 0.013620
  • polkastarterPolkastarter (POLS) $ 1.19
  • wozxEfforce (WOZX) $ 0.654505
  • bella-protocolBella Protocol (BEL) $ 1.79
  • insureinSure DeFi (SURE) $ 0.002762
  • hydraHydra (HYDRA) $ 15.23
  • crust-networkCrust Network (CRU) $ 46.34
  • iris-networkIRISnet (IRIS) $ 0.078534
  • barnbridgeBarnBridge (BOND) $ 21.53
  • eth-2x-flexible-leverage-indexETH 2x Flexible Leverage Index (ETH2X-FLI) $ 106.03
  • marketpeakPEAKDEFI (PEAK) $ 0.268867
  • verasityVerasity (VRA) $ 0.012587
  • sora-validator-tokenSora Validator Token (VAL) $ 0.809016
  • carryCarry (CRE) $ 0.009694
  • tellorTellor (TRB) $ 43.76
  • wrapped-centrifugeWrapped Centrifuge (WCFG) $ 0.989485
  • justJUST (JST) $ 0.055817
  • biliraBiLira (TRYB) $ 0.117700
  • lto-networkLTO Network (LTO) $ 0.275736
  • beefy-financeBeefy.Finance (BIFI) $ 1,013.05
  • btse-tokenBTSE Token (BTSE) $ 5.86
  • dao-makerDAO Maker (DAO) $ 2.20
  • xyo-networkXYO Network (XYO) $ 0.009158
  • mcdexMCDEX (MCB) $ 34.35
  • massMASS (MASS) $ 0.792829
  • flex-coinFLEX Coin (FLEX) $ 0.963110
  • thunder-tokenThunderCore (TT) $ 0.009753
  • alchemistAlchemist (MIST) $ 66.58
  • cvault-financecVault.finance (CORE) $ 7,467.03
  • my-defi-petMy DeFi Pet (DPET) $ 6.17
  • zero-collateral-daiZero Collateral Dai (ZAI) $ 0.001090
  • soraSora (XOR) $ 211.91
  • automataAutomata (ATA) $ 0.420938
  • slinksLINK (SLINK) $ 24.11
  • cardstarterCardstarter (CARDS) $ 16.67
  • woonkly-powerWoonkly Power (WOOP) $ 0.171618
  • unizenUnizen (ZCX) $ 2.10
  • token-pocketToken Pocket (TPT) $ 0.020465
  • certikCertiK (CTK) $ 1.26
  • casper-networkCasper Network (CSPR) $ 0.064392
  • akropolisAkropolis (AKRO) $ 0.025959
  • nftxNFTX (NFTX) $ 166.77
  • streamr-datacoinStreamr (DATA) $ 0.100689
  • sonmSONM (SNM) $ 0.159855
  • bytecoinBytecoin (BCN) $ 0.000378
  • ptokens-btcpTokens BTC (PBTC) $ 39,365.00
  • stakehound-staked-etherStakeHound Staked Ether (STETH) $ 1,074.50
  • loom-networkLoom Network (OLD) (LOOMOLD) $ 0.083052
  • seth2sETH2 (SETH2) $ 2,667.48
  • handshakeHandshake (HNS) $ 0.167452
  • legolas-exchangeLGO Token (LGO) $ 0.423341
  • super-zeroSERO (SERO) $ 0.210020
  • dia-dataDIA (DIA) $ 1.39
  • bet-protocolBEPRO Network (BEPRO) $ 0.009847
  • gnyGNY (GNY) $ 0.388281
  • zcoinFiro (FIRO) $ 5.35
  • fc-barcelona-fan-tokenFC Barcelona Fan Token (BAR) $ 22.00
  • occamfiOccamFi (OCC) $ 6.52
  • whaleWHALE (WHALE) $ 10.26
  • aionAion (AION) $ 0.129636
  • havenHaven (XHV) $ 4.22
  • rampRAMP (RAMP) $ 0.205261
  • hegicHegic (HEGIC) $ 0.111933
  • mx-tokenMX Token (MX) $ 0.637225
  • stp-networkSTP Network (STPT) $ 0.051904
  • energiEnergi (NRG) $ 1.45
  • tokenlonTokenlon (LON) $ 2.48
  • dvision-networkDvision Network (DVI) $ 0.278238
  • saffron-financesaffron.finance (SFI) $ 778.95
  • fio-protocolFIO Protocol (FIO) $ 0.182836
  • derivadaoDerivaDAO (DDX) $ 2.38
  • dego-financeDego Finance (DEGO) $ 11.44
  • cobak-tokenCobak Token (CBK) $ 3.60
  • groestlcoinGroestlcoin (GRS) $ 0.787508
  • mxcMXC (MXC) $ 0.025023
  • covalentCovalent (CQT) $ 0.528816
  • lgcy-networkLGCY Network (LGCY) $ 0.004941
  • bao-financeBao Finance (BAO) $ 0.000815
  • sentinelSentinel (DVPN) $ 0.016050
  • cream-eth2Cream ETH 2 (CRETH2) $ 2,368.09
  • hard-protocolHARD Protocol (HARD) $ 0.814194
  • index-cooperativeIndex Cooperative (INDEX) $ 29.76
  • adexAdEx (ADX) $ 0.465670
  • neutrino-system-base-tokenNeutrino System Base Token (NSBT) $ 26.98
  • o3-swapO3 Swap (O3) $ 3.39
  • steem-dollarsSteem Dollars (SBD) $ 6.95
  • sentinel-protocolSentinel Protocol (UPP) $ 0.176036
  • manchester-city-fan-tokenManchester City Fan Token (CITY) $ 20.50
  • yuan-chain-coinYuan Chain Coin (YCC) $ 0.011466
  • redfox-labs-2RedFOX Labs (RFOX) $ 0.041993
  • yooshiYooShi (YOOSHI) $ 0.00000015
  • coinmetroCoinMetro (XCM) $ 0.185712
  • refereumRefereum (RFR) $ 0.011379
  • privateumPrivateum (PVM) $ 0.692199
  • trustswapTrustswap (SWAP) $ 0.856823
  • alchemy-payAlchemy Pay (ACH) $ 0.030189
  • elastosElastos (ELA) $ 2.84
  • ionIon (ION) $ 2,565.68
  • boringdao-[old]BoringDAO [OLD] (BOR) $ 243.00
  • chain-gamesChain Games (CHAIN) $ 0.193761
  • marlinMarlin (POND) $ 0.068812
  • bnb48-club-tokenBNB48 Club Token (KOGE) $ 36.42
  • celo-dollarCelo Dollar (CUSD) $ 1.00
  • sx-networkSX Network (SX) $ 0.675637
  • raribleRarible (RARI) $ 11.56
  • quickQuickswap (QUICK) $ 327.25
  • beamBEAM (BEAM) $ 0.552250
  • bluzelleBluzelle (BLZ) $ 0.173707
  • parsiqPARSIQ (PRQ) $ 0.437599
  • hydradxHydraDX (XHDX) $ 0.115738
  • convex-financeConvex Finance (CVX) $ 3.17
  • governance-zilgovernance ZIL (GZIL) $ 115.96
  • aergoAergo (AERGO) $ 0.189856
  • kine-protocolKine Protocol (KINE) $ 2.70
  • saiSai (SAI) $ 14.06
  • alpha-quark-tokenAlpha Quark Token (AQT) $ 3.51
  • darwinia-network-native-tokenDarwinia Network Native Token (RING) $ 0.053278
  • cudosCudos (CUDOS) $ 0.030857
  • tether-eurtEuro Tether (EURT) $ 1.20
  • paris-saint-germain-fan-tokenParis Saint-Germain Fan Token (PSG) $ 22.48
  • apenftAPENFT (NFT) $ 0.000002
  • mantra-daoMANTRA DAO (OM) $ 0.143655
  • 3x-long-ethereum-token3X Long Ethereum Token (ETHBULL) $ 1,126.89
  • v-systemsV.SYSTEMS (VSYS) $ 0.019961
  • dforce-tokendForce Token (DF) $ 0.152648
  • request-networkRequest (REQ) $ 0.059909
  • decentral-gamesDecentral Games (DG) $ 157.77
  • kadenaKadena (KDA) $ 0.338291
  • dogelon-marsDogelon Mars (ELON) $ 0.00000009
  • atariAtari (ATRI) $ 0.049840
  • eterbaseEterbase Utility Token (XBASE) $ 0.002584
  • shareringShareToken (SHR) $ 0.018910
  • dockDock (DOCK) $ 0.065549
  • lattice-tokenLattice Token (LTX) $ 1.40
  • zenonZenon (ZNN) $ 6.70
  • revvREVV (REVV) $ 0.199303
  • moboxMobox (MBOX) $ 1.48
  • digixdaoDigixDAO (DGD) $ 515.19
  • verus-coinVerus Coin (VRSC) $ 0.685128
  • hermez-network-tokenHermez Network (HEZ) $ 3.92
  • yield-appYIELD App (YLD) $ 0.381336
  • morpheus-networkMorpheus Network (MRPH) $ 1.16
  • aeternityAeternity (AE) $ 0.110278
  • hoge-financeHoge Finance (HOGE) $ 0.000106
  • millionMillion (MM) $ 42.52
  • metronomeMetronome (MET) $ 3.58
  • arpa-chainARPA Chain (ARPA) $ 0.043112
  • futureswapFutureswap (FST) $ 7.98
  • xdai-stakexDAI Stake (STAKE) $ 6.94
  • chainxChainX (PCX) $ 3.84
  • loki-networkOxen (OXEN) $ 0.764565
  • btu-protocolBTU Protocol (BTU) $ 0.521415
  • iron-bank-euroIron Bank EURO (IBEUR) $ 1.19
  • unifi-protocol-daoUnifi Protocol DAO (UNFI) $ 9.67
  • dusk-networkDUSK Network (DUSK) $ 0.112428
  • paid-networkPAID Network (PAID) $ 0.436075
  • iocoinI/O Coin (IOC) $ 0.097265
  • contentosContentos (COS) $ 0.013301
  • bitkub-coinBitkub Coin (KUB) $ 0.654495
  • veritaseumVeritaseum (VERI) $ 18.52
  • nulsNuls (NULS) $ 0.423805
  • cargoxCargoX (CXO) $ 0.238407
  • raiRai Reflex Index (RAI) $ 3.01
  • nimiq-2Nimiq (NIM) $ 0.004846
  • sport-and-leisureSport and Leisure (SNL) $ 0.160052
  • galatasaray-fan-tokenGalatasaray Fan Token (GAL) $ 10.95
  • bscpadBSCPAD (BSCPAD) $ 0.691084
  • nft-art-financeNFT Art Finance (NFTART) $ 0.00000000
  • musdmStable USD (MUSD) $ 1.03
  • beltBelt (BELT) $ 8.85
  • platoncoinPlatonCoin (PLTC) $ 0.470030
  • everidEverest (ID) $ 0.325357
  • terra-krwTerraKRW (KRT) $ 0.000874
  • earthcoinEarthcoin (EAC) $ 0.002926
  • dexeDeXe (DEXE) $ 11.19
  • pooltogetherPoolTogether (POOL) $ 14.11
  • hackenaiHacken Token (HAI) $ 0.104832
  • bzx-protocolbZx Protocol (BZRX) $ 0.266333
  • viteVite (VITE) $ 0.056348
  • pangolinPangolin (PNG) $ 0.918549
  • pivxPIVX (PIVX) $ 0.559571
  • sentinel-groupSentinel [OLD] (DVPN) $ 0.018254
  • anyswapAnyswap (ANY) $ 2.11
  • drakenDraken (DRK) $ 0.036633
  • bifrostBifrost (BFC) $ 0.043987
  • get-tokenGET Protocol (GET) $ 2.28
  • boson-protocolBoson Protocol (BOSON) $ 0.872589
  • strongStrong (STRONG) $ 225.23
  • shyft-network-2Shyft Network (SHFT) $ 0.644344
  • finxfloFinxflo (FXF) $ 0.471511
  • deapcoinDEAPCOIN (DEP) $ 0.008728
  • waves-ducksWaves Ducks (EGG) $ 777.41
  • metahash#MetaHash (MHC) $ 0.012530
  • vesper-financeVesper Finance (VSP) $ 7.60
  • stackticalDSLA Protocol (DSLA) $ 0.005433
  • mapsMAPS (MAPS) $ 0.464222
  • tbtctBTC (TBTC) $ 40,012.00
  • xsgdXSGD (XSGD) $ 0.742740
  • nexusNexus (NXS) $ 0.510489
  • dragonchainDragonchain (DRGN) $ 0.093942
  • hunt-tokenHUNT (HUNT) $ 0.316650
  • unlend-financeUniLend Finance (UFT) $ 0.651895
  • gxchainGXChain (GXC) $ 0.489607
  • waultswapWaultSwap (WEX) $ 0.008699
  • hshareHyperCash (HC) $ 0.739049
  • impossible-financeImpossible Finance (IF) $ 4.46
  • shabu-shabuShabu Shabu (KOBE) $ 0.816931
  • ultiledgerUltiledger (ULT) $ 0.017189
  • frontier-tokenFrontier (FRONT) $ 0.730063
  • mirrored-googleMirrored Google (MGOOGL) $ 2,709.78
  • unisocksUnisocks (SOCKS) $ 108,700.00
  • shopping-ioShopping.io (SPI) $ 34.95
  • usdkUSDK (USDK) $ 1.00
  • neon-exchangeNash (NEX) $ 1.11
  • hedpayHEdpAY (HDP.ф) $ 0.487982
  • qaoQAO (🌐) $ 0.000016
  • hotbit-tokenHotbit Token (HTB) $ 0.045022
  • wing-financeWing Finance (WING) $ 17.72
  • lcxLCX (LCX) $ 0.056848
  • tornado-cashTornado Cash (TORN) $ 32.34
  • bosagoraBOSAGORA (BOA) $ 0.104750
  • kylin-networkKylin Network (KYL) $ 0.234477
  • mirrored-ishares-silver-trustMirrored iShares Silver Trust (MSLV) $ 24.40
  • vertcoinVertcoin (VTC) $ 0.511200
  • mirrored-amazonMirrored Amazon (MAMZN) $ 3,391.76
  • wilder-worldWilder World (WILD) $ 0.430814
  • nestNest Protocol (NEST) $ 0.015316
  • videocoinVideoCoin (VID) $ 0.201352
  • waykichainWaykiChain (WICC) $ 0.146955
  • bridge-mutualBridge Mutual (BMI) $ 0.588822
  • bitmart-tokenBitMart Token (BMX) $ 0.196826
  • sparkpointSparkPoint (SRK) $ 0.003790
  • somnium-space-cubesSomnium Space CUBEs (CUBE) $ 2.43
  • interest-bearing-bitcoinInterest Bearing Bitcoin (IBBTC) $ 39,919.00
  • cocos-bcxCOCOS BCX (COCOS) $ 0.721594
  • idextoolsDexTools (DEXT) $ 0.288288
  • fsnFUSION (FSN) $ 0.435396
  • telosTelos (TLOS) $ 0.135597
  • nav-coinNavCoin (NAV) $ 0.418449
  • mirrored-microsoftMirrored Microsoft (MMSFT) $ 287.54
  • liquityLiquity (LQTY) $ 6.01
  • zanoZano (ZANO) $ 2.30
  • refinableRefinable (FINE) $ 0.256929
  • mosslandMossland (MOC) $ 0.105842
  • wall-street-gamesWall Street Games (WSG) $ 0.00000012
  • copeCope (COPE) $ 1.79
  • movieblocMovieBloc (MBL) $ 0.008136
  • autoAuto (AUTO) $ 816.98
  • dinoswapDinoSwap (DINO) $ 2.30
  • archer-dao-governance-tokenArcher DAO Governance Token (ARCH) $ 3.95
  • edgewareEdgeware (EDG) $ 0.004588
  • rootkitRootkit (ROOT) $ 2,863.66
  • veloVelo (VELO) $ 0.298989
  • armorARMOR (ARMOR) $ 0.208315
  • the-truthThe Truth (UFO) $ 0.000001
  • signumSignum (SIGNA) $ 0.013059
  • openoceanOpenOcean (OOE) $ 0.355091
  • etheriscEtherisc DIP Token (DIP) $ 0.149659
  • cortexCortex (CTXC) $ 0.151875
  • mirrored-invesco-qqq-trustMirrored Invesco QQQ Trust (MQQQ) $ 369.43
  • zb-tokenZB Token (ZB) $ 0.298460
  • uniftyUnifty (NIF) $ 24.62
  • cutcoinCUTcoin (CUT) $ 0.186704
  • juventus-fan-tokenJuventus Fan Token (JUV) $ 12.39
  • cryptobladesCryptoBlades (SKILL) $ 45.43
  • arianeeArianee (ARIA20) $ 1.06
  • aurora-daoIDEX (IDEX) $ 0.045749
  • muse-2Muse (MUSE) $ 38.80
  • mirrored-teslaMirrored Tesla (MTSLA) $ 726.07
  • hoprHOPR (HOPR) $ 0.250617
  • mirrored-twitterMirrored Twitter (MTWTR) $ 69.19
  • smartkeySmartKey (SKEY) $ 0.133358
  • dfyn-networkDfyn Network (DFYN) $ 1.37
  • lightcoinLightcoin (LHC) $ 0.620162
  • lambdaLambda (LAMB) $ 0.014492
  • phantasmaPhantasma (SOUL) $ 0.265103
  • adappter-tokenAdappter Token (ADP) $ 0.079747
  • mithrilMithril (MITH) $ 0.042356
  • airswapAirSwap (AST) $ 0.151540
  • cumrocketCumRocket (CUMMIES) $ 0.019667
  • concentrated-voting-powerPowerPool Concentrated Voting Power (CVP) $ 1.10
  • mirrored-appleMirrored Apple (MAAPL) $ 147.14
  • visorVisor (VISR) $ 1.03
  • niobio-cashNiobio (NBR) $ 0.176039
  • atletico-madridAtletico Madrid Fan Token (ATM) $ 13.61
  • mirrored-united-states-oil-fundMirrored United States Oil Fund (MUSO) $ 48.38
  • convergenceConvergence (CONV) $ 0.027511
  • qashQASH (QASH) $ 0.072082
  • pnetworkpNetwork (PNT) $ 0.807130
  • skycoinSkycoin (SKY) $ 1.22
  • reflexer-ungovernance-tokenReflexer Ungovernance Token (FLX) $ 297.60
  • red-pulsePhoenix Global (PHB) $ 0.007463
  • safemarsSafemars (SAFEMARS) $ 0.00000007
  • mirrored-alibabaMirrored Alibaba (MBABA) $ 203.96
  • quantstampQuantstamp (QSP) $ 0.034771
  • sifchainSifchain (EROWAN) $ 0.227755
  • stafiStafi (FIS) $ 0.915515
  • veedVEED (VEED) $ 0.004303
  • peercoinPeercoin (PPC) $ 0.892072
  • smartlandsSmartlands Network (SLT) $ 4.73
  • content-value-networkContent Value Network (CVNT) $ 0.038153
  • polychain-monstersPolychain Monsters (PMON) $ 8.51
  • singularitydaoSingularityDAO (SDAO) $ 1.80
  • apolloApollo (APL) $ 0.001632
  • spartan-protocol-tokenSpartan Protocol Token (SPARTA) $ 0.299343
  • vvspvVSP (VVSP) $ 10.61
  • metamStable Governance Token: Meta (MTA) $ 0.837116
  • cindicatorCindicator (CND) $ 0.012215
  • gochainGoChain (GO) $ 0.021554
  • minidogeMiniDOGE (MINIDOGE) $ 0.00000003
  • givingtoservices-svsGivingToServices SVS (SVS) $ 0.005530
  • erc20ERC20 (ERC20) $ 0.020624
  • mercurialMercurial (MER) $ 0.422111
  • goviGovi (GOVI) $ 2.72
  • top-networkTOP Network (TOP) $ 0.005357
  • nerve-financeNerve Finance (NRV) $ 0.570030
  • pibblePibble (PIB) $ 0.001928
  • blockvBLOCKv (VEE) $ 0.006823
  • ferrum-networkFerrum Network (FRM) $ 0.194408
  • routeRouter Protocol (ROUTE) $ 4.04
  • aidos-kuneenAidos Kuneen (ADK) $ 0.894952
  • giftoGifto (GTO) $ 0.033293
  • bit-z-tokenBitZ Token (BZ) $ 0.171324
  • trias-tokenTrias Token (TRIAS) $ 4.36
  • float-protocolFloat Protocol (BANK) $ 126.30
  • solve-careSOLVE (SOLVE) $ 0.052867
  • unit-protocol-duckUnit Protocol New (DUCK) $ 0.098629
  • zoid-payZoidPay (ZPAY) $ 0.069969
  • sentivateSentivate (SNTVT) $ 0.008436
  • e-moneye-Money (NGM) $ 0.528043
  • polkadexPolkadex (PDEX) $ 7.91
  • morpheus-labsMorpheus Labs (MITX) $ 0.048670
  • sukuSUKU (SUKU) $ 0.177615
  • faralandFaraLand (FARA) $ 3.16
  • saltSALT (SALT) $ 0.240947
  • epik-protocolEpiK Protocol (EPK) $ 0.529339
  • hot-crossHot Cross (HOTCROSS) $ 0.224708
  • defidollarDefiDollar (DUSD) $ 0.998599
  • launchpoolLaunchpool (LPOOL) $ 2.28
  • cashaaCashaa (CAS) $ 0.028603
  • defi-for-youDefi For You (DFY) $ 0.054925
  • namecoinNamecoin (NMC) $ 1.28
  • byteballObyte (GBYTE) $ 25.80
  • gyenGYEN (GYEN) $ 0.009136
  • deepbrain-chainDeepBrain Chain (DBC) $ 0.006315
  • cardstackCardstack (CARD) $ 0.006778
  • xfundxFund (XFUND) $ 3,218.71
  • raiden-networkRaiden Network Token (RDN) $ 0.360410
  • universe-xyzUniverse.XYZ (XYZ) $ 0.119641
  • uniclyUnicly (UNIC) $ 148.85
  • keep3rv1Keep3rV1 (KP3R) $ 84.12
  • zilswapZilSwap (ZWAP) $ 99.76
  • selfkeySelfKey (KEY) $ 0.006921
  • mobiecoinMobieCoin (MBX) $ 0.006232
  • 0chain0chain (ZCN) $ 0.392613
  • v-id-blockchainVIDT Datalink (VIDT) $ 0.414774
  • callistoCallisto Network (CLO) $ 0.006841
  • olyseumOlyseum (OLY) $ 0.016646
  • gravitonGraviton (GTON) $ 5.29
  • chain-guardiansChain Guardians (CGG) $ 0.583994
  • tidal-financeTidal Finance (TIDAL) $ 0.008090
  • marcopoloMAP Protocol (MAP) $ 0.019014
  • coinzoom-tokenCoinZoom Token (ZOOM) $ 0.048436
  • origin-dollarOrigin Dollar (OUSD) $ 0.997202
  • neblioNeblio (NEBL) $ 1.04
  • mixmarvelMixMarvel (MIX) $ 0.003627
  • all-sportsAll Sports (SOC) $ 0.016028
  • unicly-cryptopunks-collectionUnicly CryptoPunks Collection (UPUNK) $ 0.074706
  • safe-havenSafe Haven (SHA) $ 0.003335
  • safe2SAFE2 (SAFE2) $ 352.02
  • bountymarketcapBountyMarketCap (BMC) $ 0.183416
  • 88mph88mph (MPH) $ 49.36
  • grinGrin (GRIN) $ 0.289342
  • jenny-metaverse-dao-tokenJenny Metaverse DAO Token (UJENNY) $ 1.82
  • force-protocolForTube (FOR) $ 0.032383
  • axelAXEL (AXEL) $ 0.183102
  • cover-protocolCover Protocol (COVER) $ 231.38
  • ignisIgnis (IGNIS) $ 0.023729
  • dash-diamondDash Diamond (DASHD) $ 1.90
  • stake-daoStake DAO (SDT) $ 1.33
  • wrapped-crescofinWrapped CrescoFin (WCRES) $ 14.21
  • protonProton (XPR) $ 0.003623
  • snowblossomSnowBlossom (SNOW) $ 2.07
  • dentacoinDentacoin (DCN) $ 0.000025
  • mapleMaple (MPL) $ 7.76
  • te-foodTE-FOOD (TONE) $ 0.030511
  • qi-daoQi Dao (QI) $ 1.07
  • ac-milan-fan-tokenAC Milan Fan Token (ACM) $ 8.59
  • zelcashFlux (FLUX) $ 0.095294
  • dxdaoDXdao (DXD) $ 346.59
  • kickKick (KICK) $ 0.011452
  • lbry-creditsLBRY Credits (LBC) $ 0.027587
  • likecoinLikeCoin (LIKE) $ 0.015620
  • restart-energyRestart Energy (MWAT) $ 0.037106
  • six-networkSIX Network (SIX) $ 0.061709
  • nebulasNebulas (NAS) $ 0.368234
  • glitch-protocolGlitch Protocol (GLCH) $ 0.238114
  • dxsale-networkDxSale Network (SALE) $ 1.04
  • stakenetStakenet (XSN) $ 0.141190
  • lamdenLamden (TAU) $ 0.057983
  • waltonchainWaltonchain (WTC) $ 0.572006
  • superbidSuperBid (SUPERBID) $ 3.12
  • bananoBanano (BAN) $ 0.012632
  • gmr-financeGMR Finance (GMR) $ 0.00000006
  • sirenSiren (SI) $ 0.737334
  • apy-financeAPY.Finance (APY) $ 0.436672
  • cryptotycoonCryptoTycoon (CTT) $ 21.84
  • naos-financeNAOS Finance (NAOS) $ 0.395799
  • alephAleph.im (ALEPH) $ 0.156112
  • empty-set-dollarEmpty Set Dollar (ESD) $ 0.081984
  • vecrv-dao-yvaultveCRV-DAO yVault (YVE-CRVDAO) $ 1.25
  • ztcoinZBG Token (ZT) $ 0.032656
  • genesis-visionGenesis Vision (GVT) $ 3.66
  • freeway-tokenFreeway Token (FWT) $ 0.008139
  • ice-tokenPopsicle Finance (ICE) $ 1.37
  • smartcashSmartCash (SMART) $ 0.005937
  • dvfDVF (DVF) $ 2.30
  • spendcoinSpendcoin (SPND) $ 0.016886
  • infinitecoinInfinitecoin (IFC) $ 0.000177
  • celo-euroCelo Euro (CEUR) $ 1.19
  • multivacMultiVAC (MTV) $ 0.004629
  • kanBitKan (KAN) $ 0.002971
  • dopexDopex (DPX) $ 135.72
  • santiment-network-tokenSantiment Network Token (SAN) $ 0.248834
  • equos-originEQO (EQO) $ 0.755329
  • measurable-data-tokenMeasurable Data Token (MDT) $ 0.026297
  • oilerOiler (OIL) $ 1.64
  • opacityOpacity (OPCT) $ 0.130960
  • acryptosACryptoS (ACS) $ 18.09
  • shapeshift-fox-tokenShapeShift FOX Token (FOX) $ 0.658582
  • exeedmeExeedme (XED) $ 0.227582
  • solaniumSolanium (SLIM) $ 0.379466
  • pikachuPika (PIKA) $ 0.00000017
  • robonomics-networkRobonomics Network (XRT) $ 14.90
  • lympo-market-tokenLympo Market Token (LMT) $ 0.340651
  • dora-factoryDora Factory (DORA) $ 6.32
  • stone-tokenStone Token (STN) $ 0.799851
  • electra-protocolElectra Protocol (XEP) $ 0.000866
  • tendieswapTendieSwap (TENDIE) $ 2.93
  • swingbySwingby (SWINGBY) $ 0.060725
  • gerowalletGeroWallet (GERO) $ 0.177223
  • fractalFractal (FCL) $ 0.231765
  • crownsCrowns (CWS) $ 8.30
  • deaDEA (DEA) $ 146.56
  • arthxARTHX (ARTHX) $ 0.025590
  • ovrOvr (OVR) $ 0.900984
  • unicrypt-2UniCrypt (UNCX) $ 413.75
  • tokenclubTokenClub (TCT) $ 0.025687
  • quantum-resistant-ledgerQuantum Resistant Ledger (QRL) $ 0.198797
  • benchmark-protocolBenchmark Protocol (MARK) $ 1.48
  • yieldlyYieldly (YLDY) $ 0.006906
  • gatherGather (GTH) $ 0.133593
  • insuraceInsurAce (INSUR) $ 1.46
  • bytzBYTZ (BYTZ) $ 0.001860
  • koda-financeKoda Finance (KODA) $ 0.000427
  • polkamarketsPolkamarkets (POLK) $ 0.300893
  • coin-capsuleTernoa (CAPS) $ 0.065633
  • vetherVether (VETH) $ 22.04
  • idavoll-networkIdavoll Network (IDV) $ 0.018271
  • unmarshalUnmarshal (MARSH) $ 1.25
  • adsharesAdshares (ADS) $ 0.928923
  • adaxADAX (ADAX) $ 0.273785
  • julswapJulSwap (JULD) $ 0.026425
  • particlParticl (PART) $ 1.23
  • tranche-financeTranche Finance (SLICE) $ 0.808238
  • basketdao-defi-indexBasketDAO DeFi Index (BDI) $ 336.62
  • elysiaELYSIA (EL) $ 0.005433
  • mistMist (MIST) $ 0.247430
  • wault-usdWault USD (WUSD) $ 0.954463
  • rubycoinRubycoin (RBY) $ 0.504503
  • gamercoinGamerCoin (GHX) $ 0.033666
  • thoreumThoreum (THOREUM) $ 0.009873
  • nxtNXT (NXT) $ 0.013833
  • hapiHAPI (HAPI) $ 45.88
  • propyPropy (PRO) $ 0.241201
  • foam-protocolFOAM (FOAM) $ 0.040686
  • dhedge-daodHEDGE DAO (DHT) $ 0.926878
  • enq-enecuumEnecuum (ENQ) $ 0.071760
  • burencyBurency (BUY) $ 0.030189
  • blackdragon-tokenBlackDragon Token (BDT) $ 11.82
  • kira-networkKIRA Network (KEX) $ 0.468723
  • oraichain-tokenOraichain Token (ORAI) $ 6.61
  • troyTroy (TROY) $ 0.007053
  • pandacoinPandacoin (PND) $ 0.000390
  • greentrustGreenTrust (GNT) $ 0.000010
  • pbtc35apBTC35A (PBTC35A) $ 62.16
  • spacechain-erc-20SpaceChain (ERC-20) (SPC) $ 0.032606
  • unicryptUniCrypt (Old) (UNC) $ 0.101715
  • factomFactom (FCT) $ 1.34
  • syloSylo (SYLO) $ 0.004360
  • bipMinter (BIP) $ 0.003050
  • odysseyOdyssey (OCN) $ 0.001212
  • splytSplyt (SHOPX) $ 0.145596
  • chronobankchrono.tech (TIME) $ 18.56
  • matryxMATRYX (MTX) $ 0.567201
  • era-swap-tokenEra Swap Token (ES) $ 0.007933
  • openalexa-protocolOpenAlexa Protocol (OAP) $ 4.78
  • ichi-farmICHI (ICHI) $ 3.88
  • modefiModefi (MOD) $ 0.974771
  • cashbet-coinCBC.network (CBC) $ 0.061937
  • unificationUnification (FUND) $ 0.130463
  • indexed-financeIndexed Finance (NDX) $ 3.76
  • friends-with-benefits-proFriends With Benefits Pro (FWB) $ 23.36
  • radiumValidity (VAL) $ 2.92
  • baasidBaaSid (BAAS) $ 0.002484
  • circuits-of-valueCircuits of Value (COVAL) $ 0.008747
  • trubadgerTruBadger (TRUBGR) $ 0.00000002
  • universaUniversa (UTNP) $ 0.004068
  • stackosStackOS (STACK) $ 0.061056
  • howdooHyprr (Howdoo) (UDOO) $ 0.026011
  • vitaeVitae (VITAE) $ 0.505040
  • clucoinCluCoin (CLU) $ 0.00000004
  • moeda-loyalty-pointsMoeda Loyalty Points (MDA) $ 0.639406
  • pendlePendle (PENDLE) $ 0.379704
  • unifiCovenants (UNIFI) $ 1.41
  • as-roma-fan-tokenAS Roma Fan Token (ASR) $ 7.20
  • ethpadETHPad (ETHPAD) $ 0.092930
  • oneswap-dao-tokenOneSwap DAO Token (ONES) $ 1.04
  • opiumOpium (OPIUM) $ 1.76
  • coinfirm-amltAMLT Network (AMLT) $ 0.036598
  • wowneroWownero (WOW) $ 0.236627
  • arc-governanceARC Governance (ARCX) $ 0.939018
  • blankBlank (BLANK) $ 0.549170
  • degeneratorMeme (MEME) $ 457.97
  • defi-top-5-tokens-indexDEFI Top 5 Index (DEFI5) $ 85.40
  • towerTower (TOWER) $ 0.050762
  • babbBABB (BAX) $ 0.000361
  • rainicornRainicorn (RAINI) $ 0.026357
  • apm-coinapM Coin (APM) $ 0.032496
  • oxbull-techOxbull Tech (OXB) $ 1.61
  • time-new-bankTime New Bank (TNB) $ 0.003569
  • xtokenxToken (XTK) $ 0.114273
  • cyberfiCyberFi (CFI) $ 7.24
  • umbrella-networkUmbrella Network (UMB) $ 0.173498
  • rubicRubic (RBC) $ 0.114022
  • cryptex-financeCryptex Finance (CTX) $ 6.84
  • morkMORK (MORK) $ 1.61
  • starnameStarname (IOV) $ 0.086669
  • duckdaodimeDuckDaoDime (DDIM) $ 11.21
  • meterMeter Governance (MTRG) $ 1.63
  • bloxBlox (CDT) $ 0.017039
  • zignalyZignaly (ZIG) $ 0.043143
  • hordHord (HORD) $ 0.233414
  • helmet-insureHelmet Insure (HELMET) $ 0.306754
  • cnnsCNNS (CNNS) $ 0.006333
  • fildaFilda (FILDA) $ 0.139621
  • free-coinFREE coin (FREE) $ 0.000001
  • thoughtThought (THT) $ 0.026516
  • arcblockArcblock (ABT) $ 0.114283
  • mstable-btcmStable BTC (MBTC) $ 39,246.00
  • wirexWirex (WXT) $ 0.004844
  • ubiqUbiq (UBQ) $ 0.240617
  • konomi-networkKonomi Network (KONO) $ 0.545314
  • iqeonIQeon (IQN) $ 1.99
  • yearn-lazy-apeYearn Lazy Ape (YLA) $ 1.02
  • vidyaVidya (VIDYA) $ 0.249386
  • union-protocol-governance-tokenUNION Protocol Governance Token (UNN) $ 0.017820
  • sefiSEFI (SEFI) $ 0.043421
  • swftcoinSWFTCOIN (SWFTC) $ 0.001663
  • labs-groupLABS Group (LABS) $ 0.005298
  • spankchainSpankChain (SPANK) $ 0.017803
  • syndicateSyndicate (SYNX) $ 0.260389
  • mettalexMettalex (MTLX) $ 3.05
  • equalizerEqualizer (EQZ) $ 0.542824
  • diggDIGG (DIGG) $ 42,451.00
  • dafi-protocolDafi Protocol (DAFI) $ 0.030547
  • probit-exchangeProbit Token (PROB) $ 0.268558
  • mustMust (MUST) $ 117.48
  • rabbit-financeRabbit Finance (RABBIT) $ 0.231535
  • metaverse-etpMetaverse ETP (ETP) $ 0.130975
  • blockportBUX Token (BUX) $ 0.163386
  • ghost-by-mcafeeGhost (GHOST) $ 0.622839
  • lympoLympo (LYM) $ 0.012565
  • mysteriumMysterium (MYST) $ 0.326157
  • viacoinViacoin (VIA) $ 0.455613
  • oceanex-tokenOceanEX Token (OCE) $ 0.003169
  • solrise-financeSolrise Finance (SLRS) $ 0.272436
  • propsProps Token (PROPS) $ 0.038849
  • plasma-financePlasma Finance (PPAY) $ 0.068450
  • nectar-tokenNectar (NEC) $ 0.065790
  • zero-exchange0.exchange (ZERO) $ 0.032078
  • swerve-daoSwerve (SWRV) $ 0.738867
  • polkafoundryPolkaFoundry (PKF) $ 0.390657
  • metaverse-indexMetaverse Index (MVI) $ 80.72
  • upbotsUpBots (UBXT) $ 0.028751
  • beowulfBeowulf (BWF) $ 0.010216
  • crypteriumCrypterium (CRPT) $ 0.119871
  • cops-financeCops Finance (COPS) $ 627.15
  • degen-indexDEGEN Index (DEGEN) $ 3.82
  • permission-coinPermission Coin (ASK) $ 0.001893
  • wabiWabi (WABI) $ 0.170289
  • eunoEUNO (EUNO) $ 0.001588
  • presearchPresearch (PRE) $ 0.025334
  • breadBread (BRD) $ 0.118846
  • mindsMinds (MINDS) $ 1.37
  • jupiterJupiter (JUP) $ 0.012448
  • cybermilesCyberMiles (CMT) $ 0.012444
  • shroom-financeNiftyx Protocol (SHROOM) $ 0.194125
  • spell-tokenSpell Token (SPELL) $ 0.000319
  • connect-financialConnect Financial (CNFI) $ 0.396539
  • zapZap (ZAP) $ 0.040041
  • jarvis-reward-tokenJarvis Reward Token (JRT) $ 0.052717
  • communiftyCommunifty (CNFT) $ 0.169903
  • chimaeraXAYA (CHI) $ 0.172887
  • bankless-daoBankless DAO (BANK) $ 0.037919
  • trabzonspor-fan-tokenTrabzonspor Fan Token (TRA) $ 4.70
  • mirrored-ishares-gold-trustMirrored iShares Gold Trust (MIAU) $ 20.97
  • bscexBSCEX (BSCX) $ 2.53
  • mch-coinMCH Coin (MCHC) $ 1.22
  • putincoinPutinCoin (PUT) $ 0.000472
  • tokenomyTokenomy (TEN) $ 0.082959
  • guldenGulden (NLG) $ 0.017351
  • bitcoin-2Bitcoin 2 (BTC2) $ 0.528639
  • webdollarwebdollar (WEBD) $ 0.000546
  • filecashFilecash (FIC) $ 0.120811
  • ureeqaUREEQA (URQA) $ 0.299269
  • pastelPastel (PSL) $ 0.003709
  • xend-financeXend Finance (XEND) $ 0.193733
  • pillarPillar (PLR) $ 0.035936
  • polyswarmPolySwarm (NCT) $ 0.006009
  • tigercashTigerCash (TCH) $ 0.013243
  • mobiusMobius (MOBI) $ 0.017949
  • zeroswapZeroSwap (ZEE) $ 0.179292
  • dify-financeDify.Finance (YFIII) $ 577.72
  • peony-coinPeony Coin (PNY) $ 0.592808
  • anjAragon Court (ANJ) $ 0.071608
  • digitalnoteDigitalNote (XDN) $ 0.001520
  • xmaxXMax (XMX) $ 0.000337
  • databroker-daoDaTa eXchange Token (DTX) $ 0.040863
  • ethereum-push-notification-serviceEthereum Push Notification Service - EPNS (PUSH) $ 1.10
  • medisharesMediShares (MDS) $ 0.007688
  • suterusuSuterusu (SUTER) $ 0.002498
  • media-networkMedia Network (MEDIA) $ 36.32
  • revomonRevomon (REVO) $ 0.405711
  • kuswapKuSwap (KUS) $ 6.98
  • tixl-newTixl (TXL) $ 0.136075
  • kryllKRYLL (KRL) $ 0.283517
  • gridGridPlus (GRID) $ 0.228160
  • proxyProxy (PRXY) $ 17.99
  • plutonPluton (PLU) $ 4.79
  • unido-epUnido (UDO) $ 0.199312
  • pepecashPepeCash (PEPECASH) $ 0.012629
  • fearFear (FEAR) $ 1.34
  • vexaniumVexanium (VEX) $ 0.008725
  • smart-valorSmart Valor (VALOR) $ 0.331601
  • rio-defiRioDeFi (RFUEL) $ 0.038724
  • poa-networkPOA Network (POA) $ 0.029973
  • poolz-financePoolz Finance (POOLZ) $ 3.54
  • litecoin-cashLitecoin Cash (LCC) $ 0.011681
  • lith-tokenLith Token (LITH) $ 0.001605
  • tenxTenX (PAY) $ 0.072834
  • oddzOddz (ODDZ) $ 0.323041
  • saitoSaito (SAITO) $ 0.008006
  • everexEverex (EVX) $ 0.391440
  • whiteheartWhiteheart (WHITE) $ 958.24
  • diamondDiamond (DMD) $ 2.35
  • value-liquidityValue DeFi (VALUE) $ 1.76
  • bitberry-tokenBitberry Token (BBR) $ 3.64
  • odemODEM (ODE) $ 0.038308
  • gamecreditsGameCredits (GAME) $ 0.114763
  • x-cashX-CASH (XCASH) $ 0.000135
  • anrkey-xAnRKey X ($ANRX) $ 0.088112
  • wom-tokenWOM Protocol (WOM) $ 0.083616
  • bibox-tokenBibox Token (BIX) $ 0.071286
  • gameeGAMEE (GMEE) $ 0.152189
  • step-financeStep Finance (STEP) $ 0.181254
  • fedoracoinFedoracoin (TIPS) $ 0.000014
  • prcy-coinPRCY Coin (PRCY) $ 0.973890
  • depth-tokenDepth Token (DEP) $ 0.017678
  • pussy-financialPussy Financial (PUSSY) $ 0.000038
  • covestingCovesting (COV) $ 0.425387
  • yam-2YAM (YAM) $ 0.656935
  • axionAxion (AXN) $ 0.000084
  • hitchainHitChain (HIT) $ 0.000132
  • vanilla-networkVanilla Network (VNLA) $ 12.44
  • tronpadTRONPAD (TRONPAD) $ 0.028095
  • openanxOAX (OAX) $ 0.144075
  • achainAchain (ACT) $ 0.009388
  • enigmaEnigma (ENG) $ 0.097463
  • singulardtvSingularDTV (SNGLS) $ 0.009050
  • boringdaoBoringDAO (BORING) $ 0.016510
  • compound-wrapped-btccWBTC (CWBTC) $ 788.70
  • internet-node-tokenINTchain (INT) $ 0.015709
  • seedify-fundSeedify.fund (SFUND) $ 0.732881
  • inverse-financeInverse Finance (INV) $ 195.38
  • k21K21 (K21) $ 0.715633
  • wault-finance-oldWault Finance (OLD) (WAULT) $ 10.23
  • idleIDLE (IDLE) $ 4.57
  • coinpokerCoinPoker (CHP) $ 0.024924
  • wagerrWagerr (WGR) $ 0.036495
  • decentrDecentr (DEC) $ 0.107490
  • franklinFranklin (FLY) $ 0.027754
  • turtlecoinTurtleCoin (TRTL) $ 0.000074
  • egretiaEgretia (EGT) $ 0.002007
  • bitcoreBitCore (BTX) $ 0.416863
  • falcon-tokenFalcon Project (FNT) $ 0.000803
  • coinhe-tokenCoinHe Token (CHT) $ 0.116768
  • blackpool-tokenBlackPool Token (BPT) $ 3.19
  • kalmarKalmar (KALM) $ 2.98
  • monethaMonetha (MTH) $ 0.022174
  • smartmeshSmartMesh (SMT) $ 0.004599
  • airbloc-protocolAirbloc (ABL) $ 0.027342
  • reserveReserve (RSV) $ 0.998215
  • hedgetHedget (HGET) $ 4.33
  • stakecubeStakecube (SCC) $ 0.818855
  • robotRobot (ROBOT) $ 46.04
  • paintMurAll (PAINT) $ 0.000669
  • koinosKoinos (KOIN) $ 0.077716
  • dataDATA (DTA) $ 0.000669
  • waultswap-polygonWaultSwap Polygon (WEXPOLY) $ 0.001828
  • mahadaoMahaDAO (MAHA) $ 3.47
  • pancake-bunnyPancake Bunny (BUNNY) $ 14.55
  • dynamicDynamic (DYN) $ 0.483250
  • xido-financeXido Finance (XIDO) $ 71.47
  • woofyWoofy (WOOFY) $ 0.031521
  • myriadcoinMyriad (XMY) $ 0.004122
  • deus-financeDEUS Finance (DEUS) $ 5.35
  • waultWault (WAULTX) $ 0.009554
  • dlp-duck-tokenDLP Duck Token (DUCK) $ 0.159475
  • tokencardMonolith (TKN) $ 0.203613
  • powertrade-fuelPowerTrade Fuel (PTF) $ 0.311378
  • clintex-ctiClinTex CTi (CTI) $ 0.087775
  • creampyeCreampye (PYE) $ 0.00000001
  • veroxVerox (VRX) $ 375.31
  • btc-2x-flexible-leverage-indexBTC 2x Flexible Leverage Index (BTC2X-FLI) $ 36.09
  • french-digital-reserveFrench Digital Reserve (FDR) $ 0.622222
  • capCap (CAP) $ 72.64
  • nervenetworkNerveNetwork (NVT) $ 0.029724
  • unlimitedipUnlimitedIP (UIP) $ 0.005741
  • blocknetBlocknet (BLOCK) $ 0.905087
  • keanu-inuKeanu Inu (KEANU) $ 0.00000000
  • definerDeFiner (FIN) $ 0.221731
  • the-abyssAbyss (ABYSS) $ 0.030983
  • honeyHoney (HNY) $ 349.14
  • dogiraDogira (DOGIRA) $ 0.082342
  • rbase-financerbase.finance (RBASE) $ 0.287566
  • cofixCoFiX (COFI) $ 0.573084
  • hyveHyve (HYVE) $ 0.207014
  • bitcoin-privateBitcoin Private (BTCP) $ 1.47
  • pickle-financePickle Finance (PICKLE) $ 9.14
  • crypto-village-accelerator-cvagCrypto Village Accelerator CVAG (CVAG) $ 0.070779
  • curateCurate (XCUR) $ 1.31
  • nyzoNyzo (NYZO) $ 0.382973
  • horizon-protocolHorizon Protocol (HZN) $ 0.159858
  • insights-networkINSTAR (INSTAR) $ 0.032838
  • raze-networkRaze Network (RAZE) $ 0.126140
  • apwineAPWine (APW) $ 1.95
  • qlinkQLC Chain (QLC) $ 0.028454
  • autonioAutonio (NIOX) $ 0.074777
  • b-protocolB.Protocol (BPRO) $ 3.66
  • appcoinsAppCoins (APPC) $ 0.060631
  • graphlinq-protocolGraphLinq Protocol (GLQ) $ 0.021158
  • digicol-tokenDigiCol Token (DGCL) $ 0.104624
  • avalaunchAvalaunch (XAVA) $ 0.759403
  • redpanda-earthRedPanda Earth (REDPANDA) $ 0.00
  • auruscoinAurusDeFi (AWX) $ 2.97
  • daohausDAOhaus (HAUS) $ 16.32
  • exnetwork-tokenExNetwork Token (EXNT) $ 0.106529
  • dexkitDexKit (KIT) $ 2.18
  • reapchainReapChain (REAP) $ 0.104550
  • any-blocknetANY Blocknet (ABLOCK) $ 0.844164
  • pangeaPangea Arbitration Token (Bitnation) (XPAT) $ 0.000197
  • realio-networkRealio Network (RIO) $ 1.17
  • trittiumTrittium (TRTT) $ 0.051177
  • coinvestCoin (COIN) $ 0.196285
  • orakuruOrakuru (ORK) $ 0.329922
  • ruler-protocolRuler Protocol (RULER) $ 32.55
  • coinCoin (COIN) $ 0.209722
  • standard-protocolStandard Protocol (STND) $ 0.387512
  • yvault-lp-ycurveyUSD (YVAULT-LP-) $ 1.30
  • the-crypto-propheciesThe Crypto Prophecies (TCP) $ 0.155646
  • agrelloAgrello (DLT) $ 0.079708
  • feeder-financeFeeder Finance (FEED) $ 0.145173
  • proximaxProximaX (XPX) $ 0.001005
  • oduwa-coinOduwa Coin (OWC) $ 0.431005
  • leverj-gluonLeverj Gluon (L2) $ 0.022535
  • b20B20 (B20) $ 1.31
  • antimatterAntiMatter (MATTER) $ 0.213130
  • bitcnybitCNY (BITCNY) $ 0.154793
  • pancake-hunnyPancake Hunny (HUNNY) $ 0.410725
  • viberateViberate (VIB) $ 0.035048
  • fuse-network-tokenFuse (FUSE) $ 0.056383
  • vfoxVFOX (VFOX) $ 0.313312
  • jackpotJackpot (777) $ 0.098435
  • sideshift-tokenSideShift Token (XAI) $ 0.153218
  • iot-chainIoT Chain (ITC) $ 0.086973
  • arc-governance-oldARC Governance (Old) (ARCX) $ 9,216.86
  • bnktothefutureBnkToTheFuture (BFT) $ 0.018806
  • sporeSpore (SPORE) $ 0.00000000
  • julienJULIEN (JULIEN) $ 0.851743
  • wanswapWanSwap (WASP) $ 0.059282
  • footballstarsFootballStars (FTS) $ 0.000007
  • goldcoinGoldcoin (GLC) $ 0.140856
  • believerBELIEVER (BLVR) $ 0.347531
  • ethermonEthermon (EMON) $ 0.235298
  • furucomboFurucombo (COMBO) $ 0.336849
  • piedao-dough-v2PieDAO DOUGH v2 (DOUGH) $ 0.348840
  • csp-dao-networkCSP DAO Network (NEBO) $ 5.59
  • ripio-credit-networkRipio Credit Network (RCN) $ 0.011277
  • linkeyeLinkeye (LET) $ 0.009583
  • geeqGEEQ (GEEQ) $ 0.646622
  • blockbankBlockBank (BBANK) $ 0.138219
  • eleven-financeEleven Finance (ELE) $ 1.56
  • spheroid-universeSpheroid Universe (SPH) $ 0.050643
  • latokenLATOKEN (LA) $ 0.096487
  • onx-financeOnX Finance (ONX) $ 0.657221
  • einsteiniumEinsteinium (EMC2) $ 0.026370
  • manifold-financeManifold Finance (FOLD) $ 13.80
  • lua-tokenLuaSwap (LUA) $ 0.057460
  • gameswap-orgGameswap (GSWAP) $ 0.669252
  • unistakeUnistake (UNISTAKE) $ 0.036528
  • mirrored-etherMirrored Ether (METH) $ 2,786.88
  • rupiah-tokenRupiah Token (IDRT) $ 0.000070
  • ruffRuff (RUFF) $ 0.006219
  • game-ace-tokenGame Ace Token (GAT) $ 6.41
  • auroraAurora (AOA) $ 0.001374
  • dextfDEXTF (DEXTF) $ 0.271260
  • bird-moneyBird.Money (BIRD) $ 69.89
  • tiki-tokenTiki Token (TIKI) $ 0.005735
  • og-fan-tokenOG Fan Token (OG) $ 4.48
  • pchainPlian (PI) $ 0.006888
  • blockchain-certified-data-tokenEvidenZ (BCDT) $ 0.156380
  • e13371337 (1337) $ 1.10
  • sirin-labs-tokenSirin Labs Token (SRN) $ 0.010712
  • dovuDovu (DOV) $ 0.019029
  • raven-protocolRaven Protocol (RAVEN) $ 0.001283
  • block-ape-scissorsBlock Ape Scissors (BAS) $ 0.115972
  • nucleus-visionNucleus Vision (NCASH) $ 0.001939
  • unslashed-financeUnslashed Finance (USF) $ 0.881309
  • mogul-productionsMogul Productions (STARS) $ 0.019209
  • planet-financePlanet Finance (AQUA) $ 120.27
  • nsure-networkNsure Network (NSURE) $ 0.253279
  • genaro-networkGenaro Network (GNX) $ 0.018295
  • dfohubdfohub (BUIDL) $ 1.75
  • mirrored-bitcoinMirrored Bitcoin (MBTC) $ 40,428.00
  • neumarkNeumark (NEU) $ 0.192285
  • aspireAspire (ASP) $ 0.047874
  • uselessUseless (USELESS) $ 0.00000001
  • sync-networkSync Network (SYNC) $ 0.046087
  • agave-tokenAgave Token (AGVE) $ 197.51
  • pearPear (PEAR) $ 2.61
  • counterpartyCounterparty (XCP) $ 2.09
  • idenaIdena (IDNA) $ 0.116760
  • razor-networkRazor Network (RAZOR) $ 0.059597
  • hodl-tokenHODL 2.0 (HODL) $ 0.00000002
  • equilibrium-eosdtEOSDT (EOSDT) $ 1.00
  • unilayerUniLayer (LAYER) $ 0.269206
  • public-index-networkPublic Index Network (PIN) $ 0.034468
  • open-monetary-systemOpen Monetary System (OMS) $ 0.919112
  • polkacoverPolkacover (CVR) $ 0.130625
  • unimex-networkUniMex Network (UMX) $ 0.764509
  • hybrixHybrix (HY) $ 2.35
  • moarMoar Finance (MOAR) $ 1.54
  • dos-networkDOS Network (DOS) $ 0.040529
  • offshiftOffshift (XFT) $ 1.44
  • b21B21 (B21) $ 0.100916
  • effect-networkEffect Network (EFX) $ 0.025653
  • charged-particlesCharged Particles (IONX) $ 0.810512
  • bonded-financeBonded Finance (BOND) $ 0.013785
  • yupYup (YUP) $ 0.775864
  • kattanaKattana (KTN) $ 3.58
  • spectrecoinAlias (ALIAS) $ 0.190933
  • float-protocol-floatFloat Protocol: Float (FLOAT) $ 1.45
  • wasabixWasabiX (WASABI) $ 5.75
  • creditsCREDITS (CS) $ 0.021536
  • zmineZMINE (ZMN) $ 0.008193
  • epic-cashEpic Cash (EPIC) $ 0.408747
  • xioBlockzero Labs (XIO) $ 0.132136
  • kambriaKambria (KAT) $ 0.003100
  • nft-protocolNFT Protocol (NFT) $ 0.121790
  • ether-1Etho Protocol (ETHO) $ 0.086821
  • charg-coinCharg Coin (CHG) $ 1.00
  • spacelensSpacelens (SPACE) $ 0.058303
  • inventoryclubInventoryClub (VNT) $ 0.135099
  • mirrored-facebookMirrored Facebook (MFB) $ 360.86
  • spookyswapSpookyswap (BOO) $ 2.57
  • kccpadKCCPad (KCCPAD) $ 0.059178
  • fuel-tokenJetfuel Finance (FUEL) $ 38.64
  • bscstarterStarter.xyz (START) $ 5.68
  • penguin-financePenguin Finance (PEFI) $ 0.342852
  • deeponionDeepOnion (ONION) $ 0.210661
  • yeeYee (YEE) $ 0.001584
  • unitradeUnitrade (TRADE) $ 0.127441
  • hive_dollarHive Dollar (HBD) $ 1.00
  • amberAmbrosus (AMB) $ 0.032633
  • urus-tokenUrus Token (URUS) $ 8.76
  • mochi-marketMochi Market (MOMA) $ 0.239013
  • tritonEquilibria (XEQ) $ 0.122349
  • napoleon-xNapoleon X (NPX) $ 0.180851
  • cryptocurrency-top-10-tokens-indexCryptocurrency Top 10 Index (CC10) $ 59.38
  • battle-petsBattle Pets (PET) $ 0.251433
  • hiveterminalHiveterminal token (HVN) $ 0.012562
  • pumapayPumaPay (PMA) $ 0.000170
  • apy-visionAPY.vision (VISION) $ 4.87
  • ucashU.CASH (UCASH) $ 0.000425
  • carbonCarbon (CRBN) $ 0.137577
  • crusaders-of-cryptoCrusaders of Crypto (CRUSADER) $ 0.00000001
  • midasMidas (MIDAS) $ 2.05
  • waifu-tokenWaifu Token (WAIF) $ 0.005067
  • non-fungible-yearnNon-Fungible Yearn (NFY) $ 57.08
  • eosforceEOSForce (EOSC) $ 0.015952
  • hydro-protocolHydro Protocol (HOT) $ 0.010814
  • unclUNCL (UNCL) $ 25.91
  • gspiShopping.io Governance (GSPI) $ 4.40
  • octofiOctoFi (OCTO) $ 12.55
  • pop-chest-tokenPOP Network (POP) $ 0.002752
  • feathercoinFeathercoin (FTC) $ 0.017735
  • compound-augurcREP (CREP) $ 0.307911
  • dev-protocolDev Protocol (DEV) $ 3.16
  • ycashYcash (YEC) $ 0.389067
  • sattSaTT (SATT) $ 0.001027
  • gains-farmGains Farm (GFARM2) $ 121.37
  • nodeseedsNodeseeds (NDS) $ 78.64
  • prosperProsper (PROS) $ 0.972273
  • zenfuseZenfuse (ZEFU) $ 0.069588
  • qunqunQunQun (QUN) $ 0.006356
  • boscoin-2BOScoin (BOS) $ 0.009514
  • utu-coinUTU Coin (UTU) $ 0.046840
  • multiplier-bscMultiplier (BSC) (BMXX) $ 1.85
  • stratosStratos (STOS) $ 0.522467
  • jurJur (JUR) $ 0.016204
  • zclassicZclassic (ZCL) $ 0.454500
  • swarmSwarm Network (SWM) $ 0.053439
  • suncontractSunContract (SNC) $ 0.034668
  • bloomBloom (BLT) $ 0.074193
  • total-crypto-market-cap-tokenTotal Crypto Market Cap (TCAP) $ 210.33
  • gainsGains (GAINS) $ 0.123855
  • deltahub-communityDeltaHub Community (DHC) $ 0.537653
  • cache-goldCACHE Gold (CGT) $ 58.22
  • senseSense (SENSE) $ 0.003619
  • switcheoSwitcheo (SWTH) $ 0.018497
  • open-governance-tokenOPEN Governance Token (OPEN) $ 0.357520
  • auroracoinAuroracoin (AUR) $ 0.213224
  • infinity-esahamInfinity Esaham (INFS) $ 4.13
  • oxbitcoin0xBitcoin (0XBTC) $ 0.538041
  • gridcoin-researchGridcoin (GRC) $ 0.009796
  • cafeswap-tokenCafeSwap Token (BREW) $ 0.794136
  • merculetMerculet (MVP) $ 0.000875
  • electronicguldenElectronic Gulden (EFL) $ 0.195076
  • unicly-mystic-axies-collectionUnicly Mystic Axies Collection (UAXIE) $ 0.408057
  • rendogerenDOGE (RENDOGE) $ 0.200079
  • wepowerWePower (WPR) $ 0.006637
  • monavaleMonavale (MONA) $ 488.78
  • longdrink-financeLongdrink Finance (LONG) $ 2.92
  • quai-daoQuai Dao (QUAI) $ 0.080209
  • thekeyTHEKEY (TKY) $ 0.000801
  • origoOrigo (OGO) $ 0.027023
  • carverticalcarVertical (CV) $ 0.000540
  • stealthcoinStealth (XST) $ 0.103674
  • wingsWings (WINGS) $ 0.043877
  • blackhat-coinBlackHat Coin (BLKC) $ 1.09
  • nord-financeNord Finance (NORD) $ 1.82
  • proto-gold-fuelProto Gold Fuel (PROTO) $ 0.055151
  • toacoinToaCoin (TOA) $ 0.000414
  • ultrainUltrain (UGAS) $ 0.014180
  • hakka-financeHakka Finance (HAKKA) $ 0.020646
  • geodbGeoDB (GEO) $ 0.146807
  • neurotokenNeurotoken (NTK) $ 0.045936
  • daexDAEX (DAX) $ 0.011167
  • ares-protocolAres Protocol (ARES) $ 0.026127
  • aga-tokenAGA Token (AGA) $ 0.874618
  • lendingblockLendingblock (LND) $ 0.004998
  • polydogePolyDoge (POLYDOGE) $ 0.00000000
  • memeticMemetic (MEME) $ 0.096821
  • everitokenEveriToken (EVT) $ 0.007846
  • high-performance-blockchainHigh Performance Blockchain (HPB) $ 0.103054
  • premiaPremia (PREMIA) $ 0.366715
  • tadpole-financeTadpole (TAD) $ 12.44
  • cryptopayCryptopay (CPAY) $ 0.100161
  • gambitGambit (GMT) $ 9.63
  • lyraLyra (LYR) $ 0.000386
  • chonkChonk (CHONK) $ 98.92
  • safeswapSafeswap (SSGT) $ 0.092351
  • daostackDAOstack (GEN) $ 0.078623
  • transfercoinTransfercoin (TX) $ 0.458769
  • boom-tokenBoom Token (BOOM) $ 0.005867
  • basis-cashBasis Cash (BAC) $ 0.069479
  • eddaswapEDDASwap (EDDA) $ 931.38
  • shardShard Coin (SHARD) $ 0.145123
  • holyheld-2Mover (MOVE) $ 0.445260
  • xvixXVIX (XVIX) $ 23.87
  • amoveoAmoveo (VEO) $ 47.18
  • yieldwatchYieldwatch (WATCH) $ 0.382952
  • surf-financeSurf.Finance (SURF) $ 0.430529
  • mirrored-goldman-sachsMirrored Goldman Sachs (MGS) $ 386.25
  • plotxPlotX (PLOT) $ 0.053856
  • snowball-tokenSnowball (SNOB) $ 0.241054
  • sdefisDEFI (SDEFI) $ 11,713.04
  • matrix-ai-networkMatrix AI Network (MAN) $ 0.024543
  • tera-smart-moneyTERA (TERA) $ 0.005665
  • nftbNFTb (NFTB) $ 0.031308
  • phorePhore (PHR) $ 0.149210
  • berry-dataBerry Data (BRY) $ 1.27
  • growth-defiGROWTH DeFi (GRO) $ 10.72
  • roobeeRoobee (ROOBEE) $ 0.003039
  • yflinkYF Link (YFL) $ 77.74
  • aitraAITRA (AITRA) $ 0.812677
  • qiibeeqiibee (QBX) $ 0.008611
  • elastic-daoElasticDAO (EGT) $ 170.62
  • you-chainYOU Chain (YOU) $ 0.004887
  • primecoinPrimecoin (XPM) $ 0.141462
  • aidcoinAidCoin (AID) $ 0.065242
  • one-ledgerOneLedger (OLT) $ 0.008164
  • ethereum-metaEthereum Meta (ETHM) $ 0.000036
  • ulordUlord (UT) $ 0.026945
  • swapdexSwapDEX (SDX) $ 0.050926
  • unicly-hashmasks-collectionUnicly Hashmasks Collection (UMASK) $ 0.035499
  • deri-protocolDeri Protocol (DERI) $ 0.064170
  • oneethoneETH (ONEETH) $ 1.06
  • motacoinMotaCoin (MOTA) $ 0.050787
  • rockiRocki (ROCKS) $ 0.447315
  • power-index-pool-tokenPower Index Pool Token (PIPT) $ 3.42
  • stream-protocolStream Protocol (STPL) $ 0.026367
  • krownKROWN (KRW) $ 0.001977
  • 42-coin42-coin (42) $ 82,765.00
  • golden-dogeGolden Doge (GDOGE) $ 0.00
  • cubeCube (AUTO) $ 0.000515
  • digix-goldDigix Gold (DGX) $ 46.06
  • wild-creditWild Credit (WILD) $ 0.377587
  • pinknodePinknode (PNODE) $ 0.067369
  • potcoinPotcoin (POT) $ 0.015087
  • tierionTierion (TNT) $ 0.007955
  • catecoinCateCoin (CATE) $ 0.00000010
  • big-data-protocolBig Data Protocol (BDP) $ 0.140210
  • stelliteScala (XLA) $ 0.000335
  • plairPlair (PLA) $ 0.000067
  • public-mintPublic Mint (MINT) $ 0.147444
  • vipstarcoinVIPSTARCOIN (VIPS) $ 0.000052
  • askobar-networkAsko (ASKO) $ 0.026224
  • speraxSperax (SPA) $ 0.011659
  • cnnContent Neutrality Network (CNN) $ 0.000056
  • axpireaXpire (AXPR) $ 0.011773
  • twinciTwinci (TWIN) $ 1.66
  • u-networkU Network (UUU) $ 0.000479
  • mirrored-airbnbMirrored Airbnb (MABNB) $ 147.48
  • uniwhalesUniWhales (UWL) $ 0.495522
  • medical-token-currencyDoc.com (MTC) $ 0.004296
  • lixir-protocolLixir Finance (LIX) $ 2.95
  • parachuteParachute (PAR) $ 0.005013
  • bsc-stationBSC Station (BSCS) $ 0.084823
  • piedao-balanced-crypto-piePieDAO Balanced Crypto Pie (BCP) $ 2.92
  • yaxisyAxis (YAXIS) $ 4.13
  • bnsd-financeBNSD Finance (BNSD) $ 0.023026
  • somee-social-oldSoMee.Social [OLD] (ONG) $ 0.036007
  • oin-financeOIN Finance (OIN) $ 0.181375
  • moon-nation-gameMoon Nation Game (MNG) $ 0.011902
  • daps-tokenDAPS Coin (DAPS) $ 0.000052
  • basketdaoBasketDAO (BASK) $ 56.59
  • advertise-coinAdvertise Coin (ADCO) $ 0.072254
  • concealConceal (CCX) $ 0.275273
  • eosbetEarnBet (BET) $ 0.046104
  • verisafeVeriSafe (VSF) $ 0.000394
  • blind-boxesBlind Boxes (BLES) $ 0.266419
  • givly-coinGIV Token (GIV) $ 0.005506
  • linkaLINKA (LINKA) $ 0.002590
  • yfdai-financeYfDAI.finance (YF-DAI) $ 767.37
  • seenSEEN (SEEN) $ 3.68
  • piedao-defi-large-capPieDAO DEFI Large Cap (DEFI+L) $ 3.73
  • worldcoinWorldCoin (WDC) $ 0.021826
  • complifiCompliFi (COMFI) $ 3.06
  • ternioTernio (TERN) $ 0.007056
  • revainRevain (REV) $ 0.006289
  • nft-starsNFT Stars (NFTS) $ 2.21
  • true-chainTrueChain (TRUE) $ 0.127088
  • pera-financePera Finance (PERA) $ 0.246882
  • spiderdaoSpiderDAO (SPDR) $ 0.013483
  • exrt-networkEXRT Network (EXRT) $ 0.006818
  • shield-financeShield Finance (SHLD) $ 0.008435
  • unicly-bored-ape-yacht-club-collectionUnicly Bored Ape Yacht Club Collection (UAPE) $ 0.002989
  • peanutPeanut (NUX) $ 0.370560
  • dracula-tokenDracula Token (DRC) $ 0.204868
  • polylasticPolylastic (POLX) $ 0.000322
  • bitcoin-greenBitGreen (BITG) $ 0.235277
  • resfinex-tokenResfinex Token (RES) $ 0.030016
  • exrnchainEXRNchain (EXRN) $ 0.000032
  • defi-yield-protocolDeFi Yield Protocol (DYP) $ 0.272320
  • blackcoinBlackCoin (BLK) $ 0.048108
  • sint-truidense-voetbalverenigingSint-Truidense Voetbalvereniging Fan Token (STV) $ 14.58
  • aventusAventus (AVT) $ 0.352130
  • bitcoinzBitcoinZ (BTCZ) $ 0.000293
  • unicly-fewocious-collectionUnicly Fewocious Collection (UFEWO) $ 0.029071
  • moonswapMoonSwap (MOON) $ 0.289369
  • sak3SAK3 (SAK3) $ 14,489.25
  • vaiotVaiot (VAI) $ 0.296743
  • mooncoinMooncoin (MOON) $ 0.000013
  • centaurCentaur (CNTR) $ 0.001751
  • unipilotUnipilot (PILOT) $ 4.72
  • onooksOnooks (OOKS) $ 0.284777
  • gem-exchange-and-tradingGem Exchange And Trading (GXT) $ 0.061089
  • habitatHabitat (HBT) $ 0.541180
  • quadrant-protocolQuadrant Protocol (EQUAD) $ 0.005268
  • expertyExperty (EXY) $ 0.098683
  • basketcoinBasketCoin (BSKT) $ 0.178521
  • flitsFlits (FLS) $ 0.658708
  • beekanBeeKan / Beenews (BKBT) $ 0.000704
  • honest-miningHonest (HNST) $ 0.022683
  • crowny-tokenCrowny Token (CRWNY) $ 0.010799
  • faceFaceter (FACE) $ 0.005275
  • depayDePay (DEPAY) $ 1.35
  • mirrored-netflixMirrored Netflix (MNFLX) $ 45.81
  • argonArgon (ARGON) $ 0.040614
  • uniqlyUniqly (UNIQ) $ 0.694531
  • espersEspers (ESP) $ 0.000102
  • royaleRoyale (ROYA) $ 0.127464
  • suqaSINOVATE (SIN) $ 0.003670
  • paypolitan-tokenPaypolitan Token (EPAN) $ 0.085469
  • auric-networkAuric Network (AUSCM) $ 0.036150
  • bitscreenerBitScreener (BITX) $ 0.016542
  • pawtocolPawtocol (UPI) $ 0.010822
  • happycoinHappyCoin (HAPPY) $ 0.00000000
  • doki-doki-financeDoki Doki (DOKI) $ 54.93
  • unifarmUniFarm (UFARM) $ 0.070601
  • playcentPlaycent (PCNT) $ 0.123932
  • dust-tokenDUST Token (DUST) $ 0.011259
  • ideaologyIdeaology (IDEA) $ 0.118210
  • aircoin-2AirCoin (AIR) $ 0.00000000
  • veriblockVeriBlock (VBK) $ 0.004341
  • snowswapSnowswap (SNOW) $ 8.34
  • yggdrashYggdrash (YEED) $ 0.000408
  • sake-tokenSakeToken (SAKE) $ 0.036767
  • mirrored-amc-entertainmentMirrored AMC Entertainment (MAMC) $ 30.22
  • megacryptopolisMegaCryptoPolis (MEGA) $ 13.18
  • pinkcoinPinkcoin (PINK) $ 0.005912
  • bitcashpayBitcashPay (BCP) $ 0.007322
  • swapz-appSWAPZ.app (SWAPZ) $ 0.021605
  • melo-tokenMelo Token (MELO) $ 0.000065
  • palgoldPalGold (PALG) $ 3.62
  • yield-protocolYield Protocol (YIELD) $ 0.039711
  • mirrored-gamestopMirrored GameStop (MGME) $ 149.50
  • pallapayPallapay (PALLA) $ 0.059835
  • siaprime-coinScPrime (SCP) $ 0.060778
  • nagaNAGA (NGC) $ 0.033966
  • partnerPartner (PRC) $ 0.000331
  • bankless-bed-indexBankless BED Index (BED) $ 125.54
  • par-stablecoinParallel (PAR) $ 1.18
  • payruePropel (PROPEL) $ 0.000565
  • indahashindaHash (IDH) $ 0.007989
  • mirrored-proshares-vixMirrored ProShares VIX (MVIXY) $ 7.86
  • okcashOKCash (OK) $ 0.031863
  • bitcoin-proBitcoin Pro (BTCP) $ 20.34
  • litexLITEX (LXT) $ 0.001924
  • chainswapChainswap (ASAP) $ 0.195620
  • world-tokenWorld Token (WORLD) $ 0.027525
  • alliance-fan-tokenAlliance Fan Token (ALL) $ 2.55
  • catbreadCatBread (CATBREAD) $ 0.00000000
  • wowswapWOWswap (WOW) $ 7.72
  • skrumble-networkSkrumble Network (SKM) $ 0.002448
  • crd-networkCRD Network (CRD) $ 0.005369
  • medicalchainMedicalchain (MTN) $ 0.011044
  • dynamic-set-dollarDynamic Set Dollar (DSD) $ 0.020673
  • amonAmon (AMN) $ 0.003509
  • shardusShardus (ULT) $ 0.086107
  • unidexUniDex (UNIDX) $ 0.718616
  • chainge-financeChainge Finance (CHNG) $ 0.037725
  • delta-exchange-tokenDelta Exchange Token (DETO) $ 0.085067
  • sphereSphere (SPHR) $ 0.205121
  • xmonXMON (XMON) $ 1,796.64
  • babydoge-coin-ethBabyDoge ETH (BABYDOGE) $ 0.00000001
  • auctusAuctus (AUC) $ 0.071831
  • digital-reserve-currencyDigital Reserve Currency (DRC) $ 0.002528
  • yieldYield (YLD) $ 7.97
  • netbox-coinNetbox Coin (NBX) $ 0.032255
  • smart-mfgSmart MFG (MFG) $ 0.009621
  • aga-rewards-2AGA Rewards (AGAR) $ 158.10
  • hempcoin-thcHempcoin (THC) $ 0.009572
  • tosdisTosDis (DIS) $ 47.18
  • portionPortion (PRT) $ 0.015046
  • meritcoinsMeritcoins (MRC) $ 0.000379
  • quarkQuark (QRK) $ 0.009142
  • fsw-tokenFalconswap (FSW) $ 0.065808
  • dapp-comDapp.com (DAPPT) $ 0.001768
  • tripioTripio (TRIO) $ 0.000925
  • defidollar-daoDefiDollar DAO (DFD) $ 0.112313
  • topbidderTopBidder (BID) $ 0.498812
  • signataSignata (SATA) $ 0.125498
  • quiverxQuiverX (QRX) $ 0.027252
  • spaceswap-milk2Spaceswap MILK2 (MILK2) $ 0.075920
  • macaronswapMacaronSwap (MCRN) $ 5.30
  • midas-cashMcashchain (MCASH) $ 0.003736
  • emercoinEmerCoin (EMC) $ 0.050988
  • internxtInternxt (INXT) $ 3.88
  • bifiBiFi (BIFI) $ 0.022552
  • impermaxImpermax (IMX) $ 0.157001
  • ultralphaUltrAlpha (UAT) $ 0.079459
  • polkawarPolkaWar (PWAR) $ 0.246454
  • darwinia-commitment-tokenDarwinia Commitment Token (KTON) $ 63.73
  • enreachdaoEnreachDAO (NRCH) $ 1.69
  • lepriconLepricon (L3P) $ 0.009307
  • polkadogPolkadog (PDOG) $ 0.061892
  • 2gether-22gether (2GT) $ 0.031648
  • cotraderCoTrader (COT) $ 0.000127
  • dmm-governanceDMM: Governance (DMG) $ 0.047832
  • goose-financeGoose Finance (EGG) $ 0.591237
  • denariusDenarius (D) $ 0.310184
  • apyswapAPYSwap (APYS) $ 0.245340
  • smartcredit-tokenSmartCredit Token (SMARTCREDI) $ 1.74
  • compound-saicSAI (CSAI) $ 0.273766
  • ethichubEthicHub (ETHIX) $ 0.516636
  • coldstackColdstack (CLS) $ 1.44
  • 1world1World (1WO) $ 0.091830
  • secure-padSecure Pad (SEPA) $ 10.05
  • simple-tokenOST (OST) $ 0.003301
  • bitcoin-plusBitcoin Plus (XBC) $ 13.55
  • eosdaceosDAC (EOSDAC) $ 0.002369
  • swapfolioSwapfolio (SWFL) $ 0.083350
  • earnxEarnX (EARNX) $ 0.00000049
  • professional-fighters-league-fan-tokenProfessional Fighters League Fan Token (PFL) $ 2.12
  • bitballBitball (BTB) $ 0.003514
  • digitex-futures-exchangeDigitex Token (DGTX) $ 0.002599
  • zhegiczHEGIC (ZHEGIC) $ 0.100786
  • versoVerso (VSO) $ 0.051055
  • utopia-genesis-foundationUtopia Genesis Foundation (UOP) $ 0.217604
  • bull-coinBull Coin (BULL) $ 0.00000000
  • serey-coinSerey Coin (SRY) $ 0.002146
  • yoyowYOYOW (YOYOW) $ 0.012707
  • collateral-payCollateral Pay (COLL) $ 0.336252
  • cryption-networkCryption Network (CNT) $ 0.268450
  • ufocoinUniform Fiscal Object (UFO) $ 0.000557
  • name-changing-tokenName Change Token (NCT) $ 0.055634
  • degen-artsDegen Arts (DAC) $ 39.61
  • nolimitcoinNoLimitCoin (NLC2) $ 0.005034
  • assy-indexASSY Index (ASSY) $ 0.959756
  • omniOmni (OMNI) $ 3.50
  • beaconBeacon (BECN) $ 1.32
  • vibeVIBE (VIBE) $ 0.011483
  • azukiAzuki (AZUKI) $ 0.099906
  • fairgameFairGame (FAIR) $ 0.003072
  • solfarmSolFarm (TULIP) $ 2.76
  • blockchain-cuties-universe-governanceBlockchain Cuties Universe Governance (BCUG) $ 3.01
  • aezoraAezora (AZR) $ 0.023752
  • masqMASQ (MASQ) $ 0.141567
  • phoenixdaoPhoenixDAO (PHNX) $ 0.040935
  • shirtumShirtum (SHI) $ 0.035989
  • nyan-v2Nyan V2 (NYAN-2) $ 75.18
  • finance-voteFinance Vote (FVT) $ 0.010486
  • bombBOMB (BOMB) $ 2.56
  • cake-monsterCake Monster (MONSTA) $ 0.000324
  • iteration-syndicateIteration Syndicate (ITS) $ 44.69
  • fanstimeFansTime (FTI) $ 0.000326
  • airightaiRight (AIRI) $ 0.009475
  • pocmonPocMon (PMON) $ 0.00000001
  • cpchainCPChain (CPC) $ 0.005254
  • mint-clubMint Club (MINT) $ 0.000002
  • crownCrown (CRW) $ 0.074009
  • sashimiSashimi (SASHIMI) $ 0.028150
  • adbankadbank (ADB) $ 0.002327
  • stakewiseStakeWise (SWISE) $ 0.052564
  • fontFont (FONT) $ 5.17
  • ethartItems (ARTE) $ 5.33
  • losslessLossless (LSS) $ 0.163589
  • essentiaEssentia (ESS) $ 0.001877
  • superlauncherSuperLauncher (LAUNCH) $ 0.507813
  • gleec-coinGleec Coin (GLEEC) $ 0.153707
  • nft-indexNFT Index (NFTI) $ 904.31
  • aichainAICHAIN (AIT) $ 0.003214
  • launchxLaunchX (LNCHX) $ 0.287063
  • rainbow-tokenRainbow Token (RNBW) $ 0.372651
  • team-heretics-fan-tokenTeam Heretics Fan Token (TH) $ 4.68
  • dragonbiteDragonBite (BITE) $ 0.008668
  • valutoValuto (VLU) $ 0.025603
  • zipZipper Network (ZIP) $ 0.000122
  • mywishMyWish (WISH) $ 0.207233
  • koho-chainKoHo Chain (KHC) $ 0.147034
  • canyacoinCanYaCoin (CAN) $ 0.061596
  • etha-lendETHA Lend (ETHA) $ 0.249093
  • libra-creditLibraToken (LBA) $ 0.002902
  • vegawallet-tokenVegaWallet Token (VGW) $ 0.078933
  • cornichonCornichon (CORN) $ 0.104284
  • pepemon-pepeballsPepemon Pepeballs (PPBLZ) $ 140.74
  • tribeoneTribeOne (HAKA) $ 0.068760
  • lead-tokenLead Token (LEAD) $ 0.004348
  • machixMachi X (MCX) $ 0.006159
  • safemooncashSafeMoonCash (SAFEMOONCA) $ 0.00
  • bobs_repairBob's Repair (BOB) $ 0.007360
  • sumokoinSumokoin (SUMO) $ 0.070721
  • smaugs-nftSmaugs NFT (SMG) $ 0.055430
  • uranusUranus (URAC) $ 0.000939
  • spiritswapSpiritSwap (SPIRIT) $ 0.017243
  • flixxoFlixxo (FLIXX) $ 0.037692
  • young-boys-fan-tokenYoung Boys Fan Token (YBO) $ 1.93
  • sureremitSureRemit (RMT) $ 0.002574
  • kuma-inuKuma Inu (KUMA) $ 0.00000002
  • bismuthBismuth (BIS) $ 0.080710
  • dpratingDPRating (RATING) $ 0.000446
  • beaxy-exchangeBeaxy (BXY) $ 0.005535
  • wolfsafepoorpeopleWolfSafePoorPeople (WSPP) $ 0.00000000
  • apollon-limassolApollon Limassol Fan Token (APL) $ 7.55
  • ac-exchange-tokenACDX Exchange Token (ACXT) $ 0.159322
  • pentaPenta Network Token (PNT) $ 0.000088
  • cloakcoinCloakcoin (CLOAK) $ 0.331280
  • papelPapel Token (PAPEL) $ 0.00000003
  • evedoEvedo (EVED) $ 0.129526
  • sparkpoint-fuelSparkPoint Fuel (SFUEL) $ 0.057263
  • piedao-defiPieDAO DEFI++ (DEFI++) $ 3.70
  • reth2rETH2 (RETH2) $ 2,699.10
  • intelligent-investment-chainIntelligent Investment Chain (IIC) $ 0.000159
  • edenchainEdenchain (EDN) $ 0.003279
  • polkararePolkarare (PRARE) $ 0.068424
  • zoraclesZoracles (ZORA) $ 310.28
  • nix-bridge-tokenVoice Token (VOICE) $ 51.91
  • alpacaAlpaca City (ALPA) $ 0.165596
  • tranchessTranchess (CHESS) $ 0.580920
  • option-roomOptionRoom (ROOM) $ 0.146329
  • xsigmaxSigma (SIG) $ 0.230304
  • yield-optimization-platformYield Optimization Platform & Protocol (YOP) $ 0.177531
  • metaverse-nft-indexMetaverse NFT Index (PLAY) $ 1.61
  • bitcoin-classicBitcoin Classic (BXC) $ 0.118180
  • xfinanceXfinance (XFI) $ 76.03
  • squirrel-financeSquirrel Finance (NUTS) $ 1.39
  • kittenfinanceKittenFinance (KIF) $ 47.62
  • xaurumXaurum (XAUR) $ 0.024854
  • moontographyMoontography (MTGY) $ 0.003825
  • wrapped-origin-axieWrapped Origin Axie (WOA) $ 11,988.88
  • kulupuKulupu (KLP) $ 0.041113
  • axis-defiAxis DeFi (AXIS) $ 0.252865
  • multiplierMultiplier (MXX) $ 0.023636
  • governor-daoGovernor DAO (GDAO) $ 0.597746
  • basis-shareBasis Share (BAS) $ 4.29
  • dds-storeDDS.Store (DDS) $ 2.27
  • wrapped-dgldWrapped-DGLD (WDGLD) $ 178.24
  • stateraStatera (STA) $ 0.021638
  • pascalcoinPascal (PASC) $ 0.049340
  • versoviewVersoView (VVT) $ 0.047103
  • gg-tokenGG Token (GGTK) $ 0.517787
  • bintex-futuresBintex Futures (BNTX) $ 1.18
  • emanateEmanate (EMT) $ 0.011483
  • curecoinCurecoin (CURE) $ 0.068035
  • perth-mint-gold-tokenPerth Mint Gold Token (PMGT) $ 1,814.69
  • rapidsRapids (RPD) $ 0.031517
  • herocoinHEROcoin (PLAY) $ 0.011311
  • signaturechainSignatureChain (SIGN) $ 0.002198
  • moonpirateMoonPirate (MOONPIRATE) $ 0.00
  • butterfly-protocol-2Butterfly Protocol (BFLY) $ 0.118665
  • endorEndor Protocol Token (EDR) $ 0.002358
  • vericoinVeriCoin (VRC) $ 0.049368
  • dotmoovsdotmoovs (MOOV) $ 0.007050
  • litedogeLiteDoge (LDOGE) $ 0.000102
  • beholderBehodler (EYE) $ 0.298010
  • tidex-tokenTidex Token (TDX) $ 0.165803
  • vaultVAULT (VAULT) $ 4.45
  • liquidity-dividends-protocolLiquidity Dividends Protocol (LID) $ 0.018006
  • bartertradeBarterTrade (BART) $ 0.018562
  • litecashLitecash (CASH) $ 0.007084
  • value-network-tokenValue Network Token (VNTW) $ 0.214223
  • king-arthurKing Arthur (BKING) $ 0.00000000
  • contentboxContentBox (BOX) $ 0.001758
  • club-atletico-independienteClub Atletico Independiente Fan Token (CAI) $ 2.55
  • somee-socialSoMee.Social (SOMEE) $ 0.033000
  • elon-doge-tokenElonDoge Token (EDOGE) $ 0.00000000
  • nextexchangeNEXT (NEXT) $ 0.102850
  • sekuritanceSekuritance (SKRT) $ 0.017564
  • bittubeBitTube (TUBE) $ 0.005126
  • prophecyProphecy (PRY) $ 0.021712
  • less-networkLess Network (LESS) $ 0.023459
  • roseon-financeRoseon Finance (ROSN) $ 0.105660
  • wheat-tokenWheat Token (WHEAT) $ 4.14
  • future-of-finance-fundFuture Of Finance Fund (FFF) $ 92.56
  • marsMars (MARS) $ 0.012590
  • dehiveDeHive (DHV) $ 1.33
  • chads-vcCHADS VC (CHADS) $ 0.040231
  • find-your-developerFYDcoin (FYD) $ 0.002727
  • cryptokekCryptokek (KEK) $ 0.036879
  • deflectDeflect (DEFLCT) $ 3.50
  • global-coin-researchGlobal Coin Research (GCR) $ 0.392620
  • dimecoinDimecoin (DIME) $ 0.000003
  • smartofgivingsmARTOFGIVING (AOG) $ 0.024243
  • dfx-financeDFX Finance (DFX) $ 0.319458
  • mobilegoMobileGo (MGO) $ 0.020255
  • mytokenMyToken (MT) $ 0.000820
  • polkacipherPolkaCipher (CPHR) $ 0.035563
  • daoventuresDAOventures (DVD) $ 0.153637
  • auxiliumAuxilium (AUX) $ 0.011238
  • wearesatoshiNativeCoin (N8V) $ 0.062374
  • katalyoKatalyo (KTLYO) $ 0.118705
  • componentComponent (CMP) $ 1.67
  • dextrustDextrust (DETS) $ 0.045217
  • stobox-tokenStobox Token (STBU) $ 0.044932
  • duneDune (DUN) $ 0.003340
  • bcvBitCapitalVendor (BCV) $ 0.001804
  • energy-ledgerEnergy Ledger (ELX) $ 0.011318
  • tolarTolar (TOL) $ 0.006800
  • safe-coin-2SafeCoin (SAFE) $ 0.044902
  • yel-financeYel.Finance (YEL) $ 0.016871
  • defisocialDefiSocial (DFSOCIAL) $ 239.78
  • chainiumWeOwn (CHX) $ 0.010410
  • coinbene-tokenCoinbene Token (CONI) $ 0.033829
  • hyperionHyperion (HYN) $ 0.007213
  • swag-financeSWAG Finance (SWAG) $ 0.013897
  • patientoryPatientory (PTOY) $ 0.017737
  • polyient-games-governance-tokenPolyient Games Governance Token (PGT) $ 86.07
  • ghostprismGHOSTPRISM (GHOST) $ 0.420733
  • pivot-tokenPivot Token (PVT) $ 0.000298
  • zen-protocolZen Protocol (ZP) $ 0.036553
  • piratecashPirateCash (PIRATE) $ 0.042684
  • lever-networkLever Network (LEV) $ 0.178052
  • adamant-messengerADAMANT Messenger (ADM) $ 0.013655
  • bitto-exchangeBITTO (BITTO) $ 0.151369
  • stakedzenStakedZEN (STZEN) $ 58.38
  • virgox-tokenVirgoX Token (VXT) $ 0.034091
  • earnbaseEarnbase (ENB) $ 4.92
  • scifi-indexSCIFI Index (SCIFI) $ 2.23
  • robust-tokenRobust Token (RBT) $ 41.43
  • hollygoldHollyGold (HGOLD) $ 0.317011
  • hashgardHashgard (GARD) $ 0.000144
  • 2key2key.network (2KEY) $ 0.020610
  • dark-magicDark Magic (DMAGIC) $ 0.358072
  • remmeRemme (REM) $ 0.001521
  • mm-tokenMM Token (MM) $ 3.41
  • thingsoperatingsystemThingsOperatingSystem (TOS) $ 0.001790
  • sacksSacks (SACKS) $ 5,714.25
  • skullSkull (SKULL) $ 0.181638
  • tardigrades-financeTardigrades Finance (TRDG) $ 0.00
  • grey-tokenGrey Token (GREY) $ 0.00000057
  • nftifyNFTify (N1) $ 0.076761
  • veilVEIL (VEIL) $ 0.013372
  • smileycoinSmileycoin (SMLY) $ 0.000042
  • darkpaycoinDARK (D4RK) $ 0.195351
  • citizen-financeCitizen Finance (CIFI) $ 11.30
  • petrachorPetrachor (PTA) $ 0.002498
  • webcoinWebcoin (WEB) $ 0.001373
  • zebiZebi (ZCO) $ 0.002735
  • tradestarsTradeStars (TSX) $ 0.140364
  • toshi-tokenToshimon (TOSHI) $ 27.31
  • midas-goldMidas Gold (MDG) $ 4.71
  • yfbitcoinYFBitcoin (YFBTC) $ 182.31
  • rocket-vault-financeRocket Vault (RVF) $ 0.049183
  • lightstreamsLightstreams Photon (PHT) $ 0.027945
  • jade-currencyJade Currency (JADE) $ 0.023224
  • relevantRelevant (REL) $ 1.01
  • edc-blockchainEDC Blockchain (EDC) $ 0.017294
  • polkabridgePolkaBridge (PBR) $ 0.067977
  • polka-cityPolkacity (POLC) $ 0.154225
  • pigeoncoinPigeoncoin (PGN) $ 0.000177
  • shield-protocolShield Protocol (SHIELD) $ 5.78
  • steakbank-financeSteakBank Finance (SBF) $ 0.002047
  • cryptexCryptEx (CRX) $ 15.59
  • robonomics-web-servicesRobonomics Web Services (RWS) $ 26,424.00
  • oroORO (ORO) $ 0.108557
  • renzecrenZEC (RENZEC) $ 117.86
  • scry-infoScry.info (DDD) $ 0.003027
  • hodltreeHodlTree (HTRE) $ 0.286776
  • geyserGeyser (GYSR) $ 0.201850
  • gamyfi-tokenGamyFi Token (GFX) $ 0.813639
  • polkalokrPolkalokr (LKR) $ 0.073219
  • hanu-yokiaHanu Yokia (HANU) $ 0.000001
  • alphacatAlphacat (ACAT) $ 0.000387
  • b-cube-aiB-cube.ai (BCUBE) $ 0.142353
  • alqoALQO (XLQ) $ 0.018108
  • hashcoinHashCoin (HSC) $ 0.000035
  • monetaryunitMonetaryUnit (MUE) $ 0.005581
  • verosVeros (VRS) $ 1.30
  • istanbul-basaksehir-fan-tokenİstanbul Başakşehir Fan Token (IBFK) $ 2.11
  • audiocoinAudioCoin (ADC) $ 0.001148
  • kiwigoKiwigo (KGO) $ 0.029747
  • crosswalletCrossWallet (CWT) $ 0.010151
  • euler-toolsEuler Tools (EULER) $ 0.017513
  • bitcoin-rhodiumxRhodium (XRC) $ 1.05
  • bankroll-networkBankroll Network (BNKR) $ 0.060067
  • algovestAlgoVest (AVS) $ 0.281157
  • kangalKangal (KANGAL) $ 0.000013
  • birakeBirake (BIR) $ 0.013184
  • educoinEducoin (EDU) $ 0.000139
  • spice-financeSPICE (SPICE) $ 0.215880
  • project-shivomProject SHIVOM (OMX) $ 0.001318
  • zeedexZeedex (ZDEX) $ 0.396209
  • hushHush (HUSH) $ 0.118950
  • rage-fanRage.Fan (RAGE) $ 0.019621
  • marginswapMarginswap (MFI) $ 0.202782
  • topinvestmentcoinTICOEX Token (Formerly TopInvestmentCoin) (TICO) $ 0.050616
  • nft-platform-indexNFT Platform Index (NFTP) $ 21.28
  • halalchainHalalChain (HLC) $ 0.004040
  • lienLien (LIEN) $ 3.40
  • yuki-coinYUKI COIN (YUKI) $ 0.000090
  • ormeus-ecosystemOrmeus Ecosystem (ECO) $ 0.000347
  • coinusCoinUs (CNUS) $ 0.001933
  • naboxNabox (NABOX) $ 0.000011
  • pylon-financePylon Finance (PYLON) $ 145.36
  • unicly-aavegotchi-astronauts-collectionUnicly Aavegotchi Astronauts Collection (UGOTCHI) $ 1.21
  • based-moneyBased Money ($BASED) $ 0.136372
  • disbalancerdisBalancer (DDOS) $ 0.417357
  • buysellBuySell (BULL) $ 0.237565
  • starbaseStarbase (STAR) $ 0.005735
  • miss-dogeMiss Doge (MDOGE) $ 0.00000000
  • sapienSapien (SPN) $ 0.003544
  • the-4th-pillar4thpillar technologies (FOUR) $ 0.008256
  • rope-tokenRope Token (ROPE) $ 0.189804
  • ispolinkIspolink (ISP) $ 0.001187
  • donutDonut (DONUT) $ 0.008354
  • steam-exchangeSteam Exchange (STEAMX) $ 0.000012
  • lobstex-coinLobstex (LOBS) $ 0.054272
  • pinkmoonPinkMoon (PINKM) $ 0.00000000
  • obortechObortech (OBOT) $ 0.011814
  • datumDatum (DAT) $ 0.001153
  • mobifiMobiFi (MOFI) $ 0.019423
  • humaniqHumaniq (HMQ) $ 0.006208
  • alunaAluna (ALN) $ 0.067421
  • x8-projectX8X Token (X8X) $ 0.015304
  • qwertycoinQwertycoin (QWC) $ 0.000008
  • zlotzLOT (ZLOT) $ 130.68
  • polisPolis (POLIS) $ 0.086654
  • chi-gastoken-bscChi Gastoken (BSC) (CHI) $ 0.023878
  • bgovBGOV (BGOV) $ 0.017374
  • phantasma-energyPhantasma Energy (KCAL) $ 0.024358
  • mochimoMochimo (MCM) $ 0.113385
  • inmediateDirect Insurance Token (DIT) $ 0.002383
  • cvcoinCVCoin (CVN) $ 0.074940
  • liq-protocolLIQ Protocol (LIQ) $ 0.139434
  • zenzoZENZO (ZNZ) $ 0.047226
  • bonfiBonFi (BNF) $ 0.003920
  • lendefiLendefi (LDFI) $ 0.219374
  • rate3Rate3 (RTE) $ 0.001109
  • add-xyz-newAdd.xyz (NEW) (ADD) $ 0.230803
  • gokumarket-creditGokuMarket Credit (GMC) $ 0.343136
  • vesper-vdollarVesper V-Dollar (VUSD) $ 1.00
  • smoothySmoothy (SMTY) $ 0.206813
  • reflect-financereflect.finance (RFI) $ 0.120460
  • calicoinCaliCoin (CALI) $ 0.036166
  • shadowsShadows (DOWS) $ 0.112886
  • 0xcert0xcert (ZXC) $ 0.002591
  • nix-platformNIX (NIX) $ 0.021764
  • catex-tokenCatex Token (CATT) $ 0.000958
  • ubexUbex (UBEX) $ 0.000336
  • cryptobulls-tokenCryptobulls Token (CBT) $ 0.00000001
  • firdaosFirdaos (FDO) $ 0.665401
  • exclusivecoinExclusiveCoin (EXCL) $ 0.180507
  • lottoLotto (LOTTO) $ 0.014110
  • primasPrimas (PST) $ 0.020677
  • feraFera (FERA) $ 0.006879
  • polkainsure-financePolkainsure Finance (PIS) $ 13.62
  • keyfiKeyFi (KEYFI) $ 0.480298
  • base-protocolBase Protocol (BASE) $ 1.63
  • piedao-defi-small-capPieDAO DEFI Small Cap (DEFI+S) $ 2.40
  • sharder-protocolSharder protocol (SS) $ 0.004537
  • ucotUbique Chain of Things (UCOT) (UCT) $ 0.001970
  • moneytokenMoneyToken (IMT) $ 0.000109
  • chartexChartEx (CHART) $ 0.012578
  • klondike-finance-v2Klondike Finance v2 (KLONX) $ 4.46
  • echolinkEchoLink (EKO) $ 0.002043
  • tapmydataTapmydata (TAP) $ 0.079958
  • relite-financeRelite Finance (RELI) $ 0.030581
  • reosc-ecosystemREOSC Ecosystem (REOSC) $ 0.000329
  • monkMonk (MONK) $ 0.078059
  • drops-ownership-powerDrops Ownership Power (DOP) $ 0.467268
  • afen-blockchainAFEN Blockchain (AFEN) $ 0.008714
  • ixicashIxiCash (IXI) $ 0.000241
  • coretoCoreto (COR) $ 0.005222
  • tokenpayTokenPay (TPAY) $ 0.044266
  • stabilizeStabilize (STBZ) $ 1.45
  • myx-networkMYX Network (MYX) $ 0.001170
  • sav3SAV3 (SAV3) $ 0.045967
  • cryptonovaeCryptonovae (YAE) $ 0.031492
  • flypmeFlypMe (FYP) $ 0.058484
  • stkSTK (STK) $ 0.002862
  • coin-artistCoin Artist (COIN) $ 0.719016
  • bitcoin-confidentialBitcoin Confidential (BC) $ 0.000133
  • menlo-oneMenlo One (ONE) $ 0.002309
  • ionomyIonomy (ION) $ 0.024699
  • unique-oneUnique One (RARE) $ 0.388344
  • olivecashOlive Cash (OLIVE) $ 0.255731
  • odin-protocolOdin Protocol (ODIN) $ 0.042326
  • trueflipTrueFlip (TFL) $ 0.144880
  • dmstDMScript (DMST) $ 0.030178
  • creativecoinCREA (CREA) $ 0.044145
  • atromg8ATROMG8 (AG8) $ 0.022937
  • vidVid (VI) $ 0.037972
  • fintruxFintruX (FTX) $ 0.011670
  • release-ico-projectRELEASE (REL) $ 0.000013
  • stipendStipend (SPD) $ 0.075313
  • dctdaoDCTDAO (DCTD) $ 0.225442
  • ryoRyo Currency (RYO) $ 0.029969
  • changeChange (CAG) $ 0.048114
  • safcoinSafCoin (SAF) $ 0.109334
  • aschAsch (XAS) $ 0.007783
  • noblecoinNobleCoin (NOBL) $ 0.000394
  • porkswapPorkSwap (PSWAP) $ 1.46
  • prism-networkPrism Network (PRISM) $ 24.70
  • pancaketoolsPancakeTools (TCAKE) $ 0.006429
  • mantis-networkMantis Network (MNTIS) $ 0.499096
  • zeroZero (ZER) $ 0.090133
  • almace-shardsAlmace Shards (ALMX) $ 92.39
  • boutsproBoutsPro (BOUTS) $ 0.019013
  • fujicoinFujicoin (FJC) $ 0.000378
  • wenlamboWenlambo (WENLAMBO) $ 0.00000002
  • experience-chaineXPerience Chain (XPC) $ 0.000008
  • sxagsXAG (SXAG) $ 25.79
  • sadasADA (SADA) $ 1.39
  • flash-stakeFlashstake (FLASH) $ 0.080075
  • yearn-secureYearn Secure (YSEC) $ 0.959060
  • curioCurio (CUR) $ 0.455065
  • karboKarbo (KRB) $ 0.098825
  • box-tokenBOX Token (BOX) $ 0.025450
  • infinitoInfinito (INFT) $ 0.000723
  • snowgemTENT (TENT) $ 0.023908
  • sarcophagusSarcophagus (SARCO) $ 0.540381
  • bavalaBavala (BVA) $ 0.034807
  • maticpadMaticPad (MATPAD) $ 0.042609
  • crdtCRDT (CRDT) $ 0.004826
  • otcbtc-tokenOTCBTC Token (OTB) $ 0.012533
  • portalPortal (PORTAL) $ 0.001246
  • the-champcoinThe ChampCoin (TCC) $ 0.004801
  • tokpieTOKPIE (TKP) $ 0.011196
  • moontoolsMoonTools (MOONS) $ 23.20
  • arthARTH (ARTH) $ 0.00
  • kinekoKineko (KKO) $ 0.332425
  • gowithmiGoWithMi (GMAT) $ 0.000354
  • zippieZippie (ZIPT) $ 0.002178
  • dogey-inuDogey-Inu (DINU) $ 0.00000000
  • globexGlobex (GEX) $ 0.000023
  • zero-utility-tokenZero Utility Token (ZUT) $ 905.27
  • detherDether (DTH) $ 0.010313
  • the-bitcoin-familyThe Bitcoin Family (FAMILY) $ 0.167654
  • growth-rootGrowth Root (GROOT) $ 474.99
  • fess-chainFesschain (FESS) $ 0.001582
  • upfiringUpfiring (UFR) $ 0.036863
  • spacecowboySpaceCowBoy (SCB) $ 17.35
  • carlive-chainCarlive Chain (IOV) $ 0.000133
  • ai-doctorAI Doctor (AIDOC) $ 0.001924
  • soar-2Soar (SOAR) $ 0.107714
  • racRAC (RAC) $ 1.40
  • imoIMO (IMO) $ 0.076408
  • totemfiTotemFi (TOTM) $ 0.194324
  • riecoinRiecoin (RIC) $ 0.014183
  • deli-of-thronesDeFi of Thrones (DOTX) $ 0.172804
  • mu-dankMU DANK (DANK) $ 0.038286
  • davDAV Network (DAV) $ 0.001219
  • chi-gastokenChi Gastoken (CHI) $ 0.419187
  • snetworkSnetwork (SNET) $ 0.003610
  • nuco-cloudNuco.Cloud (NCDT) $ 0.129735
  • actiniumActinium (ACM) $ 0.028240
  • black-eye-galaxyBlack Eye Galaxy (BYG) $ 0.048666
  • sota-financeSOTA Finance (SOTA) $ 0.023658
  • dmarketDMarket (DMT) $ 0.016298
  • defi-omegaDeFi Omega (DFIO) $ 7.73
  • kometKomet (KOMET) $ 37.04
  • safe-dealSafeDeal (SFD) $ 1.16
  • extradnaextraDNA (XDNA) $ 0.000439
  • tendiesTendies (TEND) $ 0.109588
  • eskaEska (ESK) $ 0.027194
  • nftx-hashmasks-indexNFTX Hashmasks Index (MASK) $ 2,256.06
  • fyoozFyooz (FYZ) $ 0.189172
  • ixcoinIxcoin (IXC) $ 0.038636
  • noderunnersNode Runners (NDR) $ 55.88
  • yeld-financeYeld Finance (YELD) $ 13.60
  • zrcoinZrCoin (ZRC) $ 0.207421
  • domraiderDomRaider (DRT) $ 0.000780
  • degenvcDegenVC (DGVC) $ 0.809271
  • bsclaunchBSClaunch (BSL) $ 0.124907
  • equitraderEquiTrader (EQT) $ 0.054747
  • terablockTeraBlock (TBC) $ 0.025149